var title_f43_3_44080="Taking round ligament";
var content_f43_3_44080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Taking round ligament during laparoscopic hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44080=[""].join("\n");
var outline_f43_3_44080=null;
var title_f43_3_44081="Patient information: Alcohol withdrawal (The Basics)";
var content_f43_3_44081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/17/37137\">",
"         Patient information: Alcohol poisoning (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/28/39361\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/23/4468\">",
"         Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Alcohol withdrawal (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/alcohol-withdrawal-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H24443875\">",
"      <span class=\"h1\">",
"       What is alcohol withdrawal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Alcohol withdrawal is a condition that happens when a person who often drinks large amounts of alcohol suddenly stops drinking alcohol. People with alcohol withdrawal often have a headache, a stomach ache, and trouble sleeping. But sometimes, the symptoms are much more serious and even life threatening.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24443890\">",
"      <span class=\"h1\">",
"       What are the symptoms of alcohol withdrawal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Mild symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Trouble sleeping",
"       </li>",
"       <li>",
"        Trembling",
"       </li>",
"       <li>",
"        Feeling anxious",
"       </li>",
"       <li>",
"        Having an upset stomach and not wanting to eat",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Sweating",
"       </li>",
"       <li>",
"        Feeling like your heart is beating fast, beating hard, or seems to skip a beat -- These heartbeat changes are called &ldquo;palpitations.&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms often start within 6 hours after a person stops drinking. They might go away within 1 or 2 days. But some people also get more serious symptoms, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Seizures - These are waves of abnormal electrical activity in the brain. They can make a person pass out, or move or behave strangely. With alcohol withdrawal, seizures usually happen within 12 to 48 hours after the person stops drinking.",
"       </li>",
"       <li>",
"        Hallucinations &ndash; Hallucinations are when you hear, see, feel, smell, or taste things that aren&rsquo;t there. With alcohol withdrawal, the most common type is seeing things that aren&rsquo;t there. This symptom tends to happen within 12 to 24 hours after the person&rsquo;s last drink and stop within 1 or 2 days.",
"       </li>",
"       <li>",
"        Delirium tremens or DT &ndash; This is the most serious form of alcohol withdrawal. Symptoms include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Hallucinations",
"       </li>",
"       <li>",
"        Feeling confused about where you are or who you are",
"       </li>",
"       <li>",
"        Feeling very upset and anxious",
"       </li>",
"       <li>",
"        Uncontrolled shaking",
"       </li>",
"       <li>",
"        A fast heartbeat",
"       </li>",
"       <li>",
"        High blood pressure",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Sweating",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The symptoms start 2 to 4 days after a person stops drinking and can last up to 5 days.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24443905\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away, even if you have mild symptoms of alcohol withdrawal. The symptoms can get more serious and possibly fatal if you are not treated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24443920\">",
"      <span class=\"h1\">",
"       Is there a test for alcohol withdrawal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam. But he or she might do tests to check for other problems. These tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        A CT scan of your head &ndash; A CT scan is an imaging test that can create pictures of the brain.",
"       </li>",
"       <li>",
"        A lumbar puncture (sometimes called a &ldquo;spinal tap&rdquo;) &ndash; During this procedure, your doctor puts a thin needle into your lower back and takes out a small amount of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. Your doctor will send the spinal fluid to a lab for tests.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24443935\">",
"      <span class=\"h1\">",
"       How is alcohol withdrawal treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on your symptoms. If you have mild symptoms, your doctor might prescribe medicines to take at home. But to do this, you need to meet these conditions:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Have a reliable relative or friend who can stay with you for 3 to 5 days to make sure your symptoms are not getting worse",
"       </li>",
"       <li>",
"        Be able to go in for a medical visit every day",
"       </li>",
"       <li>",
"        Not be pregnant or have any physical or mental health problems",
"       </li>",
"       <li>",
"        Not have other substance abuse problems, such as taking illegal drugs",
"       </li>",
"       <li>",
"        Have never had serious alcohol withdrawal symptoms in the past",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you do not meet these conditions or if you have serious symptoms, you will be treated in the hospital. You might get medicines through a tube in your vein, called an &ldquo;IV.&rdquo; All people treated for alcohol withdrawal should also take multivitamins (as pills or through an IV).",
"     </p>",
"     <p>",
"      Your doctor or nurse will also refer you to a program to treat people with alcohol problems. In these programs, people can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        See a counselor (such as a psychologist, social worker, or psychiatrist)",
"       </li>",
"       <li>",
"        Take medicines",
"       </li>",
"       <li>",
"        Take part in a social support group like AA (Alcoholics Anonymous)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these treatments can help, and you can do more than 1 at the same time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24443950\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/28/39361?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/17/37137?source=see_link\">",
"       Patient information: Alcohol poisoning (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/23/4468?source=see_link\">",
"       Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?43/3/44081?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83392 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44081=[""].join("\n");
var outline_f43_3_44081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24443875\">",
"      What is alcohol withdrawal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24443890\">",
"      What are the symptoms of alcohol withdrawal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24443905\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24443920\">",
"      Is there a test for alcohol withdrawal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24443935\">",
"      How is alcohol withdrawal treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24443950\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/17/37137?source=related_link\">",
"      Patient information: Alcohol poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/28/39361?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/23/4468?source=related_link\">",
"      Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_3_44082="Scabies distribution";
var content_f43_3_44082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies distribution",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 551px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAInAboDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACignAyelRxzwyOUjljZh1CsCRQBJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRUVzcQWsRkuZo4Yx1eRgo/M1l/wDCVeHg+w67pW/0+1x/40m0txpNmzRUNtdW90u62nimXrmNww/SpqYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCvf3lvp9lNd30yQW0Kl5JHOAoHc185+OPjjqmoyT2fhaJbC0yVF243TOPUA8Jn8T9KyfjB44uPFniG4sbOeT+w7N9kcSdJ5AcFz688D2+tc1p3gHxFfIJRYPCjZIEhCnA9uv0rgrYht2jsdtHD2V5GNfahqeqSM+o6pfXTE5JlnZh+RNUwkdq4eJ5ophyHRip/MV3dt8KvEU8HmOLe2BHEckmWP125A/OhPhF4im3DfZxADjfKTn8ga5efzOnlt0K/hX4s+LPDrqi6h/admD/AKi+zIcegf7w/Mj2r6K+HHxG0nxrpqOjx2WphjHJYySguCOcr03KRzkCvANP+D2sNcf8TO9tbaAH5jCTIxHtwAKzPGvh4eEdYt5LJZUspFXypwx3pKvXn171tDEuLstTKeHUlfY+yaK4L4MeLJvFnhBJb599/aSG3nf++QAVf8QefcGu9r0YyUldHnyi4uzCiiiqEFFFFABRRRQAUUUUAFFFFABRRRQBHczxWtvJPcyJFDGpd3c4VVHJJNeMeJ/jtZW8txB4e057wKCqXUz7ELdiFxkj64zUX7SniKe3ttP0C1lZEuVM9yF/jQHCqfbIJx7CvC0g9fuqMn61x167i+WJ10KCkuaRY1/WtQ8Q373esXkt1M5/5aH5V9lXoo9hVb7PtjG6JSvqKka13W4JHPXNWdK+eJ4ZB8ydK4W76s7VG2gyCJ7fbPYzywSDlWjcqfzFei+Bfi/q+h3EVv4jkl1LS2ODI3M8XuD/ABD2PPvXDrEiW7r33ZFUbqNXgXd94jn61UKkoO6Yp01Jao+ztF1Wx1rTor7S7mO5tZRlXQ5/A+hHoeavV8nfB7xXceF/FNpE0zDTL+UQXEZPygk4V/YgkfhmvrGvTo1faK55tWn7N2CiiitTIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxfGt+dL8I6zeqSHhtJWUj+9tOP1xW1Wb4l0+LVvD+o2E/+ruLd4z7ZU80pXs7Dja6ufJfwpsjfeKI2aMPDbJ5rlvXov68/hX0TYQqYwW714x8EYCItVlOBteOL8QCT/OvZoJVjjAPYV4Unqeyr8ppLGuOgpxUAcYqjHexscK4P41KZxjk1XMiHFkF3zmuE+I+lLqnhbULfA8xIzLGT2ZeR/LH412cs8cshCSKxBwQCDisnW4PtFncRD/lpGyfmMVlfW5tFaWOK/ZUvn/tHW7LcfLkhSfHoVbGfyavo2vmr9lqB4PFWtxunzRWuxj/dIkAx+OP0r6Vr2sP8B5Ff4wooorcxCiiigAooooAKKKKACiiigAooooA+V/j7erdfEu6iU5FtbxQ/jjcf/Qq463O5CPVa6P44QGH4n6x6uYpB9DGtcrbPhEb04NeTV+Nnq0tIovKyNaYBww4I96rqGSRinVhTYwWZux5NSWeZGGe1ZGo7fuyejDtUU5BY4HvU0ke27IHdM1XZsOxagTKcvKrjIwc5r7J+H+qvrfgvR9QlOZZrdfMPq4+Vj+YNfG8zDYMdua+svgvC8Hwy0MSAhmjeQA+jOxH6EV2YR+80cmK+FM7aiiiu84QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArC8aay+haDJdxCPzWkSFDICUUuwXJA5IGScd+lbtYnjXT/wC0vC2pW6j955Rli9nT51/VRUyvyuxUbcyvseTeDLKCyGprbiEJJetJmFWUDKqcYbkY54OcVN4s023jtbm6Gn3N40KZaSW9kUAH0Ckkj1wMCofCd619canM/G6ZGVf7qleP0FdylqssK9Qcda8P7R7LskeXeEtIRLOx1qPT5rF3XesP2p3IHcOrfzHHFdpq1zJDprypnLLhfxrTurRLeJjyWPBJqlrtsx0AEDlBu49uaUndjjZI821fR7fQzZSf2O939slVQFupN2SeWIXgY4OCc8iuzs9P+w7o1t5rZgcMhuDKh+mSa3dKtkurWKdSRlQeKq6oPJuUAPGRTlK6CCszM+GN1b6N4pvobaK1I1W+eOTbu81CqttPptyrcdfmB9q9orxL4SRHUfFQkmG6Oz+03MRx0aRwuPyLfnXttethr+z1PLxNufQKKKK6DnCiiigAooooAKKKKACiiigAqnrF8umaXdXroZBBGX2A43HsKuVX1C1S+sbi1l/1c8bRt9CMUne2g1a+p8ufG66kvfFcN1cW6RT+QIZWjJKOQSQRnnowH4VwUTBF9Qa9N+LGnzTaX9okQ+dbSbZfqPkb9dprygvhI8djXjqTlrLc9ZpQ0WxoxS+XIpbvTixjmLRn5Cc1WnbJXB7ZoMg5A6UrDuT+e+4ux+YjaKgnZs7e/rTGb50pHfdIT2ppCbGS8hI1+83FfXvw61h7nTrLT3tkhjhs4zCVfcdq4XDcdeh49a+UPDdm+oa7axBS2ZASPRQcn+VfWPw7sfKtJrxh8rgQQ/7iZyfxYn8hW+Hb9okvmY10vZuT+R2FFFFekecFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIwDAgjIPGKWigDxe20i40HxFLY3NuyI0BEU3G2ZY3wpGD1CuoIPpXa2Ug8pfpV3x7psl3pKXtpGXvLBjMir1dMYkQfVenuBXO6ReRzwIVcFGAZT6g9K8fEU/ZVNNmerRn7WnruixrML3du8ULKHbpu6e+fr0/Gsq4bWXcWzixG4Z6sQB6dKu6x9v25sp4YV7kpuf8M8VhbLl5B/xML1pD6BAfz6Y/CsVqdEYXW5u6MTYWa2zkEoMZ7Vj61c7RcTnpEjP+QzV9IZ4LcveXf2gn7vyAFfqRjP5VRhthq2qWOmjGLqUNKO/kodz/ngL/wACojFykooJNQTkdB8JtHuLCwkuLuxks2aGKFElADtjLOxAPGWc9fSu/oor3IQUI8qPEnNzlzMKKKKokKKKKACiiigAooooAKKKKACiiigDy34keHLyY6i6QpJpl2Q8kgcAwEqEbIPUZAbjPevmK8tZbO8mtbldk0TlHX0Ir7m1Kzj1DT7mznz5U8bRtjqARjNfOfiXwh/bF9PBeD7Hq9rIIpJQmRKMDBI7g9QfSvNxMFSlzrZno4ebqx5XujyAOTwT0pwOUPtXXaj8OfEFtJm3hiu4ycboZAD9SDioLXwF4jmRl/s9o/mxmR1X8evSsOZM15Wjmd7YDd8UwMxFdfL8N/EiBf3EBBPaZeK0rL4dPaolxq92gVMs8UQJ4H+1Q5xQ1CTNP4R+HL2d3u7e1eWWVdqNt+WME4DMewJz/wB8mvpjTrRLCwt7WL7kKBAfXA61yvws002XhlLiSPy2uyHRT1WIDCD8sn/gVdlXoYalyLme7OHE1eZ8q2QUUUV0nMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXhmsT3Oh+LdYgRWlsFui4jUfNEHVX+X1GWPH5ele514zrBW/8Xa2y/MjXXl5/wByNEP6giuPG29nqdmCvzv0NHTdctbuAMXWWI8b17exHY+xq/8AadIiG9FXefauTu/C0yyGezkeGRhyyHBI9+x/Gqb6TrJGJLxwncqiqfzxXmLyPRauavibxBDCohhXzJyMrEvU+59B7/lVr4OqzeKNTmu2Ml29mh3H03nIA7DgcViWuix2wZslmJyzHkk+571p+CLoaZ41s2lO2O6R7Mk+rYZP1XH41thpKNRGWIi3SZ7PRRRXsnjhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXl3i35vHd0B2toc/XL/0xXqDsEUs5CqBkknAAryYTDV/EGpapFkwTyBIT/ejQBQw9iQSPrXFjpJU7HZgV+8v2NGCAFM1ZW3WnxR7UAqZU615sEd85FO4iUJjFct4hAW2l3cJxn6ZGf0rr5V3CsPW7D7RbyIR8rqVP0NTLR3Lg9LHrIxgYxj2ornfAusLquiRxyH/AE6zAt7lT13AcN9GHI/+tXRV78ZKSTR4couLcWFFFFUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUGgApCRWXrmvafosam+nAlf/VwIN0kh/wBlev49B3Irz3WdT1DxIxS8H2bT+1lG+d49ZWH3v90fL65rCtiIUlrub0cPOrtsdJ4i8ZIplsfD5S5vPuNc9YYD7n+Nh/dH4kVz+i6UsMa7izN1LtyWJ5JPuTk1LYWKKigBVVRgADAFayAIuB0FeXVrSrO72PRp0o0VaO4xidhC/eHSs29kuDEU8kL6mtC9ZkTzYxnb1FU5LyN4d2R0rFmiMuKJslcZpl9paTWx3BlbghlOCpByCD2IODW1p8G6PzXGA33RTrjb0HIo8yubWxJ4c8cNAY7LxMQjcKl+q4jf/roP4D7/AHT7dK79WDKGUhlIyCOc15Pc20chI45pdE1LUfDUgS2U3Omk5azZsbPUxE/d/wB08Htiu+hjfs1PvOOvg0/ep/cesUVk6P4h0vVwVsrtDOPvQSfJKn1Q8/j0rWr0U09Uec007MKKKKYgooooAKKKKACiiq97e2thAZr24it4h1eVwo/M0AWKoavq9jpEAlv7hYgeET7zufRVHJP0rmtU8Vz3g8rw/HsjPW9uEIGP9hDgsfc4H1rFttPPnvcSvJPdSffnlO529s9h7DArjrYyMNIas66WElLWeiJtV1S+8QFopka00tuPsoIMkw/6aEdB/sj8SelWLaBIkAVQMdgOlSJAIwOKecV5s5TqO8juiowXLEevSl3AA1GDUMkmG56VKlYdrk5FQzRhgQakU5ApetJ6jWhi+Vcaffi/0xxFeKNp3fclTOdjj09D1Fdjo3i2wv3SC6DWF8f+WNwcBj/sP91vw59hWJLEGGKo3FksiMjoroeqsMg/hW1HEzo6LVGdWhCtq9Gel0V5np8+p6Jj+zJw9sOtncEtH/wFuqfhke1dbpHinT7+RLeZ/sV+w/497ggFj/sN0f8AD8hXp0sTCrtozz6uHnT13Rv0UUV0GAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVz3jDxCNFtUitgsup3ORbxtyBjq7f7I/U4HeplJRV2VGLk+VFvxBr9joUCPeOzTSZENvEN0kp9FH9TgDua4hpNU1+Q3Go3tzaQt9y1tZjGkY9Cy4Ln1Ocegqnp9hJcXT3l5K9zdygCSeT7zewHRV9FHFdFDCY0xjivLq4qVR2joj0qeHjSWurMIeF44Hkl0+fbJJ98yDeWPuxO79arvaanbMd1qsg/vQvn9DiulK4ORkGgl/72frXK9dzdSaOdimugcG3mU+6kVciupsYeN8e4rUy/oKAW7gUrFcxVsndiysreX23VF/ZMX2nzN58vOfLrTxUatliKZN+xXvWmChYUJX27Vnst4RhYTj0rcppz2pMalY59YL9m4tGJ9SwAq2mn38w/e+RCPqXP8AStX5+zYp6Bu5JNNJCcmZDeHtPf5r2JLuQDAeVQcfQdqLG9uvDdxusBLdacfv2TyElf8AaiLHg/7PQ+x67XkbuTUFxaqwwwrSM5wd4kNRnpLU6rR9Ws9YtBcWEwkTOGUjDRt/dZTyp9jV6vKrmxktbs3ljNJa3YGBPF1I9GHRh7H8MV2HhLxKNW3Wd8iQapEu5kU/JKvTeme3qOoPXsT6VDFKro9GcFbDOn7y1R0tFFFdRzBRRXGeOdYl89NG0+YxyOvmXcqHDRxngKD2ZsHnqACepBqKlRU4uUi6cHUkook1jxc32uWz0SBLh4yUlupWxDG3dQBy7DuBgDoTnisGKx824N3eu93eHrPNgkeyjog9hinWFmscUcUKLHEg2qqjAArXjiVF5rx6ledZ67HqwpQorTcrJCM5PWrUahR0prMAeKTcayVkU7sW5O1dw6d6qNKO1XJ03QmsMyYlKMelNsIK5eWX5qZK2XGKhVs8io/NJnUe9QzRI1Y1OAKDhScmpOwqtdkgcd6q1iNyZRu5FA5yDUsKZiX6UwjaTmm0SmNMO4VTvNPguYWjuIkkQ9VdcitOMjFOZAVzS5R8zRQ0bXLrQFFtqBmvNLB+Sbl5rdfRh1dR69R79a7q1uIbu3juLWVJoJBuR0OQw9jXDXUeVNZ+jaq3h7VEJIXS7mQLcJ2jdjgSj05wG+ue1duHxbTUJnNXwyknOG56dRRRXpnnBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFePPctq2vXuoSEkzSmOIf3YkJVAPry31avV9Vufsel3lz/wA8YXk/JSf6V5F4ajPl2gbqI1z9cCvPx8rJRO/AR1lI7KziCKOOAKneQYwKiDYXFMJ55rhvZWOm13ccSKSiipKCiihRk0AB+7VMvtkrRlXCVh3Mu2cCiWg4amqvIBp1RxHMYqSgQg4pwakpOtAWJhMRT3cMtVypxmkz71XMyeVDJ0DqRiuYvvtFncx3dkB9rtX86HP8RHVPowyv411VY+rR7XBFRdxfMjSFn7rPRdMvYdS062vbVt0FxGsiE+hGfzqzXH/DOf8A4lN5Yk/8ed06oPRHAkH/AKER+FdhXvU5c8VLueNUjyScSnrGoQ6Tpd1f3OfKgjLkDqfQD3JwPxrzPSIppWkub3BvLhzNOR/fPYewGFHsK6b4j3f7nTtNXn7VMZZP9yPDf+hlKzLBMJXm4+peSgj0MFDlg59zQgQKtLIeKUMFWoWbua5L2RvuwpyDJptPi60luD2J8ZiNchqDlNSZR3rsekZrjdU51Q+wp1OhVHdl21bKU0HN0n1pbX7tNi5u1+tSadzffgLVS+PyA+hq5KOFqlqCkwEjtVyMYmla8wKfamTDrTdKk32q/SppxxWj1iZ7SsVUYqcVYRs1WfrTkfBFZJmjVx9wvy1z2q26SpJFKMxyKUYeoIwa6KU7hWRfpkGpn3LpdjsPBl3Je+GbB5233CJ5MrerodpP4kZ/GtuuK+Gk2F1izP8AyyuVmX2EiA/+hK1drXvUZc8FI8atHkm4hRRRWhmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGJ44fy/B2tMOv2OUfmpFcBoq7ZgPSut+Jd6IvD/9nof3+pOLdfZOrt+Cgj6kVz2mxAS9K8rHtOaR6eCVqbZrsdqk4JwM4HU1xt3fZ1OOU4UPcRsI5ZWiaM7Rwwyfmwfu9Dx35rsicLXnevs8E+FubpZIT5g85VchAxDSA4weGyAeyjiuJno4bq/6t12PQbaVZ7eOVN2x1DDcpU4PqDyKlrD8O30DWUkbNFCI8ygNId3lkk72Dcrk7vbitIX1uZRGHJfzfJwEb7+3djp0x36e9NPQynSlGTST0LNTQrk1DBJHMC0To4DFSVIOCDgj6g1aQYq4owldaDrhf3dcrff8fQxXSXkoWM5rl5yXuc0qj1Loo3bU5hWpqq2JzCM1ZFIHuLgmpIoyTk0yS4ht4HlndI40G5nc4Cj1J7UyXU4YhNuWX91tyVjLbs9NuPve+OlUrdSeWcvhRanwqVxN3qgl1WORJWtFlRY0kZSXXLDh4yPlOSBz2Pat/W7xRYTCGRTLITDHsmCEvzwG5wwwe3auOsbvz9YnmSUnC4Oy3YTPHjkeu8EpyfyqJyuzswtK0eZr+t+z/HT9O7t5fOiEnlyR5JG2RdrDBx0/D8qp6quUBq5bp5cEUYd3CKF3O25mwOpPc+9UtUOQAKHsc6tzaFz4efJq+rDs8MD49wZB/QV3dcH4MDwa+SR+7ntimf8AaVgR+jN+Vd5XsYR3pI8rFL96zzrxoxk8aRoT8sNguB6F5Gz/AOixUtqMLUXi/B8atjtYRA/9/JMVPbj5K8zFfxpHoUP4MSRjgZrAvdUnEpaCNdqeYpim/dtIwxtKseAp55PtW9J9w15tceempQosT78lFS6m82MEscbuSc5IPsMDtXOztw0Iu7l/X4no1u4kiVgQfXBzg+lWIutY2g3EUiyJHJb7HZnijjQo2AcOWB6/PnnHetqEc5q4amFaHI2mTTttiNcXOfNv5H98V0+rTiO1c55xgVg2NuW+dh15oqO7FSVlcsWy/L+FMg4vF+taEcQWM461QRcXieu6kUnudDOPkWq0y74yPUVcmH7tar1pLcwi9Cno0pSR4mPQ8VsS8rmufnzBfLKPunrW3HIHiBHenB6WCotblaTgmsz+0n34+xzqBOYiX2rlQM715+Ze3r7Vd1FoktpjcY8kI3mZ6bcc/pXAayfLmtooICTKmA8LeWJIguE2/MSuA4GeORWUtzsoQjKLcv6/Ff15XPQrW4FzbRyqsiK6hgsi7WH1B6GoLsZFVvD8xnsd4mimiLERtHn7o4wSTycg5NW7nrSbujOUeSbQ/wCH+V8Saso6NawMfqHlFd/XAeDCsfi65QnBlsQQPXbIc/8AoY/Ou/r2sI70UeRi/wCKwooorpOYKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPL/ABlcNe+M3jP+rsoVhXn+J8O5/LYPwrRtYQArd8VzOnznUNRu71jn7Tcyyj/d3EL/AOOha7G0jyo+leFUl7So2e1FezpxRHJ9w1xPiKCRbpiC7o2ZcvLhEIXATA5Knkkc813U67Sa5HXII7m4TeBuQ7kbHKNgjcPfmspo6MLNRld7HO+HdREVzNYeYGicjZNJ84kT5T5YVhjAU4x+IHWumiZ5yHG+N2RnMasHCkHhd3HJzxxj8q5DR9OW4E00ziVpm3ByuGIySCSO/OeMYro7KzuBkF5HI6Ejn8+9Jms2tt1/wP6+77+o03MUI3sqqwVhHtAZWIy24g4Y57/zq812qrXOwQXnQHgetXYrecj5+tWpNHLOKbux15dl+OxqosW/JUVoLZL1c5pn2y2gl8rIGODS33BO2iEsnKHaRWhnjNNCKeQBzS44xQS3chvI2nt2jjmETNj5igfjPIweORkfjWFPYzRmSQOBtlARDJjcnHzZxwcE8e3vWzPAx+6xFZWoQERsXkI4pM0hKysY2u6pFDbHT7WWKaa5nZPkcQsjN8w+76cZPBI9c0mg282+FJ/tSgH7RyAnz8hg+Cd2SS2Og49K5zWIUtrhrpUuA8bK5kIBEmPm5PUY2+w5rsNFgW3jQiJI2I2/I5cbATt5Psf1pM7G+WLb3f67/wBJeXe/U2+fLFRzw7z71YtRuVfpV2G1LyjjitYwctjzZTUSTw7alHEmPuniulqrYwCKMAVZb7pr2aMOSCR5dWfPK5xeq6e8mpXF2/LTMMeygYUfzP406O32R89a6ie3WReRyKy7uDbkdK4a9D3nI66Va8VHsYF38qsK8v152jvLh4kCFHErCJ1yw4O9x1B+XAxXp+qAoprzXW4UkuJXdA0eMOoQZPPDZ9F5rz5aM9bCtWafVHX+HWug4Qo7xBVBeWUOFUbh8rAbmY4UkNjGeDXQ+ZsFcR8Pi00FtKFgRlhAkXyGV/mAyN2cE71JPHp0rt+tCutCMU1Kaa6pGZeh7pwuDsz+dWooNigCpwgBzTxTRi3pYiKbY6zBxeIf9qtWY/Iay8Yuk/3qbCJ0E3+rFVWHFWnOY1+lV2HNXPcyiVJ4xKm0/hRAzxLtPNTkd6GAAqLmhla3O6WpZHlRtyjMUfmN94dvT1PYc1w2trJPq+3HmMBvBaXzFjLSEhh04GwHb+FdjrcqoisXmQB1/wBUCSTngEAHj19q8+UM15PI8SRt5uxXteRGc7eFx04JyfWofU78NF8qt3/r8bd/8/RvDj+bDJKru8b7djbwY3AUfMgHQE5znuK0513VU0bBgQAADHQVsSxjYCBVKN0cdWa57nPS3DabqtlqKdbaTEg/vRN8rj8BhvqteqV5dq0KyI6OPkcFW+h4Ndp4IvXv/C1hLM26dEMEp9XQlCfxK5/GvRwE9HBnBjobTRu0UUV6J54UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVW1SUwabdzDrHC7j8FJqzWf4iONA1M+lrL/6AaT2Gtzyfwuuyxs1PUQpn/vkV3VoPkFcToQ2w2q/9Mk/9BFdvanEY+leDT3ParbFa/farGuI164aOwvJVPzhCq/7x4H6kV12rviJq43VLG41GNbW0JEwWS8OBnIhG4L+LFR+NKznOyKi1GDkyDTImt4IlTkR4H4Cuv0yZHQcc965rTm3wrNDyjAMPcHmuo0wRyRh1AB71C3NKmxoDGKWkFKBmrMCOYkRnB5xxWbHaKikEBi3LZ71qTIdvNVouZ8H0pMqL0JbVdsSpnO0YqWnxoM5pGHNOxN9RjnCnFYmohnzuOBW2RmsPWNzPsThe5pMuG5y+pKJVdDypGD9Ku+HLjzdHsyTuaNfKY+6Haf5VT1N1htpX/uqW+uBW/pnhibSrldPCnaYIbg/77LiT/wAeUn/gVONNyi2i5zjGSTOn0dGlRMV09vBsUcc1U0ey+zQKCORWqor1MNR5Vdnk4irzS0HIMCg0opD1rsOUaenNVriLzF4HNWSMikUY4qJK+jKTtqcrq9qdrZXtXnupaTJcyi2iHz3LrAP+BsFP6E17PPbrIpDDOayE0GI6pa3H8MDmXHqcED+efwrilhLyTO2ni+WLRx6RCx8Q6vaABUjui6AdAsiq/wDMt+Va3aqvi6E2/jFpVGFubNGP+8jsD+jrU8J3Rg1xV48tWSOqk+anFklAoorIoZP93NZq83SfWrl1JgYFUYT/AKVH9aOpa2N6Q4UVG3NOuDjbTAcitJbmMdhtRTttWpTVa8O1M1maLUx9TuPs1vcXAG4xoSo9W7D8TgVxY03+zrqaylJM9nMyMwONzDucdRhu9d1Zwf2hrulWR5V7jz5P9yL5/wBW2D8azfiLZfYvGs8gGI72JLgcfxD5GH/jqH8a1VK9Fz8yoVuWsoJ9DU8OvugQH0rpmG6KuN8Oy4YLXZRMDEc1NLaxFdWdzD1NeDWp8NJsR6vaH/llciUfR0U/+hBqo6kuUNL8P38vxNqUXaW0if8AFXcf+zCtsG7VrGeJXNRueg0UUV7J5AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVheOboWnhHVn/jeBoUHq7/ACKPzYVuk4GTXDfES5FxeaXpqsMKxvJV74XhPzYk/wDAKyrT5IORpRhzzSObtY/JljTsoC/lXTpJtjGDxisCUCNwx6Yq1Ddq0YUOD+NeEnY9uS5h2pMWQ5q78PbPzdU1O9cZSNEtI/8A0N/5p+VZl2SyZOcV0vw0RR4Y8wf6yW6uGk+vmsP5AV1YKPNVv2ObFvlpW7nAaSgs7qW1wQkE0lvj02OVH6AV1lvCsa5TGDzxWRqcAtvGurxAfI8kc4H++gB/VTW3EgRcL0rGpHlm0aqXNBPyJKliXJqEVZhHFEVqRJjbhPkrMi4uyPatmf7hrJxi7/CnNWCm7ovwjNMk+9U1v0NRTfeoa0EnqQuTjisnUwAp7mtgjNUdQiHksQOazZrF6nM2Nh/aWt6dZtgrLcKXU90T52H4hcfjXsU1ujXCTFRvClM+3WvNfAUIl8ahm58izkdfqzov8gfzr1I9K9TBQSpX7nBjpt1LdhoUClpCTSDJrsOMcKU0CkNMQlIOtOA4pcUrDuNNCDGaKcBgUCOI+IwMd9ocwxtZ5oD+KBh/6LqtaHMIq/8AE0f8S3Sj3GoJj/viQH9Kz7I5iFeRjVarfyPVwrvS+ZYqOR9oqTpUbcmuU3KUmWJJ6VBD/wAfkQ/2q0JV+Qms2E/6Yn+9S6lrY37votV0bsasz/MoqoQQa0nuZQ2Jao6k2ExVtT2NUdTbgCs2XHcu+A7bzfEF9dt0t7ZIF9i7Fm/RUqf4rab9p0KHUEXMthKGJ/6ZthXH8m/4DU3w1UtZ6tOf+Wl8yj6IiL/MGum1SzXUNMu7NzhbiF4ifTcCP617NKmnQUH1R5lWo413NdGeP6MSki+orsYJcxCvP9DuXSOJpuHA2SD/AGhwf1BrtbCQPGCpyK8ZXi7HrVUpK5LeDdEag8GfL4zA/vWEn6SR/wCNWZhmMiqWgSC08YadK2Ak0ctqSexba6/+iyPxrfDu1aLZhWV6Mkj0qiiivcPGCiiigAooooAKKKKACiiigAooooAKKKKAEYZGK8oWc6z4j1G/BzE8vkxf9coyVGPqdzf8Cr0TxRfHTfD2pXinDw27sv8AvY4/XFcF4WtPstlHH/cRU/IV5+OnooHfgo7zNP7KjEbgCPSoDpNpvDKhU5zgMcVqhPkzVeRtikntXntWOtSb2MjWruG0tpXfOyNc4AyT7D3PSuz8F6bNpXh22gugBdOXnmUHIV3YsV/DOPwrhLRP7U8VaVbFd0YufPk9MRqWGf8AgWyvVxXoYCGjmcmNnqoHmHiudY/H86lH2tawAyADYhzJgMe2cjFaFpe2txHEYJ438yPzUGcEpnG7B5xnvXOeKlWf4k35b5mi+zqB5RfAwhyc/KBnOTjI6ipi5uYto8x4/JKNHv8AO3Nh9y8gE/Nx85CsAMVxV5fvZHq0MNGVCD8v8/6+86arMP3a5NQxnmRWVpHhaJtpEjbEbnG1wVDfMqqOVbvV23a43ho3nQ5SMny2Vjg7kBDZUJtJVnxnNTGWpM8Lp8R0MjfKRWeV/wBIz7Vj298wjt5C8htB5bDZKSGJVy212O6YZGNuAeBVeHXC1wg85ZbjygAr/uYnLNnkYLKyr74JP5DnzC+qyg3r/X9b/wCWp1kLACopm+asY3cjRFYp2dSfNR2ZIpTmXAj2MOmON3U/XmoLu7fE8YmwDJIULF3DYdVX54x8gDHBU5OM570nPSwRwsm/6/I2pJo4Yy80iRoMZZ2AAycDk+9UNRvohG6oskrK7RNtQ4Vgu75j0A9+nIrOd2MmZHInbA3uEDBS7hWfnY8YJBVR83TPNU75zLD5lwC3lvghm3FWDKRFIpLYYuc5XIUYFQ5G9PCxvq7/ANf16l34a3nm+NJMhQslixXaSQRujbr0P3j0yK9ZrxvwC7Hxzp7b3kDQTqHySuABwT/eyDkgDjFeyV7GBd6SPGzOKjiGl5CGgUpoFdRwBRRRTAKKKKAAUUUUAcH8Ubh1k0KBCAGuXlOULZ2oVxx0zv6ngGsuw1OBYGN0Da7V34mZcnC7mAAJ5Udak+JTPdeJ7SxUOQLF2yeYhvbBEgBBIIU8eoqrpdjdLDuUx27lXZCQrFHYgDKgAMAoABznsa8TGSbrPyPoMHTprDJyerv/AF+HZm0CrgFWBBAI+h6UBeaqwadFDK0geQsShB3YOFGApbqw5JwxPWryDLCsETNRT913GzJ+6JrHhH+mJ9a3LgfuiKxlGLtPrTkrCg9DekH7sVXIzVhzlB9KhHHNVLVmcSpPd2tu5WeeONhG0xDNg7F+830GaxdVvS7oEUJHI3ySu3yum0EupGcdQAGxmtf+zoAqpEZYIVVh5cL7FO5txPHOc+/c+tYmq6bMYGXbamSfzHnYJiJ342FozktgAfxDp+WUrndQVG+r+/8Ar/Pt5rqPhO0g0W+gnEwkS7Zj523edyK2Tt4yST0ruK83+F0ph1zWrMxNGrJFcAl928lnDMOTgHjj2r0ivdwsualFnhY2KVedu/56nhV1EV1jVYV4KX04H4yEj9CKTSdSvrUyLZwJcJMpnhjd9jsRwwUEdOnX1rR8Z2Kx+MNWt5FIiuRHcAAkZDLtPI5+8h/OodOhS4ieKSOKRZxJHdRpGzRiXaDlpDyq4AHA5zXjVotVZLzPcwqhOipS/r+v63utlNTmVpftCxIF2EpKfKKpjMjhjw4UEdBx0JqnerNdQs8BjiuopBLbssgcBlO6NjjpnA49DVyJCCCA8heKOcNbKX+ZmAYRyOcbCAPlAHygnvSGDZFNK0brLJK5dnjVGbBIXO3qAoABPOMZqNVqipxhy7f1/keiaFqUer6PaX8I2rPGHKnqh7qfcHI/Cr9cX8OJyg1OxJ+SOUXEY9FkB3D/AL7Vj+NdpXv0p+0gpdz5urD2c3EKKKK0MwooooAKKKKACiiigAooooAKKKKAOV+I8gHhuWE/8tpYovzkUn9Aay9Ijxbr781N8SXLJpNuP+Wt6GP0SNz/ADxU2mx7YkHoK8rFe9Vselh/dpFmQbY6x9Tk2QPz2rWuWrmNanHzBmwo6n0Fc1Rm9JXLfw4habxDfXGP3dtbrFn/AG3bcf0Rfzr0euX+HNi1r4ajuJVKzX7m7YHqA2Ng/BAtdRXsYeHJTSPMxE+eo2eVeJ41/wCEy1aKZQ0cvkuVYZDKYwvT/gJrTNrDdRo0qhk2bTGQCjYIKkjHJUjj0qL4mxJZaxpeoE4W6/0N/Zhl0P8A6GPxFLpkx2bW6dq8rEx5arv1PUw9RulFxew1tNlcqHuQ2VVmlMYLiVSMOgPyrnnPHU5pF0x1ZNkNohZlXhFK26oWZCgK5YkkZBPBJI99IMD0p26skkbfWKn9f1/XpcyI9Nn+1W8rxOM5VgzLI6gFyN0h5ZTuGAACvr1qpDoLwIH+zSPcRRxSJ5UygFl4MQdhuIOMkt1zjNdQsoPFO3jFVyIHipvdL+v6t3sYkmnzQrHEiZRRLtMIVfkx+7jZmy2cnIYdCM8VC1rOJY3KABPJI82dn5AO84GBv5+9yG71tTygCs64m4qZJDjXm9ynFbCPBMmMSBgsa7UKLnahXkYGeoxkgUTQwRpGUXLxoUV2JZgpOSNx560pbJptyMRFj0AyTUDc5Pdk3gWAz+MGkAylraMxPo0jAL+iNXplec/CqSVdT1yO6CrNN5Nwi91TDKFz3xtz9WNejV7WESVJWPGxbbqu4UUUV0nMFFFFABRRRQAUUUUAeaeMm2eOZC/ANhDt/wC/kuams3MgBX7g71B4zkF74zaNANtpbJGx7lmJYj8Bt/OrtqmyFRXh4n+NKx7VHSjG5NTk+8KbSp1rFDY+XlTWTtxcj61qyfdrN2nzxTkOJqBsxj6UwdKap+UUZp3JsIwyOKy79igIbpWrVO/iEi1DNIvUi8BHPjW5K9P7PGf+/gx/WvSq858AbLfxbfQsvzzWSNG3oEkbcP8Ax9a9Gr2cH/BR5eM/jM87+KNkU1HStRQfKyvayH/x9P8A0F/zrK0hI3mhlcEyRAqp3HABxnjoeneuz+I1k154TvHjBM1pi7jA7mM7iPxXcPxrhNJlGVZTlWAIPqK48bHlq83c7cHNuk0un6nVW9lAdpkUzFZTNH5p3eU2MfJ/dAGcAepqLUo8xMKsWUm5RTr1cqawkrxK53zasxPCs5tPGVkCfkuoZbc/7wxIv6K/516bXkVzJ9k1TTbnOPIvYWJ9mbYf0c167XoYCV6duxx46Nql+6Ciiiu04gooooAKKKKACiiigAooooAKKKKAPP8Ax8wfxLo9uD/q4ZpiPclFH/s1admMRD6VheIpftXj26x921ght/8AgR3Of0Za24Dha8itK9ZnqU42pRQy7fapJrkLuH+1NQttPG4/bJhC23qE6uf++Q1dDrEwWMjPJpvw5sftWq3urSDMUANpbn1bIMjfoq/gazpQ9pVSNJz9lScj0FFVEVEAVVGAB2FKeBRSN0r2zxzgviMyz6zpFq4BVYZ5SPc7FH82rNtonhGMkgdDUviqT7V44nx921t4of8AgRLOf0K1oRoDGARXi4l81VnsYf3aUSENwCDzQJT3ps8TIdy9KpvLg8mufY2SuaSy0rTccGswTj1oacY60cwchZmlJB5qo7ZPWo3mz3pI1aRsLmk3cpKxYiXJq3KgMOMCkt7cgDNTXAwhFNIlvUoeEZfs/ja3Ha5tpYT9VKuP0DV6bXkcFx9h8RaXcdAt2iMfQPmP/wBmFeuV62Blenbsebjo2qX7oKKKK7DjCiiigAooooAKKKz/ABBef2foOo3mcGC3kkH1Ckih6AtTzaxk+36jf33UXN1I6n/YDbV/8dUV0CjgAVg+GYPs9hawnqkSqfriukiTNfPN88nLue5L3Uo9hgSgoatCOl8vNachnzFI5qpg7/etRkA61CYlLZxUOJSkRxrkCnlMVPHF7VJ5XFUoMlyRTKVWuRxWk6YFUbsYGamSsXB3ZmaW/wBl8W6NPnAeSS2b6OhI/wDHkWvT68i1GcW1zY3DfdhvbeQ/TzFB/QmvXa9LASvTa8zhx0bTT8hrosiMjgMjDBB7ivG4rF9I1K60yTP+hybIyf4ojzGf++SAfdTXs1cD8SrNre80/V0z5X/HpcewY5jb/vrI/wCB1eMp89O63RODqclSz2Yac2AtaNwMx1iaXMGVeea2HcFK81PQ7ZL3jjvFaldPvGX7yxNIv1X5h+or123lWeCOVPuyKGH0IzXmevQ+ZE6kcOpU/iMV2/gyf7T4S0aXOSbSIH6hQD+orry96yiYY5XUWbNFFFekecFFFFABRRRQAUUUUAFFFFABTXdY0Z3YKijJJ6AUpIUEkgAckmvPvFGuzeIYZ9K0E4sZAY7i/wA8MvQrH656FunXGetZ1KkaavI0p03Udkczpl/NcXV1qTRLi7leZTI21Ml1CguCcDaVUDGcqa6b+1I0aUNFMqxI7y5X5kCnAOwfMQ2DggHOKzrHQRZtG63HzqRgqipxwSowPukjJHrVK9srrT7aFLcK4Q7VZUCCLDFkY4OWC9NucHOa8Jyd3Jn0ajQlaK6f1+H5kviO8ZYmaFS8pwsSd3djhR+JIFeleHdMTR9Es7BMHyYwHYfxOeWb8SSfxrzLwFp0Oq+LPtBj/cacvm/MhB3lmCAknJAIkcfVa9er08DTtFzfU8jMJJT9nF6IKQ9OenelrH8YXZsfC+q3CHEi27hD/tEYX9SK7W7K5wJXdjzzT5De31zek7jd3Dzg/wCyThB+Cha6QD5QBWLoVusEUcaj5Y1CD6AYrbrwG+Zts9tq1kuhCz4O1+lVLmy8z5ozVy4i3odpw3rWVHftDdGCZWyBu34+U89M+tS/McU3sQy20qdqhEcpbG2t5ZUlUHg0fIOiiiw+ZmbBZMxBfpV9FjhHYmqt5qMcWEDoZGUsi7vvY/8A1imaZ51yoknXaSAdoOce2e9A2na7NZG3KDUdwMrUwGAAKZKMoaoz6nKeIYXa1n8r/WhS6f7y/Mv6gV65pt2l/p1reRf6u4iWVfowBH8680vlyQfQ11vw4k3eE7aEnLWsktt9AkjBf/HcV24CWsonNjo3jGR01FFFemeaFFFFABRRRQAVzHxIkC+ELuInBneOEe+6RQf0zXT1w3xTnxbaPajrLdmU/RI2P8ytZVpctOT8jWhHmqRXmZWknOPpXQW4yBXP6J/q8mtyB8V4dM9eruX1UGnMoAqJZB60ksw29a6rpI5bO5TvZNmSKpWV4JZWUHO04PsaXUJPkasPQLjddXmf4bll/JVrlctTqjH3TtIeasFQRVKGQFRirAk4rqi1Y5ZJ3GyLxWbfDCmtGSQYrLvmyprKo0a0k7nJeKSf7LvcdViMg+q/N/SvZYZBLCki/ddQw+hrx7V085J4v78TJ+YIr07whMbjwpo0zHLPZwsT77BmunLn8SMswXws1qo67psWsaPeafPwlxGU3d1PZh7g4P4Veor03qeatDyHw5LMoEd2u25jJjlHo6nB/UV1PVRWXqNmNP8AG17E3yxXoF3CexOArj/voA/8CrUhGcA14c4cknE9hT54qRR1SPfBnuK3vh2w/wCETtYgeYXliPtiRv6YrOu4d0ZFReCdRi028u9MvGEYuJzNbu33WJADJnscjI9c+1bYSSjUs+pliU50tOh3dFFFeseYFFFFABRRRQAUUUUAFBOKK5TxzqcirBo1lIyXd6GLyIcGKEfeYehOQo+pPaonNQi5MqEHOSijM8S6l/wkd22l2LsdLhYi7kXpO4P+qB7qP4vU8etW7e2SGEAKEQDgCqFubXR7WKFAkcYwiqOPoKpanrg5ji5PYCvHqVfaS5pHrU6XKuWJJdXubxY0ORnFaEq74CCO1YukWUjym6uvlH8IPb3rZd8xnaMLjr61ijWVloin8P5BbeLb62HAubUSfjG+P5SfpXpFeceBoDL4zu5hyltabSf9qRxj9Iz+dej17GDv7JXPLxdvauwVyvxJkx4fhg/5+LuCM/QOHP6JXVVxXxLk+XRYezXTSH/gMT//ABVaV3anJ+RnQV6kUZ+nqAi471phSelZemNlRW1F0rxYK56tR2ZXdccVzPiS3EltKnQsCATXWTr3rA19P3BYUpKxVJ6mJpmok6VbzyM0ce5SxWIAKuB8gBPzDORkc1fvLzYITuaNHYMhK581CB/3zyw688dK42KRk0UMilSrCTBXceCcsrZ4zgDC4PGe+a1taBWzgIjkCmSIsoR8t8i/M5PVjnGGLfdHOajqeh7JNXfa/wDX9fjqPMnmazFb/cWOPJhAAER+UbQQOfr712tmAIlAFcDaZOuxjBUCEKFzwuNvAXquPQ813enkkjNNdDlrq0mXgnGahkHBq6B8tVJR1rSSsjli7sx7vvW98NnH2PV4/wC5fFv++o42/qa5/UDtBrX+Gbk3Gurxjz4m/OJR/StsE/3pOMX7q53NFFFeweSFFFFABRRRQAV5r8T5N/iLSYs8RWs8hH+80YH8jXpVeWfEP5/GTH/nnp8Q/wC+pJD/AOyiuXGO1FnVg1esiTRW/dCtYVzumylFXmtxJQVBzXjI9Wa1LAdvWkZz3NQtKAKpXupQwJJvliV1jMm13C8DjOT0GcDPvTuTGm5OyQ3VZ0iQ7nRSchdxxk4zj9K5Pwvqe+5uPOaFVmnYoV3fO5ySFJGCMLnPX1xVy/uneTfMpR2AISRgyIwiYnY44jIzy7cHtWPo7yeVII57llklcfJKHJPmOvIxlR0JkHoKi56UMPFRtLdrv/Vz0i2nyo5qyJjiuO03VkSOJZJIjGYoyjpL5rOSdp4AzgNxu7+1dBHcetVGZw1sPKm7SRfaQmq1zylHnrVe6nGw8027majqY1zj7Wo969B8APv8F6MfS2Rfy4/pXnTNuu1/3q9C+Hhz4N0z/cYf+PtXblz96Rz5gvdidFRRRXqnlHIfEyEf2TZXg4ltbyIq3fDnYR/49+gqrp0vmorVpfElN3hK4b+5NA/5TJWNo/EK15eM0qr0PRwutJ+pqOuRWffadHdRMrKDkYII4NaLHpUE8mxGYHpzXPJI1i2tirpOu3WhyLBq0jS6b0E7nLwf7x/iT3PI75HTu1YMoZSCpGQR3rgUvLO+Mtt5iNKmA8Z6gkZH6U/w7qTaBeQaVcM76XM/l28p/wCXdz0jPqhPAPY8dMY7MNiPsSZz4nD295Kz7HeUUUV6BwhRRRQAUUUUAIeBXlLXn2691fWWl2LI5gtn9IoyQCPYnc3/AAKvVmAZSD0IxXD2fw8t45Y47zUZ7rTYvuWrRhdwHRXYfeHsAM981y4mlOqlGJ04apCm25HFz2c9zJoWpahM7G6864ihxtVI1wqHHcsH3ZPTIA756W3tIVXeBGvckrk1X8WrFrWuX7JOIV0oJbW7ofuSEbpOO4IKKR/s+1ZGmaleR2Ed1dWchtmBdJUG9WXJw2OoyBnkd+tebXioztHZHo0ZOUE3uzqVQvgopb0Zzx+Apt4zQwOzSZOOABisg+LNPWHfJOsXAP71SnB6dQKoXOoS6zcW1jYGQveSiBJghCR5BJbJ6kKCcDPNZqLbsittXsdv8NLcf2Vd3+3m8uG2t/eRPkH4ZVj+NdfVfT7SGwsbe0tV2QQRrGi+gAwKsV7tOHJFR7HjVJ88nLuFcD8S2/0/RB2zOf8Ax1R/Wu+rgPidkahoJ7f6QP8Ax1f8KyxX8KRrhf4sSto/3RW9EmVrA0s4RcV0luMxivKoq56NbQZMvy1z+uD/AEdh7V0k4+Sue1cb0K06qsKi7s8wgUHRJI2+Ul/9kKSQR0Oct6kY4x71qa0i/wBnWisgVQU2k+VyPLjHZsdPQAcenJzNSi/s25uFlULBISyspZc5ySGIBHUDtnHT0oe9MgjSadmMY4yzZbbk5ODnIBHIzwQO2Kwfc9ulJuKt2t/maelSiXWYyqgKsPVcbTyo4/Lk9D2yK9A0wZwa898Nxs9zNdumDIcBv7wBPOc8+mfQV6NpK5Vc1UVqkcGKacm0ayp8tUZxhjWoPu1nXnBJreotDz6b1Oe1XgGtb4ZD/TNdb/agH/kP/wCvWNqrc10HwxXMWsy/3rtU/wC+Yo/8aeC/immM0ona0UUV7J44UUUUAFFFFABXlXjlg3i7UPVLa2X9ZD/WvVa8q8agf8Jbqfr5Nv8A+z1yY7+EzswP8ZGXDP5ar6VYbWrWJT++BcEKUXlhk46dcc9fSqkCkmp59FS6TcoKMzBmKfKWx2J7jtXiHtrlv7xXv9bys4SWNYvLcBm3oQynDksBwMcg9z0qld3qIZ1ln8yFo/kQ7ZWePCgMM4AO45IbOcZol8KzZiES27FNwVpF4QY+XK/x4PckVVi0OSOSCGKHyZ3LGEthnReN7SKSAcE4GCcZFJndT9ml7jX9f8N67vsJc6kNt3Dp8sk0zFQcQoyS7QNznA+bcOCOvHAFYekPLaW+GG+GSWSQA4DsVdieMZC5AJXIPHHcVtz2ixQOFgBQrKI1Nu6ZLSYALcuvPXAwQc1m6KEm83G3JuWRwh2MGDSEcn/WDts/Omn7rHye8nfv0ttZf1f0Wr01IdTjkJW3uQWlXKqJim8nax+YjcijnA6HNXV1CWB7h4pY3RJJZJShyowgKqSSSD0Pygj2qs2mPMY45oxIzwghCDunRRlhtyFRgxHf2qaPw2/m+ZKIy3y4JjU7l5JBXGAecZHYUhSlFL3mv8/z/wA0/Sy1ItViZMySpGQFzubAOQD8pPUc9aeLvzhlSxX+8VIB/OqdvokUDIyQruR2dWI5Unrg/jirjR7UORzTOGSjf3SOLm6T616P8P12eDdKH/TLP5kmvNoOLgE/w816Z4EGPBmiZ6m0jb81Br0Mu+KR52Y/DE3aKKK9Y8k5j4kOB4Ruk/iklhjUepMqVk6fGUiA79am8bXC3+t2GlKyiK1H224JOAOoQH/x5vwFZ+k69Z3mqvbQbvMCZQvgB8ZBCjvjGc9Oa8vFyUqlux6eFpy9k2l5muW4JJ4HemyrmE8ZB4NUtN1OyvJLi0t50mZQNxUgg5J+6e+Mc1z9j4luP7W23SqLG4uTboxZWEbhR8ilAdxJKk5xjJ9DXNdHTGhN3W1vx/rX/h7IseFfC1nregXjwOlrq9tdOkd1BI0gTCjA56jBI9RzVgTm4hn07WIxFdROYJcNnaOoYHjrwQfcVd8J3J07xxf2ErkpfxiWLJX7y5OAByBjdyeu2uu1jQdO1d1e+gLSqNokjdo3x6ZUgkexrshQVampR0aOavXlTqtT1T1Xz1G+Frua70aE3bh7qItDK4/jZTjd+IwfxrWqvYWdvp9pHa2cSxQRjCovbv8Aic85qxXoRTS1PNk03oFFFFMQUUUUAFVNWvE07S7y9kxst4XlOf8AZBP9Kt1z/juN5fDNwqxSTJ5kTSpGpZjGJFL4A5PAPHpmpk7JscVdpHl2pvEugWMMbq2p3xELS9HM0zZfPfgs5wemK0PExmjsrXSVZGN06W0axLtJT+LqeMIG7+lQ3EVxqmt2F6IvISSZmtWliIJWNcs+Dg4LMgz/ALJpjJdXni6yuNqSvaGREUsVQkRjew4/6aRgfjXiuLvr6nsKStp6DvFzzXy22n28Ai3SRs6MekaugwcZ6lkH410uhxS3fjSw+0Kim0glm2IcgE7UBz9HasmCET6dr+q3JAjS4trXfnG1FlR5CD6ZYDP+zW98PIkn1jWr6El7dPLtInJzuIyz89/vKPwrehS9+H3mNap7kvuO7ooor1TzArgfimpFxoEg6efKh/GIn/2Wu+ri/ikgOm6VLjlL9Rn/AHo3X+orHEK9KRth3arEy9IG6NK6a3+5iuX0U/IK6e1Py15NDc9LED7kfIa5rUu9dLOcqa57UV4NOuThzm7mNJFO9QR6Guf023tZNa1FDbxfufLA+Ud1Jrop/v7ax7aEw3/nY+W7WVwfXy5jH/QVhFNps7JNXSZt2sS7lwK6jThtVRXO2ONwrpbP+GiG5FbY1lGVrM1DIzitJT8tZ96ck11VfhOOn8RzGqZLV1PwyTGhXcn/AD1vpj+RCf8AstctfNmdR712Xw5Tb4N09yMGXzJv++5Gb+tVgF+8b8isc/3aR0tFFFeseUFIDliPSlpFGCT6mgBaKKKACvLfHUfl+Mbs/wDPWygf8nlH+FepV5x8RI8eJrV8f6ywcZ/3ZFP/ALPXLjFeizqwbtWRg2q5resfugVi2Aya37GPgV40Vc9ao7FjaPSo7qFHiZHUFWBUj1Bq8IxiobkYBq3GyMVLXQ4XWbFEkzFF5gjiWGOIN5ZRdwzh/vDgDjPasbQrIwyzfMUCzq6srZJyN5G0jA+/1HNdLrbbEuX/ALkbt+SmqMcJh1C4hxgq8fH1hjP9ahR9xvzX6nb9YnzKPk/0+X9anTaXaRQWyRQRrHGMkKowBk5P6k1d+zqTRYJmNfpWhHH8tVGNzknUbbbM9rdQDxWRfRhSa6CYYzWHqI4NKSsVTldmPnbHO5/hRj+QNereFY/K8L6OmMbbOEY/4AK8l1HKaXflfveQ6j6kY/rXtNrEILaGFekaBB+AxXflq+JnJmL+FEtISFBLEADkk9qWq+oWwvbC5tWdoxPE0Rdeq7gRke/NemeYeaOW1GS4vIkaS81afFujLwExtUn2CruP41FJbf2b4lu4bPcbfT7JLSPDAB5AgbkY6kuTnPHNdv4b8Of2VMZ7mZJ5wgii2JsSNOM4BJ5OBk+2Prx2pS7P+ElukDF/tTqmM4JAC/zWvLrU3CneW7Z6lCsnUtHZL/gGVoFn9hutFu3WM3NzbyzTN5Shm+crwRgLwVzjrWjY6M2oaF4jtIiz3EF0l3DtHlknZyo24xlQy8eua2vFGmppdt4ZIAK2x+xMf7wZM/zjH51Z8FkReItZhA2q8UMijGO7g/0qo0lGtyPZr9P+AE8ROdLnT1Tv+Lf6nPNesILTXYP3qW7JKcfeaP8AiA/4CWr1KKRJY0kjYMjgMrDoQehrzu6sl0fXbrTTGfsV5me1UcDk/On4E5+jCum8CTM/hyGFySbV3thn+6jEKPwGB+FaYW8JSpswxNpxVRHQUUUV3HEFFFFABRRRQAUUUUAc94s0K41drO4sLtLa8tS4UyRl0ZXADAgEHPAIOe1UH8FL/ZFjbwajNDfWzSMbsRg+YZDmQFT2JAwM8bRXYUVm6UJNtrc0VWaSSexn6PpNtpWkw6fbqWhRSGL8mQk5Zm9SSST9auwwxwRLHBGkca9FRQAPwFPoq0kiG77hRRRTEFcv8SUDeFZZCOYZ4JPp+9UH9Ca6isHx7CZ/BusIvLLbPIPqo3f0qKivBoum7TT8zjtFbHBrqrQ5WuP0ZwZAQeG5FdZZNxXi0HqeviEWJO9c/qrYBrelbjiue1j7pqq7M6C1OelYC4BPQcmi+tjb6P4QlYYaeznY/V2ST+pqnqjmKzu5B1WFyPrtNdb45s/suheGB/z7utufoYWH81FKhG9Kb8jatK1SCMa0JDLXT2XRa5i3H3K6WyPyrWMNy62xr9I81lXz7c1psf3QrF1Bua6Kr0OWktTn9SkEcU8x6Rxs/wCQJr0nwtb/AGTw1pVuRgx2sSke4QZry7WQZbG5iX70wEI+rsF/9mr2RVCqFUYAGAK6MvWkmZ49/ChaKKK9I84KKKKACiiigArg/iVHjUdFl/vLcQ/mqt/7Ia7yuP8AiZDv03TJh1hvkz9GVk/9mFY4hXpSXkbYd2qxZx2nffrp7IfKK5ew+WYg+tdVY8oK8SkexXNDHyA1UuB1q6vMdU7rha3mtDmhucV4uIGm3gXq0TL+Yx/WrGsxCHxhq8Y6LNFj6eRH/hUHiRRJH5YzmSaJOPeRR/Wr3iVdnjrVwf4xbyfhs2/+y1nFfuZPzR0N/vYryZvWH+rH0rTjHy1naePkH0rR6JV09jCpuVJx1rC1LgVuXB4NYGpNyRWdQ1pbmVLH5xgg7z3UEX5yrn9M17PXkWmQ/aPEOhQ4zm9Eh+iRu38wK9dr0MvVqbfmceYO9RLyCiiiu84Argrfw3fnUvs1xDm0+3NdPceYCsiby6rtznOcA8djzXe0VE6ana/QuFRwvbqYXjTT5tR0J0s08y6hkSeJM43FWBI/EZH41l+ErW6fXLm/lguIYPs6wj7RHsZm3ZPBAOBjr7967Gik6Sc1Pqhqo1Bw7lLVdMtdUt1ivIywVg6MrFWRvVWHINSafZW+n2kdtaRiOFM4XJPU5JJPJJJJyas0Vdle5F3awUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUF9brdWc9u/3Zo2jP0IxU9FAHjnh5mS3tQ/3xGqt9QMH9RXZ2rHArkFU2us6hbNw0N5Ko/wB1m3r/AOOuK6m0b5VPtXgJcs2j3JvmimXGY1j6oNymtdqy9SH7tjTqEUtzjtVTzIHhHWVkiH/AnVf616D8UI8+G4ZgP9ReQP8AQFtn/s1cMo36xpceMh9QtwR7CQN/SvRviHEZvBWrhRkpD5o/4AQ3/stdWEjejPzMsXK1aBxFoMopNb9scKMVgWJ3RjHSty1PArggddQ0i5MdZGoMACa1GOI6xNRbO6tKjMqS1M2zgN1q2mRdQ17ExHqEJf8A9kr1uvMfCatN4u09F6RRTXD/AEwEH/oZ/KvTq9LARtSv3ZxY6V6luwUUUV2nEFFFFABRRRQAVzfxFGPB9/KFyYPLn+mx1Yn8ga6SqmrWa6hpd5ZP9y4heI/RlI/rUyXMmiovlkmeUqPLu2A6ZrpdNJ2DNcdp0rS2VnK/+sMSq/sw4b9Qa6zTG/dCvAho7Hu1dY3NuM5Wql592rEbcCq9592t5/Ccsdzj9QUPq+mRtyH1C2X/AMiqf6VqeNECeOz/ANNrCJvxWRwf/QhVMR+b4v8AD8fY3u8/8Bjdv6Ctn4hxhPE2hzd5YLiE/gY2H8jV043w0n5lTlbER9CfTz8g+lXy3FZ9h9xatluayg9AmtSG5Pymufv+preufumsC++9is6htRLHg+Dz/GFlnpbW00/4kqg/QtXp1cL8PIFbVtVuccxxw24Pp95z/wChLXdV62Djy0UeXjJc1VhRRRXUcwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHl/jGIWnjWZh927t45x/vKSjfpsrUsmzEpp3xNtgJtFvRxtme2b6OhYf+PRj86pwXcNvaRvOzLGc5faSqYGcsR0HH514uKjy1X5nsYdupSSW5sI2RVG+5iaovt04UJ9kKzMDhWmQLuB4Td6kfN06VFcXsbusbK8e/Ko0mF3MCRtAJznAJHGCKxk7o2jRkncyNLg83xToqel5vP8AwGNz/SvT9ct/teiahbf89reSP81Irz3wyC/jTTxjhfOf8kx/7NXqB5GK9LAr90edjn+9XoeQeGpPOsLZz1aNT+grooRhq5bRi1lbeWEDtC5h2lwvR9vU8VrpeStDDJukKuzyJsQRu23JEJR+clQcnjp2zXlLR2PW9nKouZf11Nx2+WsLUW+9SvdSwo8u8m3izOXZ2IEbISMkAh8NxhTwMde9e7LtEvmbPMIG7Ycrnvj2pydxKi4as2fhtB5uqatekcRrFaIffBdv/Q1/Ku+rlfhpEF8MCfvdXE0x/wC+yo/8dUV1Ve5h48tOKPDxEuapJhRRRWxiFFFFABRRRQAUUUUAeM3EP2TV9Xs8YEF/IVHosmJR/wChmt7S2+QCq3jS1+zeM7pxnZd2sU3/AAJCyH9NlSaaeBXhVo8laSPbpvnoxZ0EZ+WoLpvlNSL93rUFwRg05PQzitTI01N3jzQx12/aJPyjx/7NWv8AE1Ap8P3PdL/yvweJx/MCs3RQD8QNLGelpct+sYrb+JiBtAtZD1iv7Zh+MgX+TV2UFfDP5mFV2xEfkULFsoKtM3NUrLiOrQPNcEXodUlqR3B+U1h3J3TgVs3jYU1zl/P9nhubj/nlGz/kM1M+xpSVtTtPhrBt0Ke7Jz9tu5Zh/ug+Wv6ID+NdZWZ4Ysjp3h3TLMjDQ28aN/vbRn9c1p171OPLFRPEqS5pOQUUUVZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHK/EqLzPDBkHWC5gk/8iKD+hNcVES52vMgDxOqby6CM45O9fU7c5IwAcV6D48Tf4R1L/ZjD/8AfLA/0rzaQ5sXDgNHuAZSMgjuDXk49e+n5HsZbPlg/U1pJC5leNFDlI5XQrGcOeNoBIO514DFumKbEkcUq+SH8mN/K3woF6ZUQuAM7UB+9nrWxaJBc2sQdY2RdpCsoIBHTA9qo6/NshUIx3bgOPrXG1pc7Pb391L+v6/q+pB4ckCeObBR/EJU/NN3/steoV5RoalvHekkH+Nyf+/L16svIr1cD/C+Z4+O/ifI8WiIknvgdx/0mVsLjJIlY4547VswQTuitbk/vFbE427kkcnLOgwjgAKM8n9TWFHldS1OPulzOv5SNXTeH7iNtMg+YZC4P1ry2vffqeuqrhTVv60Ibi1lhkeQBIo4jlJG+cp+6C7ol6R4OcjnP41QuNkNupj27AN2VULuPUnA9Tk/jWn4ivkjsJUQ5kcbQKw9TBg0vYeqwHP/AHzUyQKcppcx6T4Gh8nwdoq9zaxsfqy5/rW7Wf4ej8rw/pkf9y1iX8kFaFfRRVkkfOyd22FFFFMQUUUUAFFFFABRRRQBwXxKATUtFkx/rFnhJ/BXA/8AHDWXppHArd+KKf8AEt0mcdYtQjB+jq6f+zCud08ncBXj41Wq3PXwbvRsdGv3RVe4Bwamjb5RmmTnKmsW7oqO5Q8OYbx/Z56iwuCP++4q3fiWCfC5I/hu7Yn/AL/JWH4UHmePUx/yx06Vj/wKRAP/AEE10XxFVm8GakyjmEJN+COrn/0GvRw6vh2vU467tiF8jAsSStWs4qpZkDgdM1YkbFeXF6HfJala8bisO8i+0tb2nX7VcwwEezSDd/46DWtdtk1BocIuPFGjqwyqTPN/3zG2P1YVVNc1SK8xzfLTk/I9Sooor3zwgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDC8cnb4Q1c+lq5/SvNmGbV1xwxxXpPjr/kTtZ/69JP8A0GuCsIhMCjeteXmHxRPUwDtGRcs7S5ggURy5UjIBqhepM12iTtkD5sfSukgjdI9pw2OlZt9Awd55MdCAK4WtDqjLUg8Gr9o8a255PkwSzH26IP8A0I/lXqI6V5X4AuPs3i1dxwt7A8PP99DvX9N/5V6rXr4K3slY8zG39q7njOtQf2f421e3P3ZJhcL7iRQT/wCPbqt6NYZ8xUnZCG5WofEcg1DxVqN4BhVlFpH/ALsfBP8A32X/ACrZsLdWRXBxJjGR3FeZWt7WVu56UG/ZRv2K+q2MUdsGwXlLAAms3xD/AKicHqIm/wDQTXUvErMpfnb0Fct4jGFuf+uT/wDoJrKRdN3PWNKGNLsx6QoP/HRVqq2mc6baEf8APFP/AEEVZr6JHz7CiiimAUUUUAFFFFABRRRQByfxNUHwyh7i9tiP+/y1ytioeYjnGe1dP8TZMaPYRZ5lv4h/3zl//ZK5zSEy2a8jH61EvI9bA6Um/M1BFt+7I4/HNI5dUO5g34VbWLcM1DKmFINcrTRqpXYvw+g8zWdcvSPu+TaqfTClz/6MH5V1PiC0F/oWpWh58+2kj/NSK5f4f3Qi1nW9Oc4ZjHeRg91ZdjY+hQfnXaTyLFBJI5wiKWP0Ar2cNb2MbHl4i/tWeX+Gbh7vSrSbI3yQIxJ9SozWjLE7H5pW/DisjwOp/sWwGMZgU4+oz/Wulkj4zivG5T1nKzMS5jCDqT9TUvhA58YWi+ltO345jH9akvU4PFReEyE8ZWRP8VvPGPr8h/8AZTWmHVq0Sa7vRkemUUUV7p4gUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBh+OP+RP1n/r1k/lXF6OgLsfeu08c/wDIn6z/ANesn8jXFaMfnkH+1XmY/wCKJ6WC+CR0kSgrmsvWBiBx7GtW2I21m6yP3TfSuSS925tD4jj5pW09bW/X71pMtx+Ct8w/FSw/GvZdQu0stNubx+Y4ImmPuFBP9K8jvIBPYGJujgqfoRiur1W+a4+EST7vnuLGGFj7vtQ/zNdeBnaMl21MsdDmlF99Dk7BHbSYHm5mbDuf9puW/Umuk0oY2CsSAZs39M1vaUOErgjqzsqaRsXpxhq5DxMP3VyR/wA8n/8AQTXX3fBrjvER/dXH/XN//QTTqbk0T1fRznSLE+sCf+girdU9F/5A1h/17x/+girlfQLY8N7hRRRTEFFFFABRRRQAUUUUAcH8T3P2vQI+xmmf8REQP/Qqz9JGFq98UB/p/h4/9NJ//RdUtM6CvHxn8Y9fC/wTobcfLVe6XDVZg+7UV2KiS90lP3jnrSY2HjrR7kHCTl7KT3Djcv8A48g/Ouz8cTm38H6w6HDm2dEP+0w2j9SK8+8USG2+z3S9be6gmz6bZVz+ma6/4mzFNAtoF6XN7BG3uA28/wDoFdWFqWoy8jHEwvVj5mJoEKwRRxJ92NQg+gGP6VuMMrWTo4+TPtWyv3TXFT2OqruZd+vymsO2mNn4j0adTgC8WJvpIGT+bCugvxla5TXCYxBKODFdW8g/CVDRF8tRPzKXvU2vI9looor3jxAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDE8bqW8H60AMn7HKfyU1weiuDO2Dwea9P1G2F7p91avws8TRH6MCP61474Ymby7ffxIECsD/eHB/UGvNx61iz0sC7xkjuoDxVTVBvhce1WLZsiq+ofcf6VyP4TaPxHNTtsWL6itieMr8GbQ/3YoJvw81W/lWBqT+XZvIf4EZvyBNdvqNkV+FMlqB80elDj3WMH+YrfBRup+hOMlbk9TloeLRxW3pf3U+lYtqVlst6/xLura0von0rjhujoqbMt3ZrktfGba6PpE/8A6Ca6u9PX6Vyerq0y+Qgy9xLHAo93cL/WqkrysKm7K56vpcZi0yzjYYZYUUj6KKtUd6K+gPCCiiigAooooAKKKKACiiigDhPiev8ApOgP2E8q/nEx/pWfp/AWtf4ojGnaTL3TUEGfZo3X+orIs/uKa8jGr978j1sI70beZ0FucrTLo021kwopl1JWTfugl7xyvjUZ0a+I7QMw/AZ/pXTfE079J0STt9vjP5xSD+tcz4xYf2HqGf8Ang/8jXVfEqBm8MWUi/8ALveWzn6bgn/s1bYZXpVETXdqlMpaNxHWqTgVkaU2Yx9K02Oa56b0Nai1K14cgiuR8TAfZGz/AM9I/wD0YtdbdfdJrl9Wj+0XVjb/APPa9t0P081Sf0FLea9So6Qfoew0UUV754gUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4/qtsdL8WalbAYQzfaI+P4JPm/8AQ94r2CuB+KFkEfTdVVfuv9llYdlflCf+BAD/AIHXLjIc9N+R1YOfJUs+pLZvmNSO4ouRuBzVbSn32i47Vam54ryk/dPQatI47xCh+xzQoPmmxCv1chf617FcWyTWMtqR+7eMxY9iMV5TeqH1zS0blWv7cEf9tAf6V67XfgF7smcmOl70UeNeHS39jwK/31iVW+oGD/Kun075UXPXFYVhGIri7iHRZ5lA9hI1bULFSPTFeftJndJ3iT3r/KTWXoVuNQ8X6fFjMdqHvJPqBtT9WJ/4DVy/fMPHU1p/Dmx22N3qj4L30n7s+kKZVfzO5v8AgVb4aHPVT7amFefs6T89Dr6KKK9k8kKKKKACiiigAooooAKKKKAOV+J0RfwbeTKCWtXjuePRHVm/8dzXN2LZiGDXo2o2qX2n3NpN/qp4mib6MCD/ADryrw28o06KK54uIM28w9HQlW/UV5mPjrGR6WBleLidHA/FNuG5qGJsEUTNmuK+h1W1MPxYPM0yePGfM2xgf7zBf6133j5A3g7VT/zzi83/AL4Ib/2WuH1ECW90uAjPm39sp+gkDH9Fr0bxNAbrw3qsAHMtpKg+pQivQwUbwl5nFi5WnHyOJ0dsqfatckVzXhufzbK3lz/rI1f8wDW6X+WvPg7HbUV2Fycg1jafCLvxdpER+6lwZiP92NiP1xWm7ZBqv4KjNz40nlH+rtbQ5/3pHAH6I1a0VzVYozqPlpSZ6PRRRXtnjhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWf4g01NY0S90+Q7RcRFA391v4W/A4P4VoUUmr6DTtqjynwreNPABMuyXlZF/uuDhh+YNb85CkVkX1uNO8Y6lEnCSyLcgegkHP/AI8rn8a07w/uwwrwpx5HKPY9lPnSl3MC858QaUf+n+3/APQxXrVeSO2/WdJP/T/B/wCh163XoYD4H6nFjvjXoeRwkjVbsdvtU4/8itW2cAVixD/ib3v/AF9z/wDo1q1ZGwa86Xxy9T0FrGPoUdfkk+xmK2/4+JisMX++5Cr+ROfwr0vTrSPT9PtrOAYit41iX6AYrz3S4RfeL9KhI3RwmS7cf7g2r/484P4V6XXo4GFouXc8/Gy95R7BRRRXccQUUUUAFFFFABRRRQAUUUUAFeZazAdP8Y6hb7QsV0q3kXuT8r/+PKD/AMCr02uN+JVrtsbLVkHz2EwEh/6YyYVvyO1v+A1z4qnz035HRhZ8lReZlKaHPFNU5ANDnArxT1ytaDzvFmhxHkfai/8A3zFIa9RkUOjI3RgQa8v0U58baJn+9Mf/ACE3+Neo162B/hfM8zG/xPkePeEcrpNqp6ogjP8AwHj+ldAGrH0eLyJb2D/nldzx/lK1aea8uStJo9Je8kxZ2xCxrR+GVufs+rXzdZ7ry1P+zGoX/wBC31ialOsFq8jnCopZvoBk12fgezax8J6XFIMStCJZP99/nb9WNdeBjeo5djkxkrU1HublFFFeqeYFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnnxGiNr4g0u9X7txE9s591Idf0MlIJPOtAe+K2PidbCTws10Pv2U0dwPoDtb/x1mrndPfNvgntXkYyPLUv3PVwkualbsZ6ca3pI9b+D/wBCr16vIb3FrqulzucIt7AxPoPMA/rXr1dOA+B+phjvjXoeT2wzq+o+17cf+jWq7cNjJqlpAFxqWqzIcobqVgfrIx/lVq6Uopz3rzanxS9Tvhsl5Gp8P4Vl1nVLvq0UUVuD6Zy5/QpXdVyvw2gC+Hmu/wCK9uJJ/wDgOdi/+OotdVXtYePLTijyMRLmqSYUUUVsYhRRRQAUUUUAFFFFABRRRQAVU1azTUdLvLKT7lxC8R/4ECP61booA8l0a4Mun2rOcsUAY+44P61euAVTPasyzjELajGn+rhvrhEHsJWxWpfcWqkd8V89KNm12PfTvZ9yLw7z420rPZJyP++BXqFeT2lwun+JNDu5OIxceQ59BIpQH/vorXqN9cC0sri5YFlhjaQgd8DP9K9TAv8AdHmY5fvPkeY2zY1fWm6r9umI/wC+j/XNXs/uvM7YzWLo7sNHE8pBmnBmc+rOdx/Umte5/d6VnvtFebN80mz0UuVJfIoatGl5Fb2jnAvJo7c/R3Cn9M16yAAAAMAdq8qlXZfaLM2PLjvIGb2G7Gf1Feq16GAXuN+ZwY5+8kFFFFd5whRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBhePGRfBeuGTp9jlH47Tj9cVyOlW7C0Rn6kc1qfFW/2aRbaXErPPfTLuRSAfKRgznn32j8araOhXRrTd12DnzPMyOx3d89c15eNac1HsenhIONJz7szPFNl9p0eRA2x+ArD+E9j+BwfwroZfF2fAB1ZQq6iy/ZhF6XRO3b9A3zf7vNZ+qgG2wfWuClkYeIYrZpD9m2G58rt5mdm/67eKxo13SukazoKslfozsfClstro8cYyWyQzHq2OM1Z1Yf6PwOadpciGAIuOO1Lqqv9imMQXeqkjcCRx7Dn8q53qjVL37HQ/D50fwVo/ljAW3VGHoy8N+oNdDXn3wtu1t59U0YsQI3+0woWZiEbAYZIznO1iOxevQa92jNTgpI8jEU3SqygwooorUxCiiigAooooAKKKKACiiigAoqtqF7b6dZy3V5KIoIxlmP5AY7nPGK8zuvGOp+JZri20+3FnpDZRpmyJmHcA5wue+M4HfPTKrWjSV5GtKjKq/dKWmnFlOCwdxcTCRgcgv5jZ5+tbl0m/TV9cVi29stoskCYCySbgqjAAwB/St8keSqdsV4l7ts9iWiRgSQHVNS0nTk6z3CMx9EjPmMfyXH1Ir16SNZY3jkAZGBVge4NeTWUv8AZ3i/SJ34i+0eUT7SKUH/AI8Vr1mV1ijeSQhUUFmJ7AV6WAS9m/U4Mc3zr0PGdLVltlsmOTBI0GfUI5X+S10Gor/oBX/ZrF8Ogzx/am/5bFpv++2Lf+zVvSjfCQfTFedpd2O9v4bmFeXkSx2KXDbYnuYld+yKGBZj7AA17ArBlDKQVIyCDkEV49DErzKrj5o2OP5VNb65q3heZRb5u9JA/wCPZh/queinqB+YHTGOnThMRGndS6mGLw7qWceh65RVPR9SttX06G+sZN8EoyD3BBwQfcEEVcr1k76nktW0YUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVz/jjXDoWhyywfNezZitlClvnIJ3YHJCgFj9Md6UpKKuyoxc2ox3ZwXiO5Gt+Op2hVZEtClpF5i/KHBJaRCThirZyo5OwdK63yvKtYoztyiAHau0dOw7fSud8I6QYERptjeS7bt8bFjIcYdWbp8pOcDBJPPWumuDnJ7V4rfO3N9T26toKNGPRfic9rtyIo/mIAHOT296TTPBjat4ZOoORDqs2J7QkfcQA7Uf1DZJPpkf3az9XiOo61Z6e2dlzOkLY/uZy/wD46Gr11QAAAMAdAK3wdFTvKXocmLqunyxj6nkvhm5MyqXVo3xyjdVI4IPuDxXVhA0WR1rlbmL7H4y1i3Q/KLnzR9JFVz+rGuqtGymD6Vy8vLNwOiUuaKmupydzJLoOuWOpoJZILNvLnYuzYt36k7vvNnLHB42DNetqQygqQQeQR3rzjxJZiaF3eJZISmHBDuQR9whAcHDHJ9q1vhxq3mWL6LdSbrzTv3aMQR50IOFcZ64xtP0HqK7cFUs3TfyMcdT54Rrr0f8AX9dDsqKKK9E8sKKKKACiiigAooooAKKKKAOb8caHda7YW8Fs8BSOXzHgnyElx0yQCeDzjGD+Fee3MGuaeJLW5sZLd412ebBEWiOejq2Dwo7HrnoOlezUVzVsNGq7t2Z14bGSoaJJrzPCYtYd7ksSrBUSU4XOwbSWDYOQflOCR1PStyPUpXfYQCQ4DbE3BNyZCkhuqnG4kDgjjnNd9rXhbStXk864t/LushhcQnY+Qcgns2P9oGuSufhzfHcsGtQuhVlzPabn+Y8kkNySPl6dOK4ZYKpF+7qepHMMNUXvx5X95x/iW6lmskkJKTRPEyAfL+9A3FCFJ5ztOG45HJr1/wAaSNF4R1h0OG+ySDPplSK53Rvh6tvfxXOq6k94sRDJbxx+VFlW3LuGSSAcYHHQZzXcXMEV1by29xGskMqlHRhkMpGCDXXhaE6cXzdTgx2Jp1px9mtEeJ6XqTRWqRi5gRUiHzOyPwAWLEjaDwrLgdMbq0H1a4KZSOLO8AIwPJKE+WWGcEcHfgqc4HNbV78NWWRv7J1iSC3JG2C4jMoQYI2hgykDB+vvTbT4c3xlVr3XsL91vs9sFd05wpZmbgZOODXF9TrLQ9OWPwcvet8rf1/W1ji/7XeO4LyXKorMIy4Rc7iQVfYecFTyP4frWxpUWseJJ4orNJLaJiGkuGgIWEDgjLcPnqACD06cmvTNB8N6VoaAadaIkmADM/zyMAMcsece3StiuingEtZs46+aKV1Sgl59f6/rvfF8L6K+i21xHJcCdppfMO1Nig4A4GTycZNbVFFehGKirI8mUnJ3YUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABIAJPQV5JaTxeJtVl1HUJnlFxG6W9sGwsdvuGDxyGOASQepx2GPWmUMpB5BGDXhF7YXvhq/u9M3XCefJ5cUrgAG2U5BV+FyFJzzncQMDvx41ScFbY7cFJRm316HpKTq6AqQR2xzTJnyD6VzVpfRzaowUiGzs4VMcWcZZgev0X+ftU+iXgvbee9aVWMp+RFbISMZ2/ic5P1x2rzHK6O3ksyCCTyfGOiygZLXWzH+8jj+ter15n4Ytv7U8YRSqpa304GV37eYVKov1wzN7YHrXplengYtU9TgxrTqWXRHk+tlj461kNw3mxYH+z5KYP8AOuggfCpzg46VB8R9ONreWmuwD5crbXQHoT8j/gx2/RvasnWpsaWl3byBbq3JlhXGTJgfMmBzyP1xXDiIONV36nZSkp0o26aG7ePCbeX7RsMG0+YH5XbjnPtiub8QSWtpObyHNtqVtCs9rcRk/Mq8bMdNvOCPRh+C3OqQLqml3UEqtb38ZjkTIIPGVb9Cv5Vj2mm6hrdzFpNta3Ea2coIkDDZFBI3IZic/cDrgA54I7GognKS5dy2+WLu9D260nW5tYZ0BCyorgH0IzUtNjRY41RFCoowAOwFOr3TxQooooAKKKKACiiigAooooAKKKKACiiigAooooABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWXr2h2etxRLd+ajxEmOSJ9rLnqPQg+hrUopNJqzGm07o8j8R+BdRsxPLZ/6fp/niZ0DE3LIQAVxjDgYHGeQMY9YrNdS1GYxafY3T3EiiLzJbYwRRr6sdqjA9Bk9hXsNFcssHCTvsdMcXOKs9TL8OaRDomlR2cDGRgS8srDDSyH7zH6/oMDtWpRRXUlZWRzNtu7KOu6cmraPd2Eh2ieMqGxnaex/A4NeYG117T51huNNvftEeQk1nH5qOD1wewOB94DGK9dorGth41bNm1GvKldLZnlGl+AtUvCItVSC00+ScXDosxaULuDeXhQFByCSQTjccV6TpOk2OkW7Q6bbJAjNubGSWPqSeSfrV6iqp0Y0/hJqVZVPiCiiitTIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scabies usually involves the sides and webs of the fingers, the flexor aspects of the wrists, the extensor aspects of the elbows, anterior and posterior axillary folds, the skin immediately adjacent to the nipples (especially in women), the periumbilical areas, waist, male genitalia (scrotum, penile shaft and glans), the extensor surface of the knees, the lower half of the buttocks and adjacent thighs, and the lateral and posterior aspects of the feet. The back is relatively free of involvement; the head is spared except in very young children.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44082=[""].join("\n");
var outline_f43_3_44082=null;
var title_f43_3_44083="Asthma inhaler techniques in children";
var content_f43_3_44083=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?43/3/44083/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44083/contributors\" id=\"au4992\">",
"       Robert H Moore, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?43/3/44083/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44083/contributors\" id=\"se5737\">",
"       George B Mallory, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44083/contributors\" id=\"se5673\">",
"       Robert A Wood, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?43/3/44083/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44083/contributors\" id=\"de2295\">",
"       Elizabeth TePas, MD, MS",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?43/3/44083?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ASTHMA INHALER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Inhaled medications are vital in the treatment of childhood asthma, although they are only effective if they are used properly. Using an inhaler correctly delivers the medication to the lungs and leads to a better response. If the medication is used incorrectly, little or none of it reaches the lungs.",
"    </p>",
"    <p>",
"     Unfortunately, many people with asthma do not use the best inhaler technique. Almost everyone, including children, can learn proper inhaler technique with training and practice.",
"    </p>",
"    <p>",
"     This article discusses the use of asthma inhalers in children. Other topics about asthma in children are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/0/37892?source=see_link\">",
"      \"Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/60/18374?source=see_link\">",
"      \"Patient information: Asthma treatment in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/6/31841?source=see_link\">",
"      \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/25/31124?source=see_link\">",
"      \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Articles are also available for adults with asthma. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/63/39925?source=see_link\">",
"      \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/6/31841?source=see_link\">",
"      \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/20/14660?source=see_link\">",
"      \"Patient information: Asthma and pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      METERED DOSE ASTHMA INHALERS",
"     </span>",
"    </p>",
"    <p>",
"     Metered dose inhalers (MDIs) are used to deliver a variety of inhaled medications. An MDI consists of a pressurized canister, a metering valve and stem, and a mouthpiece actuator (",
"     <a class=\"graphic graphic_picture graphicRef61575 \" href=\"mobipreview.htm?36/35/37439\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The inhaler canister contains the medicine and other chemicals that help to deliver the medication to the lungs. Previously, inhalers contained a chemical known to damage the ozone layer. As a result, most inhalers in the United States were reformulated after December 2008. The new inhalers use a chemical called hydrofluoroalkane (HFA) to deliver the medication to the lungs. HFA devices may have a different taste compared to the previous inhalers, and the spray may feel softer. However, this does not mean the medicine is not reaching your lungs.",
"    </p>",
"    <p>",
"     In addition, HFA inhalers need to be cleaned and primed to prevent medication build up and blockage. Each manufacturer will provide instructions about how to use their inhaler. These instructions should be reviewed carefully. (See",
"     <a class=\"local\" href=\"#H3\">",
"      'How to use an MDI'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     HFA inhalers may be more expensive than the older inhaler. Talk to your healthcare provider if you have difficulty paying for your medications because assistance programs may be available.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      How to use an MDI",
"     </span>",
"     &nbsp;&mdash;&nbsp;Each MDI manufacturer has specific instructions for using their inhaler; the following are general instructions.",
"    </p>",
"    <p>",
"     When using a metered dose inhaler for the FIRST time (with or without a spacer or valved holding chamber), prepare the inhaler first:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Shake the inhaler for five seconds",
"      </li>",
"      <li>",
"       Prime the inhaler by pressing down the canister with the index finger to release the medication. Hold away from the face to prevent medication from getting into the eyes. Press the canister down again three times.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     After you use an inhaler for the first time, it does not need to be primed again unless you do not use it for two weeks or more.",
"    </p>",
"    <p>",
"     When using a facemask, it is important to hold the mask snugly against the child's face; even a small leak can significantly reduce the amount of medication that reaches the lungs. Flexible masks appear to provide a better seal than rigid masks.",
"    </p>",
"    <p>",
"     Instructions for using the inhaler are available in the table (",
"     <a class=\"graphic graphic_table graphicRef74044 \" href=\"mobipreview.htm?35/53/36699\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Cleaning the MDI",
"     </span>",
"     &nbsp;&mdash;&nbsp;HFA inhalers must be cleaned on a regular basis to prevent medication build up and blockages. Most manufacturers recommend cleaning the mouthpiece at least once per week. To clean:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Remove the medication canister and cap from the mouthpiece. Do not wash the canister or immerse it in water.",
"      </li>",
"      <li>",
"       Run warm tap water through the top and bottom of the plastic mouthpiece for 30 to 60 seconds.",
"      </li>",
"      <li>",
"       Shake off excess water and allow the mouthpiece to dry completely (overnight is recommended).",
"      </li>",
"      <li>",
"       If you need the inhaler before the mouthpiece is dry, shake off excess water, replace the canister, and test spray two times (away from the face).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Spacer devices",
"     </span>",
"     &nbsp;&mdash;&nbsp;Using a spacer device with an inhaler can help to deliver more medication to the lungs and dramatically decrease the amount of medicine deposited in the back of the mouth and the tongue. A spacer holds the medicine in a chamber after it has been released from the inhaler, allowing the child to inhale slowly and deeply once or twice (",
"     <a class=\"graphic graphic_picture graphicRef56533 \" href=\"mobipreview.htm?21/27/21951\">",
"      picture 2",
"     </a>",
"     and",
"     <a class=\"graphic graphic_picture graphicRef75577 \" href=\"mobipreview.htm?25/46/26341\">",
"      picture 3",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     A spacer is recommended for any child who has difficulty squeezing the canister and inhaling at the right time (particularly children less than five to six years). Spacers are recommended for all children who use inhaled glucocorticoids.",
"    </p>",
"    <p>",
"     There are many spacers on the market, although little is known about the benefit of one type versus another. In general, larger sized (100 to 700 mL) spacers appear to be more effective than smaller ones. Proper technique and frequent cleaning are important (see",
"     <a class=\"local\" href=\"#H8\">",
"      'Cleaning the spacer'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Valved-holding chambers",
"     </span>",
"     &nbsp;&mdash;&nbsp;The valved-holding chamber is a specialized spacer that incorporates a one-way valve. This allows the child to breathe in and out of a mouthpiece or face mask. With traditional spacers, the child must breathe in through the spacer and breathe out away from the spacer. The child often needs to take five to six breaths to inhale all of the medication.",
"    </p>",
"    <p>",
"     Valved-holding chamber spacers are appropriate for infants and young children. However, this type of spacer may not be appropriate for newborns and very small infants because they cannot reliably inhale with enough force to open the valves.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Preparing a new spacer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Before using a spacer for the first time, it should be treated to reduce the electrostatic charge. This can be done by washing the spacer in a dilute solution of dishwashing detergent and warm water. The device should be air dried without rinsing out the detergent. Some spacers (eg, the Pari Vortex) are electrostatic-free and no preparation is needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Cleaning the spacer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although the powder residue that is deposited in the chamber is not harmful, the spacer should be cleaned periodically. Wash it with warm water and dishwashing detergent; washing with water alone causes an electrostatic charge to develop, reducing the effectiveness of the spacer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      How to get the most out of an inhaler",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several common mistakes can prevent inhaled medications from getting to the lungs. The following tips can help to get the most out of a metered dose inhaler.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Remember to take the cap off the mouthpiece.",
"      </li>",
"      <li>",
"       Be sure there is medication in the canister (see",
"       <a class=\"local\" href=\"#H16\">",
"        'Determine when an inhaler is empty'",
"       </a>",
"       below).",
"      </li>",
"      <li>",
"       Inhale through the mouth, not the nose.",
"      </li>",
"      <li>",
"       Take a slow, deep breath at the same time you press down on the medication canister.",
"      </li>",
"      <li>",
"       If you have difficulty timing your breath while spraying the medication, there are inhalers that automatically release the medication when you take a breath (ie, Maxair Autohaler&reg;). Another alternative is a dry powder inhaler (DPI). (See",
"       <a class=\"local\" href=\"#H12\">",
"        'Dry powder asthma inhalers'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Metered dose inhaler versus nebulizer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nebulizers use compressed air to change a medication from liquid form to a fine spray that can be inhaled through a mask or mouthpiece (",
"     <a class=\"graphic graphic_picture graphicRef75577 \" href=\"mobipreview.htm?25/46/26341\">",
"      picture 3",
"     </a>",
"     ). Nebulizers may be preferred to metered dose inhalers for some children who are too ill or too young to use a hand-held device or in situations where large drug doses are necessary.",
"    </p>",
"    <p>",
"     However, studies suggest that inhalers can be used to effectively deliver medications to the lungs, even in infants [",
"     <a class=\"abstract\" href=\"mobipreview.htm?43/3/44083/abstract/1\">",
"      1",
"     </a>",
"     ]. Therefore, young age and small size does not mean that a nebulizer is required. Giving one or more doses of a short-acting bronchodilator via inhaler with a spacer and facemask is at least as effective as, and possibly better than, giving the same medication by nebulizer in most infants and children [",
"     <a class=\"abstract\" href=\"mobipreview.htm?43/3/44083/abstract/2\">",
"      2",
"     </a>",
"     ] (see",
"     <a class=\"local\" href=\"#H5\">",
"      'Spacer devices'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      BREATH ACTUATED ASTHMA INHALER",
"     </span>",
"    </p>",
"    <p>",
"     For children who have difficulty timing their breath and spraying the medication, there are inhalers that automatically release the medication when the child breathes in (ie, Maxair Autohaler&reg;). The disadvantage of this device is that some children may not be able to inhale forcefully enough to trigger the drug's release, especially during an asthma attack.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      DRY POWDER ASTHMA INHALERS",
"     </span>",
"    </p>",
"    <p>",
"     An alternative to metered dose inhalers is a dry powder inhaler (DPI). DPIs eliminate the need to coordinate taking a breath and squeezing the canister. DPIs deliver a fine powder to the lungs when the child breathes in (",
"     <a class=\"graphic graphic_picture graphicRef67084 \" href=\"mobipreview.htm?0/19/306\">",
"      picture 4",
"     </a>",
"     ). Children who use dry powdered inhalers need to inhale more forcefully than with a traditional aerosol inhaler. Thus, DPIs may not be suitable for some children who are less than six years or older children with nerve or muscle weakness. Also, the child must not blow (exhale) directly into the device before breathing in, as this can scatter the medicine before it is inhaled.",
"    </p>",
"    <p>",
"     Examples include the long acting medication Foradil&reg;, the controller medications Asmanex&reg;, Flovent&reg;, and Pulmicort&reg; flexhaler, and the combination inhaler Advair&reg;. DPIs may contain tiny amounts of lactose, which is a type of sugar.",
"    </p>",
"    <p>",
"     DPIs come in two main types:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Multiple dose devices, which contain up to 200 doses",
"      </li>",
"      <li>",
"       Single dose devices (Foradil&reg; Aerolizer, Spiriva&reg; Handihaler), which require the person to place a capsule in the device immediately before each treatment. DPI capsules should NOT be swallowed.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Instructions for using a dry powder inhaler are included in the tables (",
"     <a class=\"graphic graphic_table graphicRef51020 graphicRef59737 \" href=\"mobipreview.htm?6/8/6286\">",
"      table 2A-B",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Cleaning the DPI",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most DPIs should not be washed with soap and water. The mouthpiece can be cleaned with a dry cloth approximately once per week. Consult the instructions with your inhaler for further information.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      ASTHMA ATTACK CARE AND PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Patients with asthma should work with their healthcare provider to develop an asthma action plan that is successful in treating and preventing asthma attacks. Depending upon the severity of your child's asthma, the treatment regimen may include regular visits with the provider, use of one or more medications, avoiding asthma triggers, and home symptom monitoring. At each visit, the child",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     parent should demonstrate how they use an inhaler to ensure that the correct technique is used.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Keep an adequate supply of medication",
"     </span>",
"     &nbsp;&mdash;&nbsp;A child should always have an adequate supply of their medication(s). This includes verifying that medication is not expired and that an inhaler is available at home, at school, in the car, and when out with family or friends.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Determine when an inhaler is empty",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is not always possible to determine when an inhaler is empty by shaking it because some propellant remains in the canister after all of the medication has been used. A few inhalers now have dose counters to track the amount of medication used, including Ventolin-HFA&reg; and Flovent&reg; (",
"     <a class=\"graphic graphic_picture graphicRef69302 \" href=\"mobipreview.htm?4/55/4991\">",
"      picture 5",
"     </a>",
"     ). Ask your healthcare provider if a counter is available on your inhaler.",
"    </p>",
"    <p>",
"     If you do not have a counter, but you use your inhaler on a regular basis (eg, two puffs once per day), you should refill your prescription once per month and throw away the old inhaler.",
"    </p>",
"    <p>",
"     In the past, you may have been told to drop the canister into a bowl of water and see how it floats. However, this method is not reliable and it is no longer recommended. Spraying the inhaler is also not recommended because even an empty inhaler will continue to spray.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H171\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21386402\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/58/17315?source=see_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/52/13122?source=see_link\">",
"      Patient information: How to use your child&rsquo;s dry powder inhaler (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/34/41506?source=see_link\">",
"      Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/43/30386?source=see_link\">",
"      Patient information: Inhalers (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/22/30052?source=see_link\">",
"      Patient information: Medicines for asthma (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21386410\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/0/37892?source=see_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/60/18374?source=see_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/6/31841?source=see_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/25/31124?source=see_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/63/39925?source=see_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/20/14660?source=see_link\">",
"      Patient information: Asthma and pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11642?source=see_link\">",
"      Acute asthma exacerbations in children: Inpatient management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=see_link\">",
"      Acute asthma exacerbations in children: Outpatient management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/44/22218?source=see_link\">",
"      Acute severe asthma exacerbations in children: Intensive care unit management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link\">",
"      An overview of asthma management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37354?source=see_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26010?source=see_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31014?source=see_link\">",
"      Delivery of inhaled medication in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/57/36760?source=see_link\">",
"      The use of inhaler devices in children",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"        www.nhlbi.nih.gov/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Lung Association",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.lungusa.org/\">",
"        www.lungusa.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Academy of Allergy, Asthma, and Immunology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.aaaai.org/patients.stm\">",
"        www.aaaai.org/patients.stm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Allergy, Asthma, and",
"       <span class=\"nowrap\">",
"        Immunology",
"        <br/>",
"        <br/>",
"        (www.acaai.org/allergist)",
"       </span>",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?43/3/44083/abstract/2-5\">",
"      2-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?43/3/44083?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44083/abstract/1\">",
"      Leversha AM, Campanella SG, Aickin RP, Asher MI. Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma. J Pediatr 2000; 136:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44083/abstract/2\">",
"      Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2006; :CD000052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44083/abstract/3\">",
"      Wildhaber JH, Janssens HM, Pi&eacute;rart F, et al. High-percentage lung delivery in children from detergent-treated spacers. Pediatr Pulmonol 2000; 29:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44083/abstract/4\">",
"      Amirav I, Newhouse MT. Aerosol therapy with valved holding chambers in young children: importance of the facemask seal. Pediatrics 2001; 108:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44083/abstract/5\">",
"      Marguet C, Couderc L, Le Roux P, et al. Inhalation treatment: errors in application and difficulties in acceptance of the devices are frequent in wheezy infants and young children. Pediatr Allergy Immunol 2001; 12:224.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f43_3_44083=[""].join("\n");
var outline_f43_3_44083=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ASTHMA INHALER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           METERED DOSE ASTHMA INHALERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           BREATH ACTUATED ASTHMA INHALER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           DRY POWDER ASTHMA INHALERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           ASTHMA ATTACK CARE AND PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/35/37439\" title=\"picture 1\">",
"           Metered dose inhaler PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/27/21951\" title=\"picture 2\">",
"           MDI spacers PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/46/26341\" title=\"picture 3\">",
"           Nebulizer and spacer use PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/19/306\" title=\"picture 4\">",
"           Dry powder inhalers PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/55/4991\" title=\"picture 5\">",
"           MDI with counter PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/53/36699\" title=\"table 1\">",
"           Using MDI PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/61/23516\" title=\"table 2A\">",
"           Using powder inhalers 1 PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/11/10429\" title=\"table 2B\">",
"           Using powder inhalers 2 PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f43_3_44084="Cirrhosis";
var content_f43_3_44084=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Cirrhosis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?43/3/44084/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44084/contributors\" id=\"au6409\">",
"       Sanjiv Chopra, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?43/3/44084/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44084/contributors\" id=\"se5574\">",
"       Bruce A Runyon, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?43/3/44084/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44084/contributors\" id=\"de2797\">",
"       Anne C Travis, MD, MSc, FACG",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?43/3/44084?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CIRRHOSIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Cirrhosis is the term used to describe a diseased liver that has been severely scarred, usually due to many years of continuous injury. The most common causes include longstanding alcohol abuse, chronic hepatitis B or hepatitis C, and nonalcoholic steatohepatitis (a condition in which fat builds up in the liver and the liver becomes inflamed). Although cirrhosis cannot be cured, there are a number of things you can do to prevent the disease from worsening.",
"    </p>",
"    <p>",
"     This topic discusses the symptoms, diagnosis, and treatment of cirrhosis. Related topics are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/45/31447?source=see_link\">",
"      \"Patient information: Hepatitis B (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=see_link\">",
"      \"Patient information: Hepatitis C (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=see_link\">",
"      \"Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CIRRHOSIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The liver is a large organ (weighing about three pounds) that is located in the right upper abdomen beneath the rib cage (",
"     <a class=\"graphic graphic_figure graphicRef64960 \" href=\"mobipreview.htm?39/54/40804\">",
"      figure 1",
"     </a>",
"     ). It performs many functions that are essential to life.",
"    </p>",
"    <p>",
"     The liver is able to repair itself when it has been injured. However, the process of healing involves the creation of scar tissue. Thus, repeated or continuous injury to the liver (such as occurs with heavy alcohol use) can cause significant scarring in the liver. The body is able to tolerate a partially scarred liver without serious consequences. Eventually, the scarring can become so severe that the liver is no longer able to perform its normal functions.",
"    </p>",
"    <p>",
"     Some of the most common causes of liver injury include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Longstanding alcohol abuse (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=see_link\">",
"        \"Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Chronic hepatitis (B or C) (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/45/31447?source=see_link\">",
"        \"Patient information: Hepatitis B (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=see_link\">",
"        \"Patient information: Hepatitis C (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Nonalcoholic steatohepatitis (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/47/12018?source=see_link\">",
"        \"Patient information: Nonalcoholic steatohepatitis (NASH) (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      CIRRHOSIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     People with cirrhosis may or may not have symptoms early in the course of the disease. Some of the more common symptoms include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Scarring makes it difficult for blood to flow through the liver. As a result, pressure backs up, and veins in other areas outside of the liver become abnormally expanded. Abnormally expanded blood vessels are referred to as varices.",
"      </li>",
"      <li>",
"       One place where varices are commonly found is in the esophagus, the swallowing tube connecting the mouth with the stomach (",
"       <a class=\"graphic graphic_figure graphicRef63611 \" href=\"mobipreview.htm?8/39/8819\">",
"        figure 2",
"       </a>",
"       ). When the pressure in the varices reaches a certain level, the varices can burst, which can cause massive bleeding (known as variceal bleeding or variceal hemorrhage).",
"      </li>",
"      <li>",
"       Body fluids accumulate as a result of liver scarring and a decreased ability to manufacture blood proteins. Fluid is typically seen in the legs (edema) and abdomen (ascites) and sometimes in the lung (pleural effusion). (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"        \"Patient information: Edema (swelling) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Ascites causes the abdomen to enlarge as fluid accumulates, which can cause shortness of breath and a feeling of fullness. The fluid provides an environment where bacteria can grow, increasing the risk of infection.",
"      </li>",
"      <li>",
"       Patients with cirrhosis can have easy bruising and bleeding. Once bleeding starts (such as with variceal bleeding), it can be severe.",
"      </li>",
"      <li>",
"       Hepatic encephalopathy is a condition that develops when the liver is unable to break down toxins normally found in the bloodstream, such as ammonia. In this condition, confusion or even coma are caused by toxins that build up in the blood. In the early stages, there may be mild symptoms, such as difficulty sleeping or sleeping too much. Advanced hepatic encephalopathy can cause confusion, delirium, and even coma. Hepatic encephalopathy can develop suddenly and may become a medical emergency.",
"      </li>",
"      <li>",
"       Patients with cirrhosis have a weakened immune system and are at increased risk of infections.",
"      </li>",
"      <li>",
"       Malnutrition is common in patients with cirrhosis. Malnutrition can cause loss of muscle in various areas of the body.",
"      </li>",
"      <li>",
"       Many people with advanced cirrhosis have jaundice (yellowed skin or whites of the eyes).",
"      </li>",
"      <li>",
"       People with cirrhosis are at increased risk for developing liver cancer (hepatocellular carcinoma).",
"      </li>",
"      <li>",
"       Cirrhosis can cause fatigue and in some cases itching.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      CIRRHOSIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Testing is performed to confirm the diagnosis of cirrhosis, determine the underlying cause, determine the severity of cirrhosis, and monitor for complications. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23194?source=see_link\">",
"      \"Diagnostic approach to the patient with cirrhosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Liver biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;The best way to confirm the diagnosis of cirrhosis is a liver biopsy. This procedure is discussed in depth in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/39/4721?source=see_link\">",
"      \"Patient information: Liver biopsy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Imaging tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Imaging tests, such as ultrasound, may be recommended to evaluate the condition of the liver or determine if there are cirrhosis-related complications. However, imaging tests are not usually performed to diagnose cirrhosis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood tests may be performed to help determine the underlying cause of cirrhosis and to monitor the liver function over time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      CIRRHOSIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There have been major advances in the treatment of cirrhosis in the past few decades. In particular, it has become easier to recognize, prevent, and treat complications of cirrhosis. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17337?source=see_link\">",
"      \"Overview of the complications, prognosis, and management of cirrhosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     People with cirrhosis should see their healthcare provider regularly for monitoring and treatment of cirrhosis complications. Although cirrhosis cannot be cured, several treatments are available to minimize cirrhosis-related complications. Other treatments are recommended to help prevent complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Avoid substances that can injure the liver",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with cirrhosis should avoid consuming substances that can further damage the liver. The most common of these is alcohol. You should talk to your healthcare provider before taking any new medication (including prescription and non-prescription drugs, herbs, vitamins, or dietary supplements).",
"    </p>",
"    <p>",
"     Acetaminophen (Tylenol&reg;) is a nonprescription medication that can further injure the liver in people with cirrhosis. The exact amount of acetaminophen that is safe in cirrhosis is uncertain; some experts recommend that patients not use more than 650 mg per dose every 4 to 6 hours, with no more than 2000 mg per day. However, even low doses may not be safe for those who drink alcohol. Use of acetaminophen should be discussed with a healthcare provider.",
"    </p>",
"    <p>",
"     Nonsteroidal anti-inflammatory drugs such as ibuprofen (Advil&reg;, Motrin&reg;), naproxen (Aleve&reg;, Naprosyn&reg;), and aspirin can damage the liver and should be avoided if you have cirrhosis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Screen for and treat varices",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with cirrhosis should undergo an upper endoscopy to determine if varices (expanded blood vessels) are present in the esophagus, the tube that connects the mouth and stomach (",
"     <a class=\"graphic graphic_figure graphicRef63611 \" href=\"mobipreview.htm?8/39/8819\">",
"      figure 2",
"     </a>",
"     ). Screening for and treatment of varices is discussed in detail in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/9/12434?source=see_link\">",
"      \"Patient information: Screening for esophageal varices (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21446?source=see_link\">",
"      \"Prediction of variceal hemorrhage in patients with cirrhosis\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27418?source=see_link\">",
"      \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Vaccination",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with cirrhosis should be vaccinated against hepatitis A and B. Pneumococcal vaccine and yearly influenza vaccine are also recommended. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"      \"Patient information: Adult vaccines (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=see_link\">",
"      \"Patient information: Influenza prevention (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/57/14225?source=see_link\">",
"      \"Patient information: Pneumonia prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Treat ascites and edema",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ascites and edema can lead to complications, particularly infection. Ascites can also cause a person to feel short of breath or full. Thus, treatment is usually recommended to reduce the amount of fluid that collects in the lower legs and abdomen. Treatment usually involves taking one or more diuretic pills (fluid pills) and following a low-sodium (salt) diet. (See",
"     <a class=\"local\" href=\"#H18\">",
"      'Dietary advice'",
"     </a>",
"     below and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link\">",
"      \"Initial therapy of ascites in patients with cirrhosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Paracentesis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people do not get adequate relief from edema and ascites with fluid pills alone. In this case, periodic drainage of the fluid (paracentesis) may be required. This is done by inserting a needle into the abdomen and withdrawing a large amount of fluid from the space around the abdominal organs. The procedure can usually be performed in a doctor's office.",
"    </p>",
"    <p>",
"     Following paracentesis, it is important to continue taking your diuretic medication and to limit the amount of sodium you consume. (See",
"     <a class=\"local\" href=\"#H18\">",
"      'Dietary advice'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      TIPS",
"     </span>",
"     &nbsp;&mdash;&nbsp;A TIPS (transjugular intrahepatic portosystemic shunts) procedure may be recommended to treat ascites if diuretics, paracentesis, and changes in diet are not completely successful in relieving ascites. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/35/34359?source=see_link\">",
"      \"Indications for the use of transjugular intrahepatic portosystemic shunts\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     During the procedure, a radiologist places a device within the liver to reduce the blood pressure in the portal vein (in the liver) (",
"     <a class=\"graphic graphic_figure graphicRef63611 \" href=\"mobipreview.htm?8/39/8819\">",
"      figure 2",
"     </a>",
"     ). The procedure is usually performed with local anesthesia and sedation, and takes between one and three hours. Most patients remain in the hospital for one to three nights after the procedure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Screen for hepatocellular carcinoma",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with cirrhosis should have tests to detect hepatocellular carcinoma (cancer of the liver). Testing usually requires an ultrasound examination of the liver every six months.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Consider liver transplantation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Not all patients with cirrhosis will require a liver transplantation, and many are not eligible for one. However, because the waiting list for liver transplantation is lengthy (up to two years in some regions), it is important to know if liver transplantation is a reasonable option while you are still relatively healthy. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'Liver transplantation for cirrhosis'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Screen for encephalopathy",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with cirrhosis can develop confusion, which is sometimes subtle. Detecting confusion is important since treatment is available, and the confusion itself can lead to serious problems (eg, an automobile accident). A change in the sleep pattern (insomnia or sleeping too much) may be an early sign. Treatment may include a medication called lactulose (which will cause softening of the stool) or an antibiotic.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Dietary advice",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with advanced cirrhosis may require a specialized diet that includes lower amounts of salt. Salt restriction is usually recommended for people with early cirrhosis who tend to accumulate fluid. Protein restriction is usually not necessary. A healthcare provider or dietitian can help to determine if dietary changes are needed. A detailed discussion about a low-sodium diet is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"      \"Patient information: Low sodium diet (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The benefit of vitamins, antioxidants and other supplements on the underlying liver disease has not been established. Several herbal therapies have been reported as having a benefit in patients with cirrhosis. None have clearly been proven to be effective, although some continue to be studied. Most experts do not recommend vitamins, herbs, or other supplements for people with cirrhosis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Exercise is generally safe for people without advanced-stage cirrhosis. Exercise may increase the risk of variceal bleeding in patients with advanced disease (such as those who have ascites or varices). Thus, check with your healthcare provider regarding the risks and benefits of exercise.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      LIVER TRANSPLANTATION FOR CIRRHOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Liver transplantation involves replacing a diseased liver with a healthy liver. The majority of donated livers come from people who have suffered brain death for one reason or another. More recently, living donors have been able to donate a portion of their liver.",
"    </p>",
"    <p>",
"     More than 80 percent of people will be alive one year after liver transplantation, and the majority of these will be alive five years after transplantation. This is compared with an extremely high death in patients with very advanced cirrhosis who do not undergo transplantation. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link\">",
"      \"Model for End-stage Liver Disease (MELD)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The prognosis after transplantation depends in part upon the underlying cause of the liver disease, some of which recur following transplantation. As an example, most people who undergo transplantation for hepatitis C will develop recurrent hepatitis C after transplantation.",
"    </p>",
"    <p>",
"     Other major concerns following transplantation are the risk of anti-rejection drugs used to suppress the immune system, which have many side effects, and the risk of rejection of the transplanted organ.",
"    </p>",
"    <p>",
"     The transplantation process is elaborate, involving an extensive screening process for eligibility. Thus, not all patients with cirrhosis are eligible, and only those with the most advanced, severe cirrhosis are placed on the transplant registry. Furthermore, not all patients with cirrhosis will require a transplantation since the disease can remain relatively stable for many years, particularly if the cause of the cirrhosis (eg, alcohol) is eliminated. Treatment centers that perform liver transplantation can be found at the Centers for Medicare &amp; Medicaid Services website (",
"     <a class=\"external\" href=\"file://www.cms.gov/CertificationandComplianc/downloads/ApprovedTransplantPrograms.pdf\">",
"      file://www.cms.gov/CertificationandComplianc/downloads/ApprovedTransplantPrograms.pdf",
"     </a>",
"     ). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/61/25559?source=see_link\">",
"      \"Patient selection for liver transplantation\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our Web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27018103\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27018096\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/25/24979?source=see_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21155?source=see_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/15/40179?source=see_link\">",
"      Patient information: Hemochromatosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/40/7810?source=see_link\">",
"      Patient information: Hepatic encephalopathy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/14/38114?source=see_link\">",
"      Patient information: Nonalcoholic steatohepatitis (NASH) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/22/4451?source=see_link\">",
"      Patient information: Latest medicines for hepatitis C (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/42/44706?source=see_link\">",
"      Patient information: Liver cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/40/16002?source=see_link\">",
"      Patient information: Fluid in the belly (ascites) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/6/23651?source=see_link\">",
"      Patient information: Toxic hepatitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/40/8834?source=see_link\">",
"      Patient information: Esophageal varices (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/34/25122?source=see_link\">",
"      Patient information: Liver transplant (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27018191\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/45/31447?source=see_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=see_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=see_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/47/12018?source=see_link\">",
"      Patient information: Nonalcoholic steatohepatitis (NASH) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/39/4721?source=see_link\">",
"      Patient information: Liver biopsy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/9/12434?source=see_link\">",
"      Patient information: Screening for esophageal varices (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=see_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H865337877\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12858?source=see_link\">",
"      Assessing surgical risk in patients with liver disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/22/34153?source=see_link\">",
"      Clinical manifestations and diagnosis of hepatic encephalopathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14010?source=see_link\">",
"      Evaluation of adults with ascites",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23194?source=see_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10007?source=see_link\">",
"      Management of pain in patients with cirrhosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17337?source=see_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21446?source=see_link\">",
"      Prediction of variceal hemorrhage in patients with cirrhosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/23/17786?source=see_link\">",
"      Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27418?source=see_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35465?source=see_link\">",
"      Treatment of diuretic-resistant ascites in patients with cirrhosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/35/34359?source=see_link\">",
"      Indications for the use of transjugular intrahepatic portosystemic shunts",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/61/25559?source=see_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Gastroenterological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gastro.org/patient-center/digestive-conditions/cirrhosis-of-the-liver\">",
"      file://www.gastro.org/patient-center/digestive-conditions/cirrhosis-of-the-liver",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Liver Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.liverfoundation.org/\">",
"      www.liverfoundation.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?43/3/44084/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 2, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?43/3/44084?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44084/abstract/1\">",
"      Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol 2011; 25:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44084/abstract/2\">",
"      Fallowfield J, Hayes P. Pathogenesis and treatment of hepatic fibrosis: is cirrhosis reversible? Clin Med 2011; 11:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44084/abstract/3\">",
"      Lefton HB, Rosa A, Cohen M. Diagnosis and epidemiology of cirrhosis. Med Clin North Am 2009; 93:787.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f43_3_44084=[""].join("\n");
var outline_f43_3_44084=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CIRRHOSIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CIRRHOSIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           CIRRHOSIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           CIRRHOSIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           CIRRHOSIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           LIVER TRANSPLANTATION FOR CIRRHOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/54/40804\" title=\"figure 1\">",
"           Abdomen anatomy adult PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/39/8819\" title=\"figure 2\">",
"           Esophageal varices PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f43_3_44085="Dihydroergotamine: Pediatric drug information";
var content_f43_3_44085=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dihydroergotamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?15/13/15574?source=see_link\">",
"    see \"Dihydroergotamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/36/8773?source=see_link\">",
"    see \"Dihydroergotamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      D.H.E. 45&reg;;",
"     </li>",
"     <li>",
"      Migranal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Migranal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Blocking Agent, Intranasal",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Blocking Agent, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimigraine Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ergot Alkaloid and Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/13/15574?source=see_link\">",
"      see \"Dihydroergotamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"     <b>",
"      Intractable migraine &gt;72 hours (status migrainosus):",
"     </b>",
"     Limited data available; optimal dose not established:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:  Premedicate with antiemetic (metoclopramide or prochlorperazine have been used)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Low dose regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 6 to &lt;10 years:  0.1 mg/dose every 6 hours; improvement usually seen after 5 doses; if improvement noted, continue therapy until headache-free up to a maximum of 16 doses; if no improvement after 5 doses, discontinue therapy (O&rsquo;Brien, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;10 to 12 years: 0.15 mg/dose every 6 hours; improvement usually seen after 5 doses; if improvement noted, continue therapy until headache-free up to a maximum of 16 doses; if no improvement after 5 doses, discontinue therapy. One study reported increasing the dose by 0.05 mg increments as tolerated (ie, no abdominal discomfort).  Postmenarche female patients should complete pregnancy screening prior to first dose (Linder, 1994; O&rsquo;Brien, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adolescents &le;16 years: 0.2 mg/dose every 6 hours; improvement usually seen after 5 doses; if improvement noted, continue therapy until headache-free up to a maximum of 16 doses; if no improvement after 5 doses, discontinue therapy. Postmenarche female patients should complete pregnancy screening prior to first dose (O&rsquo;Brien, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High dose regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 6-9 years or Children &ge;10 years and &lt;25 kg: 0.5 mg/dose every 8 hours; improvement usually seen after 5 doses; if improvement noted, continue therapy until headache-free up to a maximum of 20 doses; if no improvement after 5 doses, discontinue therapy; an additional dose after headache subsides has also been suggested (Kabbouche, 2009; O&rsquo;Brien, 2011).",
"     <b>",
"      Note:",
"     </b>",
"     An initial test dose (half of the appropriate dose for age and weight) has been used; if test dose tolerated,	remainder of dose administered 30 minutes later (Kabbouche, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;10 years and &gt;25 kg and Adolescents: 1 mg/dose every 8 hours; improvement usually seen after 5 doses; if improvement noted, continue therapy until headache-free up to a maximum of 20 doses; if no improvement after 5 doses, discontinue therapy (Kabbouche, 2009; O&rsquo;Brien, 2011).",
"     <b>",
"      Note:",
"     </b>",
"     An initial test dose (half of the appropriate dose for age and weight) has been used; if test dose tolerated, remainder of dose administered 30 minutes later (Kabbouche, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intranasal: Adolescents: 1 spray (0.5 mg) into each nostril (total dose: 1 mg); repeat if needed within 15 minutes up to a total of 4 sprays (2 mg); maximum daily dose: 6 sprays (3 mg)/24-hour period;",
"     <b>",
"      Note:",
"     </b>",
"     Do not exceed 8 sprays (4 mg)/week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Migraine, cluster headache:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., SubQ: 1 mg at first sign of headache; repeat hourly to a maximum dose of 3 mg/day; maximum dose: 6 mg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 1 mg at first sign of headache; repeat hourly up to a maximum dose of 2 mg/day; maximum dose: 6 mg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intranasal: 1 spray (0.5 mg) of nasal spray should be administered into each nostril; if needed, repeat after 15 minutes, up to a total of 4 sprays (2 mg).",
"     <b>",
"      Note:",
"     </b>",
"     Do not exceed 6 sprays (3 mg) in a 24-hour period and no more than 8 sprays (4 mg) in a week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Contraindicated in severe renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Dosage reductions are probably necessary but specific guidelines are not available; contraindicated in severe hepatic dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as mesylate: 1 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     D.H.E. 45&reg;: 1 mg/mL (1 mL) [contains ethanol 6.2%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as mesylate [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Migranal&reg;: 4 mg/mL (1 mL) [contains caffeine 10 mg/mL; 0.5 mg/spray]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal: Prior to administration, the nasal spray applicator must be primed (pumped 4 times); spray once into each nostril; avoid deep inhalation through the nose while spraying or immediately after spraying; do not tilt head back. For further information, consult manufacturer labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M., SubQ: Administer without dilution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer without dilution slowly over 2-3 minutes",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not refrigerate or freeze; protect the vials from light and heat.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nasal spray: Store below 25&deg;C (77&deg;F); do not refrigerate or freeze; once the nasal spray applicator has been prepared, use within 8 hours; discard any unused nasal solution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intranasal: Treatment of migraine headache with or without aura (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Treatment of headache with or without aura and cluster headaches (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F160514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nasal spray:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, taste disturbance, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Stiffness, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Injection and nasal spray: Cerebral hemorrhage, coronary artery vasospasm, dyspnea, hypertension, MI, paresthesia, peripheral cyanosis, peripheral ischemia, stroke, subarachnoid hemorrhage, ventricular fibrillation, ventricular tachycardia. Pleural and retroperitoneal fibrosis have been reported following prolonged use of the injection; cardiac valvular fibrosis has been associated with ergot alkaloids.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dihydroergotamine, other ergot alkaloids, or any component; pregnancy; breast-feeding; uncontrolled hypertension, ischemic heart disease, angina pectoris, history of MI, silent ischemia, or coronary artery vasospasm including Prinzmetal's angina; hemiplegic or basilar migraine; peripheral vascular disease, sepsis, severe hepatic or renal dysfunction, and following vascular surgery; concurrent therapy with potent CYP3A4 inhibitors (eg, protease inhibitors, azole antifungals, and certain macrolide antibiotics); do not use within 24 hours of sumatriptan, zolmitriptan, other serotonin agonists, ergot-like agents or methysergide; concurrent use of peripheral and central vasoconstrictors",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause nausea; in pediatric patients, antiemetic prophylaxis (prochlorperazine or metoclopramide) 30 minutes prior to initial dihydroergotamine dose has been used (O&rsquo;Brien, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concomitant use with potent inhibitors of CYP3A4 (including protease inhibitors, azole antifungals, and some macrolide antibiotics) has been associated with acute ergot toxicity (ergotism) characterized by serious and/or life-threatening cerebral and peripheral ischemia",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; some cases have resulted in amputation; less potent CYP3A4 inhibitors (eg, metronidazole, fluoxetine, nefazodone, and zileuton) may carry the same risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Vasospasm or vasoconstriction can occur, possibly resulting in decreased cerebral blood flow, ECG changes, and hypertension; sustained vasoconstriction may also lead to ischemic colitis, intermittent claudication, aggravation of angina, or precipitation of MI. Do not use in any patient at risk or predisposed to vascular effects of ergot alkaloids. Ergot alkaloid use may result in ergotism (intense vasoconstriction) resulting in peripheral vascular ischemia and possible gangrene. Ergotism is usually associated with overdosage or prolonged chronic use; do not exceed dosing guidelines and avoid prolonged administration. Patients with risk factors for CAD should have a baseline cardiovascular evaluation prior to first dose; if evaluation is satisfactory, the healthcare provider should administer the first dose and cardiovascular status should be periodically evaluated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection: Rare reports of adverse cardiac events (acute MI, life-threatening arrhythmias, death) have been reported; cerebral hemorrhage, subarachnoid hemorrhage, and stroke have also occurred. Injection is not intended for prolonged use; pleural and retroperitoneal fibrosis have been reported with daily use. Cardiac valvular fibrosis has been associated with ergot alkaloid use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Nasal spray (Migranal&reg;): Local irritation to nose and throat (usually transient and mild-moderate in severity) can occur; long-term consequences on nasal or respiratory mucosa have not been extensively evaluated",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F160503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F160435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Dihydroergotamine. Management: Avoid dihydroergotamine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F160437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F160449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dihydroergotamine is oxytocic and should not be used during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ergot alkaloid alpha-adrenergic blocker which aborts vascular headaches by direct vasoconstriction of vascular smooth muscle, particularly of the carotid artery bed but also peripheral and cerebral vessels, which reduces the amplitude of pulsation in the cranial arteries; it also has partial agonist or antagonist activity against tryptaminergic and dopaminergic receptors; it is less active than ergotamine",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intranasal: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.M.: 3-4 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : &sim;800 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Intranasal: 32%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively in the liver; one active metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Biphasic: terminal half-life: ~9-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: Within 15-30 minutes; intranasal: 0.5-1 hour; I.V.: 15 minutes; SubQ: 15-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Predominately into bile and feces and 10% excreted in urine, mostly as metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: 1.5 L/minute",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/36/8773?source=see_link\">",
"      see \"Dihydroergotamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take this drug as rapidly as possible when first symptoms occur; may cause dry mouth; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; report heart palpitations, severe nausea or vomiting, or severe numbness of fingers or toes; do not assemble nasal spray until needed for use",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13232 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44085=[""].join("\n");
var outline_f43_3_44085=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708702\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160464\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160465\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057876\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057870\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160440\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160426\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057879\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057873\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057878\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160514\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057883\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057869\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057868\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160503\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160435\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160437\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160449\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057867\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057881\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057882\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057875\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13232\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13232|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/13/15574?source=related_link\">",
"      Dihydroergotamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/36/8773?source=related_link\">",
"      Dihydroergotamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_3_44086="What's new in gastroenterology and hepatology";
var content_f43_3_44086=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in gastroenterology and hepatology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/3/44086/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44086/contributors\">",
"     Peter A L Bonis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44086/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44086/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/3/44086/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     COLORECTAL CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Aspirin for the primary prevention of cardiovascular disease and cancer",
"    </span>",
"   </p>",
"   <p>",
"    Meta-analyses of randomized trials have shown aspirin to reduce the risk of non-fatal myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/1\">",
"     1",
"    </a>",
"    ],&nbsp;and long-term aspirin use reduces overall cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/2\">",
"     2",
"    </a>",
"    ]. While several published guidelines have considered the benefit of aspirin for&nbsp;the prevention of either cardiovascular disease (CVD)&nbsp;or cancer versus&nbsp;the risk of increased bleeding, most have not addressed the&nbsp;potential net benefit of aspirin in preventing both CVD and cancer.&nbsp;A meta-analysis addressing this combined outcome suggests that aspirin use in 1000 average risk patients at age 60 years would be expected to result, over a 10-year period, in&nbsp;six fewer deaths, 19 fewer non-fatal myocardial infarctions, 14 fewer cancers, and 16 more major bleeding events (",
"    <a class=\"graphic graphic_table graphicRef86941 \" href=\"mobipreview.htm?39/47/40702\">",
"     table 1",
"    </a>",
"    ).&nbsp;For individuals age 50 years or greater without excess bleeding risks, we suggest daily aspirin at a dose of 75 to 100 mg. Patients who are more concerned about the bleeding risks than the potential benefits may reasonably choose to not take aspirin for primary prevention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23529?source=see_link&amp;anchor=H1761594#H1761594\">",
"     \"Aspirin in the primary prevention of cardiovascular disease and cancer\", section on 'Recommendations for primary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Universal tumor testing for Lynch syndrome",
"    </span>",
"   </p>",
"   <p>",
"    A number of different strategies have been proposed to identify patients with colorectal cancer (CRC) who are at risk for Lynch syndrome (hereditary nonpolyposis colorectal cancer). One of the largest studies to compare the performance characteristics of universal tumor testing (testing all colorectal cancers for microsatellite instability or loss of mismatch repair proteins by immunohistochemistry) with other strategies included over 10,000 patients with CRC&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/3\">",
"     3",
"    </a>",
"    ].&nbsp;While universal tumor testing had a higher diagnostic yield compared to a &ldquo;selective strategy&rdquo; of testing individuals who met one or more Bethesda guidelines or were diagnosed with CRC prior to age 70, the incremental diagnostic yield of universal testing over the selective strategy was small (0.11 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Universal testing strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence of APC and MUTYH mutations among individuals with multiple adenomas",
"    </span>",
"   </p>",
"   <p>",
"    Multiple colorectal adenomas may be seen in individuals with familial adenomatous polyposis (FAP) and",
"    <em>",
"     MUTYH",
"    </em>",
"    &nbsp;associated polyposis (MAP). A cross-sectional study examined the prevalence of",
"    <em>",
"     APC",
"    </em>",
"    &nbsp;and",
"    <em>",
"     MUTYH",
"    </em>",
"    &nbsp;mutations in over 8000 individuals with a personal or family history suggestive of a polyposis syndrome who underwent clinical genetic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/4\">",
"     4",
"    </a>",
"    ]. The prevalence of",
"    <em>",
"     APC",
"    </em>",
"    &nbsp;and",
"    <em>",
"     MUTYH",
"    </em>",
"    mutations was 80 and 2 percent, respectively, among individuals with &gt;1000 adenomas (classic polyposis), 56 and 8 percent, respectively, among individuals with 100 to 999 adenomas (classic polyposis), 10 and 7 percent, respectively, among individuals with 20 to 99 adenomas (attenuated polyposis), and 5 and 4 percent, respectively, among individuals with 10 to 19 adenomas. In this study, 34 percent of individuals with classic polyposis and 81 percent of individuals with attenuated polyposis had no mutation in either the",
"    <em>",
"     APC",
"    </em>",
"    &nbsp;or",
"    <em>",
"     MUTYH",
"    </em>",
"    &nbsp;gene, suggesting the presence of unidentified genes associated with multiple colorectal adenomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=see_link&amp;anchor=H1251987850#H1251987850\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Postpolypectomy surveillance for serrated adenoma/polyp",
"    </span>",
"   </p>",
"   <p>",
"    The United States Multi-Society Task Force on Colorectal Cancer recommends that patients with sessile serrated",
"    <span class=\"nowrap\">",
"     adenoma/polyps",
"    </span>",
"    <span class=\"nowrap\">",
"     (SSA/P)",
"    </span>",
"    that are &lt;10 mm and with no dysplasia should undergo a repeat colonoscopy in five years. Individuals with",
"    <span class=\"nowrap\">",
"     SSA/P",
"    </span>",
"    &ge;10 mm and a",
"    <span class=\"nowrap\">",
"     SSA/P",
"    </span>",
"    with dysplasia should undergo a repeat colonoscopy in three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/5\">",
"     5",
"    </a>",
"    ]. These are the first guidelines to address colonoscopy surveillance intervals in patients with",
"    <span class=\"nowrap\">",
"     SSA/Ps.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link&amp;anchor=H27#H27\">",
"     \"Approach to the patient with colonic polyps\", section on 'Surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Rescreening for colorectal cancer",
"    </span>",
"   </p>",
"   <p>",
"    Although colonoscopy is frequently chosen for the first-round of screening for colorectal cancer (CRC), the choice of screening modality following an initial negative study may differ. Since the risk of disease is significantly lower for second-round screening and beyond, options for subsequent testing may include no screening or testing using less-invasive or less-costly modalities. In the absence of trial data, a computer simulation model found that, compared with no screening, rescreening by any method following an initial negative colonoscopy reduced the risk of CRC&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/6\">",
"     6",
"    </a>",
"    ]. Rescreening with colonoscopy was projected to cause more complications and greater cost compared&nbsp;with other modalities (highly sensitive stool guaiac, fecal immunochemical testing, or CT colonography), with equivalent benefit measured as life-years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=see_link&amp;anchor=H3759928#H3759928\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\", section on 'Other factors that may impact screening test choice'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ENDOSCOPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adenoma detection rate in screening colonoscopy",
"    </span>",
"   </p>",
"   <p>",
"    Guidelines suggest that endoscopists performing average-risk screening colonoscopies&nbsp;should have minimum adenoma detection rates of 25 percent for men and 15 percent for women.&nbsp;However, in a prospective series&nbsp;of average-risk adults undergoing screening colonoscopy, the adenoma detection rate for men was 41 percent and for women was 25 percent (with advanced adenoma detection rates of 15 and 9 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/7\">",
"     7",
"    </a>",
"    ]. This study suggests that current benchmarks may be too low.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/28/31178?source=see_link&amp;anchor=H60870301#H60870301\">",
"     \"Overview of colonoscopy in adults\", section on 'Quality indicators'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL AND GASTRIC DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Blood transfusion thresholds for acute upper GI bleeding",
"    </span>",
"   </p>",
"   <p>",
"    The decision to initiate blood transfusions in patients with acute upper gastrointestinal bleeding is based on the rapidity of bleeding and the patients' comorbid conditions. A randomized trial of patients with and without cardiovascular disease suggests that in patients who are not at increased risk for complications from anemia, outcomes are improved if a lower hemoglobin threshold (&lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    rather than &lt;9",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    is used for initiating blood transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients transfused when the hemoglobin was &lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    had lower mortality rates, were less likely to have further bleeding, and were less likely to suffer complications.",
"    <br/>",
"    <br/>",
"    We recommend giving blood transfusions to maintain the hemoglobin at &ge;7",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    rather than &ge;9",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    for the majority of patients with acute upper gastrointestinal bleeding who do not have significant comorbid illnesses. However, patients with active bleeding and hypovolemia may require blood transfusion despite an apparently normal hemoglobin. Additionally, we suggest transfusing to maintain the hemoglobin at &ge;9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for patients at increased risk of adverse events in the setting of significant anemia, such as those with unstable coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link&amp;anchor=H5079586#H5079586\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Blood transfusions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44569?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Blood transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HEPATOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Everolimus should not be used within 30 days of liver transplantation",
"    </span>",
"   </p>",
"   <p>",
"    Everolimus is a semisynthetic form of sirolimus that may have a role as an immunosuppressant following liver transplantation. However, because of an increased risk of hepatic artery thrombosis in the early post-transplantation period, the US Food and Drug Administration recommends that everolimus",
"    <strong>",
"     not",
"    </strong>",
"    be used earlier than 30 days after liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/12/30922?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of immunosuppression in adult liver transplantation\", section on 'Everolimus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bosentan in portopulmonary hypertension",
"    </span>",
"   </p>",
"   <p>",
"    Bosentan is an endothelin receptor antagonist that is beneficial in the treatment of idiopathic pulmonary arterial hypertension. The effect of first-line treatment with bosentan for portopulmonary hypertension was examined in a case series of&nbsp;34&nbsp;consecutive patients&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/10\">",
"     10",
"    </a>",
"    ].&nbsp;Over a mean treatment duration of 43 months, significant improvements were noted in the New York Heart Association (NYHA) functional class, six-minute walk distance, and hemodynamics. Four patients died during follow-up, and seven had significant elevations in liver enzymes. Further studies are needed to fully clarify the&nbsp;role of bosentan in the&nbsp;treatment of portopulmonary hypertension.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35064?source=see_link&amp;anchor=H15#H15\">",
"     \"Portopulmonary hypertension\", section on 'Bosentan and ambrisentan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hepatoxicity associated with tolvaptan",
"    </span>",
"   </p>",
"   <p>",
"    Concerns about the safety of tolvaptan were raised by a multicenter trial (TEMPO 3:4) that examined its effect on the progression of kidney disease in polycystic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A greater than 2.5-fold increase in liver enzymes was more common among patients who received tolvaptan compared with placebo. Based upon these data, a safety warning was issued in the United States by the Food and Drug Administration (FDA) regarding the use of tolvaptan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/13\">",
"     13",
"    </a>",
"    ]. The FDA recommends that liver function tests be promptly performed among patients who report symptoms that suggest liver injury, including fatigue, anorexia, right upper quadrant discomfort, dark urine, or jaundice. In addition, we suggest that liver function tests be measured three to four months after initiating therapy and then again at six-month intervals. If liver injury is suspected, tolvaptan should be discontinued and not re-initiated unless the cause for liver injury is established to be unrelated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Limitations to use of tolvaptan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Revised listing criteria for liver transplantation in patients with cirrhosis and HCC",
"    </span>",
"   </p>",
"   <p>",
"    Orthotopic liver transplantation (OLT)&nbsp;is the only potentially curative treatment for hepatocellular cancer (HCC) arising in a cirrhotic liver that is not amenable to resection.&nbsp;To be eligible for OLT, and to receive exception MELD (Model for End Stage Liver Disease) points to prioritize for donor organ allocation,&nbsp;patients with HCC must meet strict criteria developed by the Organ Procurement and Transplantation",
"    <span class=\"nowrap\">",
"     Network/United",
"    </span>",
"    Network for Organ Sharing",
"    <span class=\"nowrap\">",
"     (OPTN/UNOS).&nbsp;A",
"    </span>",
"    prelisting biopsy is not mandatory; however,&nbsp;patients must have imaging findings that are consistent with HCC.",
"    <br/>",
"    <br/>",
"    The UNOS allocation policy previously included vague language as to acceptable imaging findings.&nbsp;However, as of December 2012, there are specific imaging criteria for HCC diagnosis and classification in cirrhotic livers&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef87919 \" href=\"mobipreview.htm?39/30/40428\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/14\">",
"     14",
"    </a>",
"    ]. OPTN Class 5 nodules correspond to an imaging diagnosis of HCC. Class 5B and 5T nodules are eligible for prioritization with a higher MELD score. A single OPTN Class 5A nodule corresponds to a&nbsp;T1 stage HCC and does not qualify for automatic priority MELD points. However, combinations of two to three class 5A nodules that meet stage T2 criteria are eligible for prioritization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H713421#H713421\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'United States'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Serious skin reactions due to telaprevir, peginterferon-alfa, and ribavirin",
"    </span>",
"   </p>",
"   <p>",
"    Rash and pruritus are common side effects in patients receiving telaprevir, peginterferon-alfa, and ribavirin for chronic infection with hepatitis C virus, genotype 1. In most cases the rash is mild to moderate but can be severe in about 4 percent of patients; fatalities have been reported in patients with progressive rash and systemic symptoms who continued to receive medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Because of this, US FDA issued a safety communication and is adding a black box warning to the licensing information instructing providers to discontinue telaprevir, peginterferon-alfa, and ribavirin immediately in patients who have a rash with systemic symptoms or a progressive severe rash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/15\">",
"     15",
"    </a>",
"    ]. For patients who develop mild to moderate non-progressive rash, without systemic symptoms, alternative management options can be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148836537#H148836537\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Telaprevir'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PANCREATIC AND BILIARY DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Multiple pancreatic cysts and risk for high-grade dysplasia or invasive cancer",
"    </span>",
"   </p>",
"   <p>",
"    Typically, pancreatic resection (partial or total) is recommended for patients with pancreatic cysts&nbsp;and features that&nbsp;suggest an increased risk for malignancy&nbsp;(eg, main pancreatic duct dilation to 10 mm or more, mural nodularity, or wall thickening). However, some data suggest that patients with multiple pancreatic cysts may have high-grade dysplasia or invasive carcinoma, even in the absence of worrisome computed tomographic (CT) findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/17\">",
"     17",
"    </a>",
"    ]. In a retrospective study of 43 patients with &ge;4 pancreatic&nbsp;cysts who underwent resection, 7 patients (16 percent) lacked worrisome CT findings but were found to have high-grade dysplasia or invasive carcinoma on pathologic examination. If these findings are confirmed in prospective studies, it may be reasonable to consider total pancreatectomy for young patients with multiple cysts who are good surgical candidates.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41753?source=see_link&amp;anchor=H5510679#H5510679\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SMALL BOWEL AND COLONIC DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ustekinumab for moderate to severe Crohn's disease",
"    </span>",
"   </p>",
"   <p>",
"    Ustekinumab is a human IgG",
"    <sub>",
"     1k",
"    </sub>",
"    monoclonal antibody that blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors for these cytokines on T cells, natural killer cells and antigen presenting cells. In a phase II trial, patients with moderate to severe Crohn&rsquo;s disease resistant to tumor necrosis factor (TNF) antagonists were randomized to intravenous ustekinumab or placebo for induction and maintenance of remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/18\">",
"     18",
"    </a>",
"    ]. At six weeks, patients who received 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of ustekinumab for induction of remission had significantly higher response rates as compared with placebo (40 versus 24 percent). During the maintenance phase, patients with an initial response to ustekinumab had significantly higher rates of response and remission at 22 weeks, as compared with placebo. However, larger studies are needed to establish the efficacy of ustekinumab in this patient group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6329?source=see_link&amp;anchor=H2897067#H2897067\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Ustekinumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Fecal microbiota transplant for Clostridium difficile infection",
"    </span>",
"   </p>",
"   <p>",
"    Approximately 25 percent of patients with Clostridium difficile (C. difficile)-associated diarrhea have recurrent disease after an initial course of antibiotic therapy. In an open label randomized controlled trial, 43 patients with recurrent C. difficile infection after at least one course of antibiotic therapy were randomly assigned to one of three treatment arms: duodenal infusion of donor feces preceded by an abbreviated regimen of vancomycin (vancomycin 500 mg four times daily for four days) and bowel lavage; a standard vancomycin regimen (vancomycin 500 mg four times daily for 14 days); or a standard vancomycin regimen with bowel lavage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/19\">",
"     19",
"    </a>",
"    ]. A single infusion of donor feces resulted in significantly higher rates of resolution of C. difficile-associated diarrhea without relapse at 10 weeks as compared with a standard vancomycin regimen with or without bowel lavage (81, 23, and 31 percent, respectively). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23960?source=see_link&amp;anchor=H11299943#H11299943\">",
"     \"Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection\", section on 'Administration via nasogastric tube'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OTHER GASTROENTEROLOGY AND NUTRITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Intravenous albumin for the prevention of hepatorenal syndrome",
"    </span>",
"   </p>",
"   <p>",
"    Several trials have suggested that, in patients with spontaneous bacterial peritonitis (SBP), the administration of intravenous albumin (1.5",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    at the time that the infection is diagnosed&nbsp;and another dose of albumin (1",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    on day&nbsp;three of antibiotic treatment may improve outcomes.&nbsp;In a&nbsp;meta-analysis of four controlled trials (with a total of 288 patients), albumin infusion (in addition to antibiotics) significantly decreased the incidence of renal impairment (8 versus 31 percent) and mortality (16 versus 35 percent) compared with antibiotics alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/20\">",
"     20",
"    </a>",
"    ].&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/50/29482?source=see_link&amp;anchor=H21#H21\">",
"     \"Hepatorenal syndrome\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Antibiotic exposure and risk for inflammatory bowel disease",
"    </span>",
"   </p>",
"   <p>",
"    Genetic and environmental factors contribute to the risk of developing inflammatory bowel disease (IBD). A new study suggests that exposure during early childhood to antibiotics that target anaerobic bacteria increases the risk for IBD. This was shown in a large population study from the United Kingdom, in which anti-anaerobic antibiotic exposure increased the relative risk for IBD by 84 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44086/abstract/21\">",
"     21",
"    </a>",
"    ]. The risk was greatest for exposures before one year of age as compared with later in childhood or adolescence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/13/3288?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents\", section on 'Perinatal and early exposures'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/1\">",
"      Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/2\">",
"      Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/3\">",
"      Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012; 308:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/4\">",
"      Grover S, Kastrinos F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 2012; 308:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/5\">",
"      Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012; 143:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/6\">",
"      Knudsen AB, Hur C, Gazelle GS, et al. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med 2012; 157:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/7\">",
"      Coe SG, Wallace MB. Assessment of adenoma detection rate benchmarks in women versus men. Gastrointest Endosc 2013; 77:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/8\">",
"      Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:11.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm303659.htm (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/10\">",
"      Savale L, Magnier R, Le Pavec J, et al. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J 2013; 41:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/11\">",
"      Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 2011; 6:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/12\">",
"      Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:2407.",
"     </a>",
"    </li>",
"    <li>",
"     Samsca (tolvaptan): Drug Warning - Potential Risk of Liver Injury file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm336669.htm?source=govdelivery (Accessed on January 28, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/14\">",
"      Wald C, Russo MW, Heimbach JK, et al. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013; 266:376.",
"     </a>",
"    </li>",
"    <li>",
"     Incivek (telaprevir) In Combination with Drugs Peginterferon Alfa and Ribavirin (Incivek combination treatment): Drug Safety Communication - Serious Skin Reactions file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm332860.htm (Accessed on December 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/16\">",
"      Jacobson IM, McHutchison JG, Dusheiko GM. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: Final results of phase 3 ADVANCE study. Hepatology 2010; 52:427A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/17\">",
"      Raman SP, Kawamoto S, Blackford A, et al. Histopathologic findings of multifocal pancreatic intraductal papillary mucinous neoplasms on CT. AJR Am J Roentgenol 2013; 200:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/18\">",
"      Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/19\">",
"      van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/20\">",
"      Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013; 11:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44086/abstract/21\">",
"      Kronman MP, Zaoutis TE, Haynes K, et al. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 2012; 130:e794.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8351 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44086=[""].join("\n");
var outline_f43_3_44086=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      COLORECTAL CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Aspirin for the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Universal tumor testing for Lynch syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence of APC and MUTYH mutations among individuals with multiple adenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Postpolypectomy surveillance for serrated adenoma/polyp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Rescreening for colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adenoma detection rate in screening colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ESOPHAGEAL AND GASTRIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Blood transfusion thresholds for acute upper GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HEPATOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Everolimus should not be used within 30 days of liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bosentan in portopulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hepatoxicity associated with tolvaptan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Revised listing criteria for liver transplantation in patients with cirrhosis and HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Serious skin reactions due to telaprevir, peginterferon-alfa, and ribavirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PANCREATIC AND BILIARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Multiple pancreatic cysts and risk for high-grade dysplasia or invasive cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SMALL BOWEL AND COLONIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ustekinumab for moderate to severe Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Fecal microbiota transplant for Clostridium difficile infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OTHER GASTROENTEROLOGY AND NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Intravenous albumin for the prevention of hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Antibiotic exposure and risk for inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/8351\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/8351|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/47/40702\" title=\"table 1\">",
"      Aspirin for CVD and cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/30/40428\" title=\"table 2\">",
"      OPTN classification for nodules in cirrhotic livers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23529?source=related_link\">",
"      Aspirin in the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41753?source=related_link\">",
"      Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/13/3288?source=related_link\">",
"      Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23960?source=related_link\">",
"      Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=related_link\">",
"      Liver transplantation for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/28/31178?source=related_link\">",
"      Overview of colonoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/12/30922?source=related_link\">",
"      Overview of immunosuppression in adult liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6329?source=related_link\">",
"      Overview of the medical management of severe or refractory Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35064?source=related_link\">",
"      Portopulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_3_44087="Classification of scleroderma disorders";
var content_f43_3_44087=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification of scleroderma disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/3/44087/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44087/contributors\">",
"     Christopher P Denton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/3/44087/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44087/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/3/44087/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44087/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/3/44087/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scleroderma disorders comprise a heterogeneous group of conditions linked by the presence of thickened, sclerotic skin lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the other manifestations of these conditions are quite diverse. These differences have required the development of a classification system that takes into account the different potential complications, prognoses, and management strategies for patients with these disorders.",
"   </p>",
"   <p>",
"    The simplest division of the scleroderma-related disorders is into localized and systemic forms of the disease (",
"    <a class=\"graphic graphic_table graphicRef60398 \" href=\"mobipreview.htm?1/22/1388\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80559 \" href=\"mobipreview.htm?3/41/3741\">",
"     table 2",
"    </a>",
"    ). The term systemic sclerosis (SSc) is more appropriate for the latter forms; it emphasizes that frequent involvement of internal organs is generally the most important manifestation of these conditions.",
"   </p>",
"   <p>",
"    Disorders other than SSc can cause skin thickening. As examples, scleroderma-like skin changes can occur in some endocrine disorders (eg, diabetes mellitus and hypothyroidism), in end-stage renal disease (nephrogenic systemic fibrosis), and in conjunction with inflammatory (eg, eosinophilic fasciitis) and infiltrative (eg, amyloid) disorders. Sclerodermatous skin changes may occur as a result of exposure to certain drugs, toxins, and environmental exposures. These and other causes of sclerodermatous skin changes or non-sclerodermatous skin thickening are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43095?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LOCALIZED SCLERODERMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized scleroderma can be divided into linear scleroderma (en coup de sabre) and localized and generalized morpheae (",
"    <a class=\"graphic graphic_table graphicRef60398 \" href=\"mobipreview.htm?1/22/1388\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40985?source=see_link\">",
"     \"Localized scleroderma in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Linear scleroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linear scleroderma (most commonly occurring in childhood) causes abnormalities of the skin and subcutaneous tissues that often follow a dermatomal distribution and that are found predominantly on one side of the body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      En coup de sabre &mdash; In this type of linear scleroderma, the phrase &ldquo;en coup de sabre&rdquo; was coined to denote the resemblance of the lesions to the consequences of a sabre blow (",
"      <a class=\"graphic graphic_picture graphicRef75258 graphicRef62452 graphicRef73173 graphicRef80877 \" href=\"mobipreview.htm?21/10/21674\">",
"       picture 1A-D",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/3\">",
"       3",
"      </a>",
"      ]. The face or scalp lesion is accompanied by marked abnormalities of underlying mesenchymally-derived tissues, including the skull.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Morphea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morpheae can be divided into localized (circumscribed) or generalized disease and are characterized by patches of sclerotic skin that develop on the trunk and limbs at sites of previously normal texture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Localized morphea refers to the presence of one or more circumscribed isolated plaques of sclerotic skin (",
"      <a class=\"graphic graphic_picture graphicRef73912 \" href=\"mobipreview.htm?27/25/28063\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      By comparison, skin changes are much more widespread in generalized morphea (",
"      <a class=\"graphic graphic_picture graphicRef56113 graphicRef68904 \" href=\"mobipreview.htm?36/45/37587\">",
"       picture 3A-B",
"      </a>",
"      ). These lesions often symmetrically involve the trunk and limbs and can lead to widespread skin sclerosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to the widespread skin involvement, severe generalized morphea must be distinguished from diffuse SSc. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Limited and diffuse cutaneous SSc'",
"    </a>",
"    below.) As opposed to SSc, generalized morphea typically spares the hands and face and is not associated with major vascular symptoms or with visceral disease. Nevertheless, widespread morphea is not benign and may require the use of the same immunosuppressive and antifibrotic regimens as used in diffuse cutaneous SSc.",
"   </p>",
"   <p>",
"    Other variants include guttate morphea (",
"    <a class=\"graphic graphic_picture graphicRef55918 \" href=\"mobipreview.htm?40/4/41038\">",
"     picture 4",
"    </a>",
"    ) and morphea profunda. In guttate morphea, the shoulders and chest are frequently involved with multiple, small (2 to 10 mm in diameter), hypopigmented and pigmented papules, with minimal sclerosis. Morphea profunda is a subcutaneous variant with a significant inflammatory component and poorly defined skin borders. Bullous disease is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies to DNA topoisomerase II appear to be very prevalent in localized forms of scleroderma, including generalized morphea. This was illustrated by a study of 46 Japanese patients with linear scleroderma or morphea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/6\">",
"     6",
"    </a>",
"    ]. Anti-topoisomerase II antibodies were found in 11 of 13 patients (85 percent) with widespread morphea and in 35 of 46 patients (76 percent) with any type of localized scleroderma. A lower prevalence of anti-topoisomerase II antibodies is found in patients with SSc (14 percent), with systemic lupus erythematosus (8 percent), and with dermatomyositis (10 percent) and in healthy persons (7 percent). Unlike testing for antibodies to topoisomerase I (anti-Scl-70), a commercial assay for anti-topoisomerase II is not available.",
"   </p>",
"   <p>",
"    It has been observed that other autoantibodies associated with SSc and other autoimmune rheumatic diseases also occur in localized scleroderma. However, such antibodies are not predictive of systemic manifestations, and their significance is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SYSTEMIC SCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of skin involvement and the accompanying pattern of internal organ involvement form the basis for the classification of SSc (",
"    <a class=\"graphic graphic_table graphicRef80559 \" href=\"mobipreview.htm?3/41/3741\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/1\">",
"     1",
"    </a>",
"    ]. The skin sclerosis score is a cornerstone for the classification of SSc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/8\">",
"     8",
"    </a>",
"    ]. The most widely used scoring system grades skin sclerosis at 17 sites, with scores at each site being 0 (normal), 1 (equivocal sclerosis), 2 (definite sclerosis), or 3 (hide-bound). The rate of increase and the maximum skin score can reflect disease severity and mortality, particularly among patients with diffuse disease.",
"   </p>",
"   <p>",
"    The principal subsets of SSc are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diffuse cutaneous SSc (dcSSc)",
"     </li>",
"     <li>",
"      Limited cutaneous SSc (lcSSc)",
"     </li>",
"     <li>",
"      SSc sine scleroderma, in which patients have only internal organ involvement",
"     </li>",
"     <li>",
"      Environmentally-induced scleroderma",
"     </li>",
"     <li>",
"      Overlap syndromes, in which features of SSc coexist with elements of other rheumatic disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Limited and diffuse cutaneous SSc",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSc is generally subdivided into limited and diffuse cutaneous subsets. One-third of patients with SSc have the more severe diffuse form of the disease.",
"   </p>",
"   <p>",
"    These two subsets are principally distinguished by the extent of skin sclerosis and by the forms of organ involvement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited cutaneous SSc &mdash; Patients with limited cutaneous SSc (lcSSc) typically have skin sclerosis restricted to the hands and, to a lesser extent, to the face and neck. They also have prominent vascular manifestations and may suffer from the CREST syndrome (",
"      <strong>",
"       C",
"      </strong>",
"      alcinosis cutis,",
"      <strong>",
"       R",
"      </strong>",
"      aynaud phenomenon,",
"      <strong>",
"       E",
"      </strong>",
"      sophageal dysmotility,",
"      <strong>",
"       S",
"      </strong>",
"      clerodactyly, and",
"      <strong>",
"       T",
"      </strong>",
"      elangiectasia). The presence of severe vascular abnormalities on nailfold capillary microscopy may be another sensitive indicator of the presence of lcSSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diffuse cutaneous SSc &mdash; Patients with dcSSc have extensive skin sclerosis and are at a greater risk for the development of significant renal, lung, and cardiac disease. The central criterion for the diagnosis of dcSSc is the extension of skin sclerosis proximal to the wrists (particularly over the proximal limbs and trunk but commonly sparing the upper back). Since early active dcSSc has a lower survival rate than that of many malignancies, it is usually regarded as the most important disease subset in which to establish an early definitive diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     SSc sine scleroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSc sine scleroderma is a rare form of the illness and is characterized by the typical vascular features and visceral fibrosis of systemic disease without skin sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/12\">",
"     12",
"    </a>",
"    ]. Despite visceral involvement, the prognosis of those with this disorder is similar to patients with limited cutaneous SSc. In one study, five-year survival was approximately 80 percent for both groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Environmentally-induced scleroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmentally-induced scleroderma is characterized by the generally diffuse distribution of skin sclerosis in combination with a history of exposure to an agent suspected of precipitating scleroderma. Candidate initiating agents include vinyl chloride, epoxy resins, pesticides, and a number of organic solvents used in paints. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/65?source=see_link\">",
"     \"Risk factors for and possible causes of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Overlap syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who demonstrate some features of SSc (or uncommonly localized scleroderma) in combination with manifestations of other rheumatic diseases, such as systemic lupus erythematosus, dermatomyositis, or rheumatoid arthritis, are considered to have an overlap syndrome. This heterogeneous group poses an important management problem and also provides indirect evidence that common etiologic and pathogenetic processes may underlie these various conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42968?source=see_link\">",
"     \"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with certain clinical features may have an increased risk of developing SSc. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The accurate diagnosis of patients who present with the Raynaud phenomenon (RP) is important since some may develop SSc or another connective tissue disorder. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"      </a>",
"      .) Such patients are sometimes designated as having &ldquo;autoimmune Raynaud phenomenon&rdquo; and are characterized by abnormal nailfold capillaroscopic findings and by the presence of positive antinuclear antibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/14\">",
"       14",
"      </a>",
"      ]. Individuals with definite RP who also demonstrate one of the hallmark autoantibodies of SSc, such as anticentromere, antitopoisomerase I, or anti RNA polymerase I or III antibodies, may be designated as having pre-scleroderma.",
"     </li>",
"     <li>",
"      Immunogenetic associations may predict the ultimate clinical phenotype in patients in the early stages of an overlap syndrome. Among 56 patients initially diagnosed with mixed connective tissue disease, for example, 13 eventually developed SSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/15\">",
"       15",
"      </a>",
"      ]. An increased likelihood of developing SSc was found with the inheritance of human leukocyte antigen (HLA)-DR5.",
"     </li>",
"     <li>",
"      Autoantibodies directed against the interferon-inducible gene IFI-16 may also affect the phenotype of SSc. IFI-16 gene expression was greatly increased in the skin of patients with both SLE and SSc. In addition, autoantibodies to this antigen were increased in 50 percent of patients with Sj&ouml;gren&rsquo;s syndrome, in 26 percent of patients with systemic lupus erythematosus, and in 5 percent of healthy controls. Although these autoantibodies were found in only 21 percent of patients with SSc, elevated levels were found predominately in patients with lcSSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Classifying early disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification criteria that require the presence of scleroderma (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Classification systems'",
"    </a>",
"    below) may sacrifice specificity for sensitivity. Use of capillary nailfold microscopy and serologic testing for autoantibodies associated with SSc may improve the sensitivity. Classification based upon the presence of one or more of the following features has been suggested to facilitate early diagnosis of SSc in the absence of scleroderma skin changes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      RP plus abnormal wide-field capillary microscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/10,17\">",
"       10,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      RP plus autoantibodies (anti-centromere, anti-topoisomerase I, anti-fibrillarin, anti-PM-Scl, or anti-RNA polymerase I or III) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These proposed criteria for early SSc have not been tested thoroughly. Retrospective application suggests their use increases the sensitivity of criteria-based classification substantially. As an example, among 259 French-Canadian patients with a clinical diagnosis of SSc for whom capillary microscopy and autoantibody testing results were available, the sensitivity increased from 33 to 92 percent when these features were incorporated into classification criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a growing appreciation that early identification of scleroderma cases will require revision of diagnostic and classification criteria; this is an ongoing research priority [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/18\">",
"     18",
"    </a>",
"    ]. The presence of abnormal findings on nailfold capillary microscopy that are characteristic of SSc or of SSc-specific autoantibodies is predictive of the development of scleroderma in patients with the Raynaud phenomenon. In a prospective study of 586 such patients who were consecutively referred, patients with both abnormal nailfold capillary microscopy and positive autoantibodies at baseline evaluation, compared with patients with neither finding, were significantly more likely to develop SSc during 10 years of follow-up (73 versus 2 percent, adjusted hazard ratio 60.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLASSIFICATION SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heterogeneous nature of scleroderma, a greater understanding of pathogenesis, and the wide range of potential therapies have necessitated disease subclassification. Unfortunately, a number of different classification systems have developed in various countries, since some systems were not developed through international discussion and collaboration.",
"   </p>",
"   <p>",
"    The two-subset model of SSc described here, which is based upon the degree and type of skin involvement (limited and diffuse cutaneous), has been most widely used in the United Kingdom and in North America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/20\">",
"     20",
"    </a>",
"    ]. It is a useful system that identifies clinically important subgroups but has limitations in that some cases are difficult to classify, and it does not take account of overlap features present in up to one-fifth of cases. However, the validity of this model is supported, in part, by the observation that the time course of disease, as well as the pattern and extent of disease complications, appears to correlate with the subsets of SSc (",
"    <a class=\"graphic graphic_table graphicRef67889 \" href=\"mobipreview.htm?42/17/43292\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/21\">",
"     21",
"    </a>",
"    ]. An example of an alternative classification system was a system used in some European countries in which a third category of SSc (intermediate cutaneous SSc) was recognized. This disorder was characterized by an intermediate pattern of skin change among patients that extended onto (but not beyond) the forearms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strategies to look at different rates of progression or improvement in dcSSc suggest that there may be defined subgroups within the diffuse subset, which may reflect differences in inherent genetic or other characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/23\">",
"     23",
"    </a>",
"    ]. Such differences may underlie the relatively poor correlation between severity of skin changes and organ-based complications observed in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is likely that newer classification systems that take into account the increasing number of genetic and serologic predictors of end-organ involvement in SSc will increasingly augment and ultimately replace these older systems. This approach may help to identify subgroups at particular risk of life-threatening complications, such as renal crisis, lung fibrosis, and possibly pulmonary hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/25\">",
"     25",
"    </a>",
"    ]. (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Future approaches'",
"    </a>",
"    below)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the two-subset classification system of SSc is of value, it is limited by the fact that clinical outcomes within each major subset are so varied. As an example, although overall survival is worse for dcSSc than for lcSSc, certain patients with lcSSc have very high mortality rates:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with lcSSc who develop isolated pulmonary hypertension (approximately 10 percent of cases) have a mortality rate of 60 percent at five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with lcSSc who develop significant lung fibrosis or acute renal failure have a similarly poor prognosis as those with dcSSc and have an equivalent degree of organ involvement.",
"     </li>",
"     <li>",
"      Some cases of dcSSc show regression of skin at later stages of their disease and may no longer fulfill criteria for diffuse subset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fortunately, some predictors of these complications are being recognized. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Future approaches'",
"    </a>",
"    below.) These predictors should ultimately be incorporated into better and more reliable approaches to classification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Future approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification of SSc and related disorders may ultimately be based upon genetic and immunologic markers such as the presence of particular autoantibodies, which are associated with an increased risk of specific complications (",
"    <a class=\"graphic graphic_table graphicRef59732 \" href=\"mobipreview.htm?10/18/10541\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/63/19450?source=see_link\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One major limitation of this type of classification system is the variable association between race, types of disease, and patterns of autoantibodies or histocompatibility haplotypes. As an example, HLA-DR52a is associated with an increased risk of lung fibrosis in Caucasians but is not a risk factor in other racial groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Autoantibodies and disease manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenic elements that underlie the association between particular autoantibodies, specific disease subtypes, and different patient populations are becoming increasingly clear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies in Japanese and European patients suggest that antibodies to topoisomerase-I (Scl-70) are associated with an increased risk of pulmonary fibrosis in both the dcSSc and the lcSSc subsets [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/29-33\">",
"       29-33",
"      </a>",
"      ]. The ability and propensity to produce these antibodies have subsequently been shown to be closely associated with the inheritance of a particular major histocompatibility complex (MHC) class II haplotype. Patients with SSc and these particular class II alleles were found to invariably express anti-topoisomerase antibodies. Furthermore, isolated lymphocyte cultures from healthy individuals with these same haplotypes also responded to recombinant topoisomerase-I by producing antibodies against this protein [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. An association of either anti",
"      <span class=\"nowrap\">",
"       Th/To",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       anti-U11/U12-ribonucleoprotein",
"      </span>",
"      (RNP) autoantibodies with lung fibrosis has been observed in both limited and diffuse SSc subsets [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anticentromere antibodies (ACA) are almost always indicative of lcSSc and are particularly seen in the classical CREST variants of this condition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/33,39\">",
"       33,39",
"      </a>",
"      ]. Particular class II HLA haplotypes and the presence of particular amino acids in the second hypervariable region among patients with HLA-DQB1 may be associated with the development of ACAs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is likely that similar MHC associations will eventually be defined for the other SSc hallmark antibodies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/63/19450?source=see_link\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the striking features of the hallmark autoantibodies in SSc is their relatively exclusive association with specific types of scleroderma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/41\">",
"     41",
"    </a>",
"    ]. The significance of this characteristic remains unclear, but it strengthens the view that subgroups defined serologically are genuinely distinct and do not represent a continuous spectrum of autoantibody expression. In the black North American population, for example, antibodies to U3-RNP have been associated with a particularly severe form of diffuse SSc and are especially associated with an increased risk of developing pulmonary hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a system based upon risk predictors and serologically-based subsets is promising, it cannot replace the established system based upon skin sclerosis. A proportion of both lcSSc patients and dcSSc patients do not have any autoantibodies other than nonspecific antinuclear antibodies. Nevertheless, advances in understanding the clinical associations of serological or genetic markers permit the analysis of specific autoantibodies to augment the classification system (",
"    <a class=\"graphic graphic_table graphicRef59732 \" href=\"mobipreview.htm?10/18/10541\">",
"     table 4",
"    </a>",
"    ). Antibody-based subsets are useful in clinical management as they can help predict likelihood of later organ-based complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Molecular correlates of SSc subsets",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is potential for biochemical analysis to provide additional complementary approaches to disease classification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/45\">",
"     45",
"    </a>",
"    ]. Studies of gene expression profiles from scleroderma skin biopsies have suggested further methods of distinguishing SSc subsets, with subgroups within both the dcSSc and lcSSc subsets each showing distinct patterns of gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44087/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The clinical implications of this research remain to be determined, but studies of this type may help to develop more targeted therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H819403\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The scleroderma disorders comprise a heterogeneous group of conditions linked by the presence of thickened, sclerotic skin lesions. The simplest division of the scleroderma-related disorders is into localized and systemic forms of the disease (",
"      <a class=\"graphic graphic_table graphicRef60398 \" href=\"mobipreview.htm?1/22/1388\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef80559 \" href=\"mobipreview.htm?3/41/3741\">",
"       table 2",
"      </a>",
"      ). The term systemic sclerosis (SSc) is more appropriate for the latter forms; it emphasizes that frequent involvement of internal organs is generally the most important manifestation of these conditions. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Localized scleroderma can be divided into linear scleroderma (en coup de sabre), which most commonly occurs in childhood and follows a dermatomal distribution on one side of the body, and localized and generalized morpheae, which are characterized by patches of sclerotic skin that develop on the trunk and limbs at sites of previously normal texture (",
"      <a class=\"graphic graphic_table graphicRef60398 \" href=\"mobipreview.htm?1/22/1388\">",
"       table 1",
"      </a>",
"      ). Unlike SSc, generalized morphea typically spares the hands and face and is not associated with major vascular symptoms or with visceral disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Localized scleroderma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extent of skin involvement and the accompanying pattern of internal organ involvement form the basis for the classification of SSc (",
"      <a class=\"graphic graphic_table graphicRef80559 \" href=\"mobipreview.htm?3/41/3741\">",
"       table 2",
"      </a>",
"      ). Use of capillary nailfold microscopy and serologic testing for autoantibodies associated with SSc may improve the sensitivity of classification criteria that require the presence of scleroderma. The principal subsets of SSc are (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Systemic sclerosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Diffuse cutaneous SSc (dcSSc) (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Limited and diffuse cutaneous SSc'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Limited cutaneous SSc (lcSSc) (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Limited and diffuse cutaneous SSc'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      SSc sine scleroderma, in which patients have only internal organ involvement (see",
"      <a class=\"local\" href=\"#H7\">",
"       'SSc sine scleroderma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Environmentally-induced scleroderma (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Environmentally-induced scleroderma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Overlap syndromes, in which features of SSc coexist with elements of other rheumatic disorders (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Overlap syndromes'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the two-subset classification system of SSc is of value, it is limited by the fact that clinical outcomes within each major subset are so varied, and some cases remain difficult to classify. The classification of SSc and related disorders may ultimately be based upon genetic and immunologic markers such as the presence of particular autoantibodies, which are associated with an increased risk of specific complications (",
"      <a class=\"graphic graphic_table graphicRef59732 \" href=\"mobipreview.htm?10/18/10541\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Classification systems'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Limitations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Future approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/1\">",
"      Black CM. Scleroderma--clinical aspects. J Intern Med 1993; 234:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/2\">",
"      Falanga V, Medsger TA Jr, Reichlin M, Rodnan GP. Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med 1986; 104:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/3\">",
"      Black CM. Scleroderma and fasciitis in children. Curr Opin Rheumatol 1995; 7:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/4\">",
"      Falanga V. Localized scleroderma. Med Clin North Am 1989; 73:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/5\">",
"      Rencic A, Goyal S, Mofid M, et al. Bullous lesions in scleroderma. Int J Dermatol 2002; 41:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/6\">",
"      Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma. Arthritis Rheum 2004; 50:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/7\">",
"      Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol 2006; 18:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/8\">",
"      Black CM. Measurement of skin involvement in scleroderma. J Rheumatol 1995; 22:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/9\">",
"      LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/10\">",
"      Lonzetti LS, Joyal F, Raynauld JP, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001; 44:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/11\">",
"      Silman AJ. Scleroderma. Baillieres Clin Rheumatol 1995; 9:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/12\">",
"      Molina JF, Anaya JM, Cabrera GE, et al. Systemic sclerosis sine scleroderma: an unusual presentation in scleroderma renal crisis. J Rheumatol 1995; 22:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/13\">",
"      Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/14\">",
"      Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/15\">",
"      Gendi NS, Welsh KI, Van Venrooij WJ, et al. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum 1995; 38:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/16\">",
"      Mondini M, Vidali M, De Andrea M, et al. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. Arthritis Rheum 2006; 54:3939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/17\">",
"      LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/18\">",
"      Matucci-Cerinic M, Allanore Y, Czirj&aacute;k L, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 2009; 68:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/19\">",
"      Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58:3902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/20\">",
"      Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/21\">",
"      Steen VD, Medsger TA Jr. Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am 1990; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/22\">",
"      Valentini G. Classification of systemic sclerosis. Clin Dermatol 1994; 12:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/23\">",
"      Shand L, Lunt M, Nihtyanova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007; 56:2422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/24\">",
"      Hanitsch LG, Burmester GR, Witt C, et al. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. Rheumatology (Oxford) 2009; 48:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/25\">",
"      Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy. Lancet 1996; 347:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/26\">",
"      Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/27\">",
"      Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/28\">",
"      Black C, Briggs D, Welsh K. The immunogenetic background of scleroderma--an overview. Clin Exp Dermatol 1992; 17:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/29\">",
"      Kuwana M, Medsger TA Jr, Wright TM. T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. J Clin Invest 1995; 96:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/30\">",
"      Kuwana M, Okano Y, Kaburaki J, Inoko H. HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma). Ann Rheum Dis 1995; 54:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/31\">",
"      Kuwana M, Kaburaki J, Okano Y, et al. The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). J Clin Invest 1993; 92:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/32\">",
"      Diot E, Giraudeau B, Diot P, et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999; 116:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/33\">",
"      Ingegnoli F, Trabattoni D, Saresella M, et al. Distinct immune profiles characterize patients with diffuse or limited systemic sclerosis. Clin Immunol 2003; 108:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/34\">",
"      Kuwana M, Medsger TA Jr, Wright TM. T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis. J Immunol 1995; 155:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/35\">",
"      Whyte J, Artlett C, Harvey G, et al. HLA-DQB1 associations with anti-topoisomerase-1 antibodies in patients with systemic sclerosis and their first degree relatives. United Kingdom Systemic Sclerosis Study Group. J Autoimmun 1994; 7:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/36\">",
"      Reveille JD, Durban E, MacLeod-St Clair MJ, et al. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 1992; 90:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/37\">",
"      Mitri GM, Lucas M, Fertig N, et al. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003; 48:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/38\">",
"      Fertig N, Domsic RT, Rodriguez-Reyna T, et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009; 61:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/39\">",
"      Tan EM, Rodnan GP, Garcia I, et al. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980; 23:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/40\">",
"      Reveille JD, Owerbach D, Goldstein R, et al. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma). J Clin Invest 1992; 89:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/41\">",
"      Fanning G, Bunn C, Welsh KI, Black CM. HLA and the mutual exclusivity of autoantibodies in SSc (abstract). Arthritis Rheum 1994; 39:S234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/42\">",
"      Okano Y, Steen VD, Medsger TA Jr. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992; 35:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/43\">",
"      Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009; 60:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/44\">",
"      Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010; 6:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/45\">",
"      Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008; 3:e2696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/46\">",
"      Sargent JL, Milano A, Connolly MK, Whitfield ML. Scleroderma gene expression and pathway signatures. Curr Rheumatol Rep 2008; 10:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44087/abstract/47\">",
"      Bos CL, van Baarsen LG, Timmer TC, et al. Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers. Genes Immun 2009; 10:210.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7545 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-481C146FAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44087=[""].join("\n");
var outline_f43_3_44087=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H819403\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LOCALIZED SCLERODERMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Linear scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Morphea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SYSTEMIC SCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Limited and diffuse cutaneous SSc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SSc sine scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Environmentally-induced scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Overlap syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Classifying early disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLASSIFICATION SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Future approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Autoantibodies and disease manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Molecular correlates of SSc subsets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H819403\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7545\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7545|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/21/25938\" title=\"picture 1A\">",
"      En coup de sabre - central forehead",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/52/2883\" title=\"picture 1B\">",
"      En coup de sabre - alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/26/12704\" title=\"picture 1C\">",
"      En coup de sabre - two examples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/52/42816\" title=\"picture 1D\">",
"      En coup de sabre - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/25/28063\" title=\"picture 2\">",
"      Circumscribed morphea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/38/1632\" title=\"picture 3A\">",
"      Generalized morphea - trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/40/26255\" title=\"picture 3B\">",
"      Generalized morphea - legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/4/41038\" title=\"picture 4\">",
"      Guttate morphea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7545|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/22/1388\" title=\"table 1\">",
"      Localized scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/41/3741\" title=\"table 2\">",
"      Systemic sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/17/43292\" title=\"table 3\">",
"      Features of systemic sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/18/10541\" title=\"table 4\">",
"      Autoantibodies in scleroderma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43095?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40985?source=related_link\">",
"      Localized scleroderma in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/63/19450?source=related_link\">",
"      Pathogenesis of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/65?source=related_link\">",
"      Risk factors for and possible causes of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42968?source=related_link\">",
"      Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_3_44088="Bipolar disorder in adults: Pharmacotherapy for acute depression";
var content_f43_3_44088=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bipolar disorder in adults: Pharmacotherapy for acute depression",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/3/44088/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44088/contributors\">",
"     Jeffrey Stovall, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/3/44088/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44088/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/3/44088/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/3/44088/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/3/44088/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3148202429\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is an illness characterized by periods of pathologic mood elevation. Patients with bipolar I disorder have manic episodes or mixed (concurrent mood elevation and depression) episodes, and nearly always experience depressive episodes. The clinical course in patients with bipolar II disorder is characterized by one or more episodes of major depression, with at least one hypomanic episode.",
"   </p>",
"   <p>",
"    Recognition of bipolar disorder is important for at least two reasons: it is associated with substantial morbidity and mortality if untreated, and treatment differs from that of unipolar depression. Bipolar disorder is often misdiagnosed, especially when patients present with symptoms of depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/1\">",
"     1",
"    </a>",
"    ]. A careful history, including information from family members, may find evidence of prior manic, mixed, or hypomanic episodes.",
"   </p>",
"   <p>",
"    The treatment of acute bipolar depression is reviewed here. Treatment of acute mania, mixed states, hypomania; maintenance treatment; and the epidemiology, clinical manifestations, and diagnosis of bipolar disorder are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"     \"Bipolar disorder in adults: Maintenance treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3148204449\">",
"    <span class=\"h1\">",
"     STAGE OF ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals for treating for bipolar depression are based upon the patient's current stage of illness, generally categorized as three phases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The acute phase of treatment focuses upon managing the patient&rsquo;s safety and the presenting symptoms. Patients in the acute phase may be suicidal, psychotic, and display such poor judgment as to pose an imminent risk to themselves. Hospitalization is often necessary until the severity of symptoms lessens.",
"     </li>",
"     <li>",
"      The continuation phase lasts weeks to months, during which remission of symptoms and restoration of functioning is preserved with ongoing treatment. The goal is to prevent relapse of the mood episode.",
"     </li>",
"     <li>",
"      The maintenance phase of treatment lasts months to years after recovery from the mood episode, and aims to prevent recurrence of a new mood episode. Long-term or lifetime maintenance is recommended for patients who have suffered one manic episode [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. Maintenance treatment is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"       \"Bipolar disorder in adults: Maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48563594\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of bipolar depression begins with the clinical assessment for risk of suicide, aggressiveness, and violence to others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Patients should reduce their use of alcohol, and other substance use disorders should also be evaluated and treated. In addition, clinicians should address current psychosocial problems when patients are amenable. Patients who experience a breakthrough depressive episode while on maintenance therapy should be assessed for adherence to treatment, and initially managed by optimizing their current medication dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although depressive episodes occur more frequently than manic episodes, and have greater impact on the quality of life, treatment of bipolar depression has not been as extensively studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Treatment of depressive syndromes is based upon what has been established for bipolar I disorder, even though bipolar II disorder is more prevalent.",
"   </p>",
"   <p>",
"    Drug classes commonly used to treat patients with acute depressive episodes include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antidepressants",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"     </li>",
"     <li>",
"      Anticonvulsants",
"     </li>",
"     <li>",
"      Second-generation antipsychotics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goal of treatment is full remission of the depressive syndrome. However, some patients may not fully remit with any of the currently available medications, and it is important to maintain realistic expectations and avoid unhelpful polypharmacy. Persistent efforts to achieve full remission may be one reason that a study of 4035 bipolar patients, treated at 22 mood disorder specialty clinics, found use of three or more medications occurred in 40 percent of the patients, while 18 percent of patients received four or more medications. In addition, clinicians may need to consider other treatment options, such as psychotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89770741\">",
"    <span class=\"h1\">",
"     SPECIFIC TREATMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3148203905\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     Fluoxetine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    efficaciously treats bipolar depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. As an example, a randomized trial (833 patients with bipolar I depression) found that remission occurred in significantly more patients who received fluoxetine plus olanzapine, compared with olanzapine alone or placebo alone (49 versus 33 and 25 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the evidence is mixed whether adjunctive antidepressants in general are efficacious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/12\">",
"     12",
"    </a>",
"    ]. The efficacy and risks of using antidepressants to treat bipolar major depression are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37417?source=see_link\">",
"     \"Bipolar disorder in adults: Treating major depression with antidepressants\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3148203912\">",
"    <span class=\"h2\">",
"     Lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple placebo-controlled trials, many completed prior to 1980, have evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    therapy in patients with bipolar depression. A review of these older studies, involving 160 patients, found that the \"unequivocal\" lithium response rate (ie, a good or moderate response to lithium, and subsequent relapse with placebo) was approximately 36 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/13\">",
"     13",
"    </a>",
"    ]. Onset of the antidepressant effect of lithium, at six to eight weeks, is much later than the onset of its antimanic effect. Use of lithium to treat acute bipolar manic and mixed episodes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link&amp;anchor=H1829248939#H1829248939\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'Lithium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=see_link\">",
"     \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3148203920\">",
"    <span class=\"h2\">",
"     Lamotrigine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     Lamotrigine",
"    </a>",
"    is efficacious for treating bipolar depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Evidence for the efficacy of lamotrigine includes a meta-analysis of five randomized trials (1072 patients with bipolar major depression) that compared lamotrigine (100 to 400 mg per day) with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/16\">",
"     16",
"    </a>",
"    ]. Response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred in significantly more patients who received lamotrigine than placebo (44 versus 35 percent). A planned subgroup analysis found that lamotrigine was superior to placebo for severe depression at baseline, but not for moderate depression. Discontinuation of treatment was comparable for lamotrigine and placebo.",
"   </p>",
"   <p>",
"    Therapy usually begins with a dose of 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for two weeks, then 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for two weeks. The dose can be titrated by 50 mg per week thereafter as clinically indicated; the usual maximum daily dose is 200 mg.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     Lamotrigine",
"    </a>",
"    interacts with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , such that valproate increases lamotrigine serum levels and carbamazepine decreases lamotrigine levels. There is more evidence supporting use of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -lamotrigine combination, compared with combinations of lamotrigine with either valproate or carbamazepine.",
"   </p>",
"   <p>",
"    Systemic side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    include rash and nausea. A rash may develop in up to 10 percent of patients during the initial one to two months of therapy, and necessitates discontinuation of the drug. The risk of developing a life-threatening rash such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or angioedema is approximately 1 in 1000 adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H710474\">",
"    <span class=\"h3\">",
"     Lamotrigine plus lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    includes an eight week, randomized trial that compared lamotrigine (200 mg per day) plus lithium (target serum concentration 0.6 to 1.2",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    [0.6 to 1.2",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    with placebo plus lithium in 124 patients with bipolar major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/17\">",
"     17",
"    </a>",
"    ]. Response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred in significantly more patients who received adjunctive lamotrigine than placebo (52 versus 32 percent). The incidence of specific adverse events (including benign rash) did not differ significantly between the two groups; one case of serious rash developed with placebo.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3148203927\">",
"    <span class=\"h2\">",
"     Valproate (Divalproex)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of four controlled trials (142 patients) found divalproex was efficacious for treating bipolar depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/18\">",
"     18",
"    </a>",
"    ]. Remission occurred in significantly more patients who received divalproex compared with patients who received placebo (41 versus 24 percent). Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    to treat acute bipolar manic and mixed episodes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3148203934\">",
"    <span class=\"h2\">",
"     Second-generation antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     Quetiapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    are each efficacious as monotherapy for treating bipolar depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/9,19-22\">",
"     9,19-22",
"    </a>",
"    ]. By contrast,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    monotherapy and adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    are not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H317515\">",
"    <span class=\"h3\">",
"     Quetiapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    in patients with bipolar major depression includes the following randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      with placebo in 666 patients, and found that remission occurred in more patients who received quetiapine 600 or 300 mg once per day, compared with placebo (70 and 70 versus 55 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      with placebo in 618 patients, and found that remission occurred in more patients who received quetiapine 600 mg daily compared with placebo (69 versus 55 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A pooled analysis of two eight-week trials that compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      with placebo in 694 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/25\">",
"       25",
"      </a>",
"      ]. Remission occurred in significantly more patients who received quetiapine 300 or 600 mg per day than placebo (54 and 55 versus 32 percent). The most common adverse effects of quetiapine included weight gain, dry mouth, sedation, dizziness, and constipation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     Quetiapine",
"    </a>",
"    is typically started at 50 mg once daily at bedtime. The dose is then increased every day by 50 to 100 mg to reach the target dose of 300 to 600 mg per day within one to two weeks of starting the medication. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H317524\">",
"    <span class=\"h3\">",
"     Olanzapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     Olanzapine",
"    </a>",
"    monotherapy and olanzapine plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    were compared with placebo in a randomized trial of 833 bipolar I patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/9\">",
"     9",
"    </a>",
"    ]. Both monotherapy and combination therapy were superior to placebo, and the combination was superior to monotherapy. Remission rates for olanzapine plus fluoxetine, olanzapine monotherapy, and placebo were 49, 37, and 25 percent respectively. Adverse events that occurred significantly more often with either the combination, or olanzapine alone, compared with placebo included weight gain, increased appetite, dry mouth, and weakness. Treatment emergent mania did not differ significantly between fluoxetine plus olanzapine, olanzapine alone, and placebo (6 and 6 and 7 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     Fluoxetine",
"    </a>",
"    is usually started at 20 mg once daily in the morning. For patients who do not respond within two to four weeks, the dose is increased by 10 to 20 mg per day, depending upon how well the medication is tolerated. Patients who remain unresponsive to treatment should receive additional increases of 10 to 20 mg per day every two to four weeks as tolerated, to an effective dose. The maximum dose is 60 mg per day.",
"    <br/>",
"    <br/>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     Olanzapine",
"    </a>",
"    is typically started at 5 mg once daily at bedtime. For patients who do not respond within one week, the dose is increased by 5 mg per day. Patients who remain unresponsive to treatment should receive additional increases of 5 mg per day every week as tolerated, to an effective dose. The maximum dose is 15 to 20 mg per day, depending upon tolerability.",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583076\">",
"    <span class=\"h2\">",
"     Electroconvulsive therapy (ECT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroconvulsive therapy (ECT) remains one of the more reliable and effective treatments for refractory or life-threatening depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/26\">",
"     26",
"    </a>",
"    ]. An overview of ECT, the technique for performing it, and medical consultation for ECT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41305?source=see_link\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=see_link\">",
"     \"Technique for performing electroconvulsive therapy (ECT) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21145?source=see_link\">",
"     \"Medical consultation for electroconvulsive therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3148203941\">",
"    <span class=\"h2\">",
"     Omega 3 fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary supplementation with omega 3 fatty acids from fish oils may have modest to moderate benefits for bipolar depression. Of five randomized trials that were identified by a systematic review, analysis of the one trial that met inclusion criteria found that improvement of depression was superior with adjunctive omega 3 fatty acid (eicosapentaenoic acid), compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/27\">",
"     27",
"    </a>",
"    ]. A subsequent meta-analysis of five, modestly to moderately heterogeneous randomized trials (291 patients with bipolar depression), using less restrictive inclusion criteria as well as data from a new study, found that improvement was significantly greater with omega 3 fatty acids than placebo during treatment lasting a mean of 13 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/28\">",
"     28",
"    </a>",
"    ]. Given the limited available data, few serious adverse effects, and other health benefits, use of omega 3 fatty acids (1 to 2 grams per day) as an adjunctive treatment is reasonable in patients with bipolar depression, particularly those with increased cardiovascular risk who might also benefit from the their effects on elevated triglycerides. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=see_link\">",
"     \"Lipid lowering with diet or dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92878688\">",
"    <span class=\"h2\">",
"     Investigational approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is an NMDA receptor antagonist that is used as an anesthetic and may be effective for bipolar major depression (as well as unipolar major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/29\">",
"     29",
"    </a>",
"    ]). A crossover trial compared a single intravenous infusion of ketamine (0.5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    with a single infusion of saline, administered two weeks apart, in 18 patients with treatment-resistant bipolar major depression who were receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ; patients were randomly assigned to the order in which they received the two adjunctive infusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/30\">",
"     30",
"    </a>",
"    ]. Improvement of symptoms was significantly greater with adjunctive ketamine than with saline, and response (improvement from baseline on the depression rating scale &ge;50 percent) to ketamine occurred in 71 percent and to saline in 6 percent. Transient side effects that occurred only with ketamine included dissociation; feeling strange, weird, or bizarre; dry mouth; tachycardia; and increased blood pressure. A subsequent trial using the same methods in 15 patients found that response to ketamine occurred in 79 percent and to saline in 0 percent; dissociation was the most common side effect with either treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a report described improvement of bipolar major depression with adjunctive intramuscular",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    that was administered for nine months in one patient and six months in another patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/32\">",
"     32",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3148203948\">",
"    <span class=\"h1\">",
"     SUGGESTED PATIENT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar depression should be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    . For patients who fail to respond to monotherapy, the addition of a second drug, including an atypical antipsychotic, may be required. Adding an antidepressant to lithium or valproate has not been shown to be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     Lamotrigine",
"    </a>",
"    may be particularly effective in treating bipolar major depression and is a reasonable choice to add to another medication, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/35\">",
"     35",
"    </a>",
"    ]. It should be noted, however, that there are significant drug interactions, such that valproate increases lamotrigine serum levels and carbamazepine decreases lamotrigine levels.",
"   </p>",
"   <p>",
"    ECT is a reasonable alternative in patients with suicidal ideation, psychosis, or depression during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1136242\">",
"    <span class=\"h2\">",
"     Medication combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polytherapy is frequently recommended for treatment of bipolar depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/3,36-39\">",
"     3,36-39",
"    </a>",
"    ]. The best established medication combination is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1136249\">",
"    <span class=\"h3\">",
"     Adjunctive antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     Fluoxetine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    efficaciously treats bipolar depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. However, the evidence is mixed regarding whether adjunctive antidepressants in general are efficacious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/12\">",
"     12",
"    </a>",
"    ]. The role of adjunctive antidepressants is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37417?source=see_link&amp;anchor=H20879421#H20879421\">",
"     \"Bipolar disorder in adults: Treating major depression with antidepressants\", section on 'Role of antidepressants'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1136256\">",
"    <span class=\"h3\">",
"     Other combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     Lamotrigine",
"    </a>",
"    may be efficacious as add-on therapy for depressed bipolar patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/17,35\">",
"     17,35",
"    </a>",
"    ]. Adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    (or the longer lasting isomer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/43/31413?source=see_link\">",
"     armodafinil",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    , folate, or N-acetylcysteine may also be useful.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial (124 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ) found remission occurred in significantly more patients who received adjunctive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      , compared with placebo (52 versus 32 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two randomized trials (342 patients treated with antimanic drugs and antidepressants) each found that depressive symptoms improved significantly more with adjunctive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. However, the larger study (N=257) found no significant difference in remission or response rates.",
"     </li>",
"     <li>",
"      Two randomized trials (43 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      or an anticonvulsant) each found that response with adjunctive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"       pramipexole",
"      </a>",
"      was significantly higher compared with placebo (60 and 67 versus 9 and 20 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      A randomized trial (75 patients treated with antimanic and antidepressant medications) found that remission occurred in significantly more patients who received adjunctive N-acetylcysteine compared with placebo (51 versus 18 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When combining medications, clinicians should also consider",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/19-21,45\">",
"     19-21,45",
"    </a>",
"    ], divalproex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/18\">",
"     18",
"    </a>",
"    ], or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/9\">",
"     9",
"    </a>",
"    ], which have demonstrated efficacy as monotherapy compared with placebo for bipolar depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3148204931\">",
"    <span class=\"h1\">",
"     TREATMENT FOR BIPOLAR II DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar II disorder is diagnosed in patients who have episodes of hypomania and major depression. Hypomanic episodes can disrupt the patient's functioning, but are less severe compared with the manic episodes that occur in bipolar I disorder. The level of associated functional impairment in patients with bipolar II disorder is closely linked to the severity of the depressive episodes that predominate in bipolar II disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relatively little research has focused specifically on the treatment of patients with bipolar II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Many studies either exclude patients with bipolar II disorder or lump them together with bipolar I patients in the analyses. Treatment guidelines often provide little guidance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/3,6\">",
"     3,6",
"    </a>",
"    ], but this has started to change [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/48\">",
"     48",
"    </a>",
"    ]. We suggest patients with bipolar II disorder should be treated with the same medications used for bipolar I, until further studies are available that indicate otherwise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 13 studies (including seven controlled trials) evaluated the risk of inducing mania or hypomania with antidepressant treatment in bipolar disorder and found that the risk of antidepressant-associated",
"    <span class=\"nowrap\">",
"     mania/hypomania",
"    </span>",
"    for patients with bipolar II disorder was 50 percent less than the risk for patients with bipolar I disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/3/44088/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, the mood elevations that were provoked in bipolar II patients were less severe than in bipolar I patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26973987\">",
"    <span class=\"h1\">",
"     SPECIAL CIRCUMSTANCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26974003\">",
"    <span class=\"h2\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of geriatric bipolar major depression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16330?source=see_link&amp;anchor=H13749357#H13749357\">",
"     \"Geriatric bipolar disorder: Acute treatment\", section on 'Bipolar major depression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3148204938\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of bipolar major depression during pregnancy, the teratogenic and postnatal risks of pharmacotherapy for bipolar disorder; the principles of teratology; preconception and prenatal maintenance pharmacotherapy for bipolar patients; and preconception counseling for patients with bipolar disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38248?source=see_link\">",
"     \"Bipolar disorder in pregnant women: Treatment of major depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=see_link\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19574?source=see_link\">",
"     \"Principles of teratology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2874?source=see_link\">",
"     \"Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40329?source=see_link\">",
"     \"Bipolar disorder in women: Contraception and preconception assessment and counseling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=see_link\">",
"       \"Patient information: Bipolar disorder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48563801\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar disorder is an illness characterized by periods of pathologic mood elevation. Patients with bipolar I disorder have manic episodes or mixed (concurrent mood elevation and depression) episodes, and nearly always experience depressive episodes. Bipolar II disorder is characterized by one or more episodes of major depression, with at least one hypomanic episode. (See",
"      <a class=\"local\" href=\"#H3148202429\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals for treating bipolar depression depend upon the stage of illness. The acute phase focuses upon managing the patient&rsquo;s safety and symptoms, the continuation phase aims to achieve full symptom remission and prevent relapse, and the maintenance phase focuses upon maintaining recovery and preventing recurrence of a new mood episode. (See",
"      <a class=\"local\" href=\"#H3148204449\">",
"       'Stage of illness'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"       \"Bipolar disorder in adults: Maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients presenting with acute bipolar depression should be assessed for suicide risk and aggressiveness, and substance use disorders treated. (See",
"      <a class=\"local\" href=\"#H48563594\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute bipolar depression, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      &nbsp;plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , other medication combinations, and ECT are also effective. Antidepressants have not been effective as adjunctive therapy to lithium or valproate for bipolar depression. Antidepressant monotherapy may precipitate mania, but may be effective and tolerated in some patients with bipolar II disorder. (See",
"      <a class=\"local\" href=\"#H317515\">",
"       'Quetiapine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3148203912\">",
"       'Lithium'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3148203920\">",
"       'Lamotrigine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1136242\">",
"       'Medication combinations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1583076\">",
"       'Electroconvulsive therapy (ECT)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3148204931\">",
"       'Treatment for bipolar II disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with bipolar depression, adjunctive omega 3 fatty acids (1 to 2 grams per day) are a reasonable option. (See",
"      <a class=\"local\" href=\"#H3148203941\">",
"       'Omega 3 fatty acids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/1\">",
"      Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003; 64:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/2\">",
"      Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/3\">",
"      American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/4\">",
"      Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 Suppl 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/5\">",
"      Keck PE Jr, McElroy SL, Arnold LM. Bipolar disorder. Med Clin North Am 2001; 85:645.",
"     </a>",
"    </li>",
"    <li>",
"     Hirschfeld, RM. Guideline Watch: Practice guideline for the treatment of patients with bipolar disorder. Arlington, VA; American Psychiatric Association www.psych.org/psych_pract/treatg/pg/prac_guide.cfm (Accessed on May 11, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/7\">",
"      Ernst CL, Goldberg JF. Antidepressant properties of anticonvulsant drugs for bipolar disorder. J Clin Psychopharmacol 2003; 23:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/8\">",
"      Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 2005; 62:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/9\">",
"      Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/10\">",
"      Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/11\">",
"      Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol 2009; 12:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/12\">",
"      Vieta E. Antidepressants in bipolar depression. Acta Psychiatr Scand 2008; 118:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/13\">",
"      Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993; 13:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/14\">",
"      Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 2004; 65 Suppl 10:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/15\">",
"      Bowden CL. Novel treatments for bipolar disorder. Expert Opin Investig Drugs 2001; 10:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/16\">",
"      Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/17\">",
"      van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/18\">",
"      Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord 2010; 124:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/19\">",
"      Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/20\">",
"      McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/21\">",
"      Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/22\">",
"      Suppes T, Hirschfeld RM, Vieta E, et al. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2008; 9:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/23\">",
"      Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/24\">",
"      Sachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/25\">",
"      Weisler RH, Calabrese JR, Thase ME, et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008; 69:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/26\">",
"      Hilty DM, Brady KT, Hales RE. A review of bipolar disorder among adults. Psychiatr Serv 1999; 50:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/27\">",
"      Montgomery P, Richardson AJ. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev 2008; :CD005169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/28\">",
"      Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 2012; 73:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/29\">",
"      Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/30\">",
"      Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/31\">",
"      Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012; 71:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/32\">",
"      Cusin C, Hilton GQ, Nierenberg AA, Fava M. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry 2012; 169:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/33\">",
"      Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/34\">",
"      Belmaker RH. Treatment of bipolar depression. N Engl J Med 2007; 356:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/35\">",
"      Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/36\">",
"      Goldberg JF, Brooks JO 3rd, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 2009; 70:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/37\">",
"      Blanco C, Laje G, Olfson M, et al. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002; 159:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/38\">",
"      Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010; 11:81.",
"     </a>",
"    </li>",
"    <li>",
"     Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38. National Institute for Health and Clinical file://guidance.nice.org.uk/CG38/Guidance (Accessed on December 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/40\">",
"      Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007; 164:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/41\">",
"      Calabrese JR, Ketter TA, Youakim JM, et al. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 2010; 71:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/42\">",
"      Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/43\">",
"      Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/44\">",
"      Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/45\">",
"      Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/46\">",
"      McElroy SL, Keck PE Jr, Pope HG Jr, et al. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am J Psychiatry 1992; 149:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/47\">",
"      Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006; 20:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/48\">",
"      Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/49\">",
"      Benazzi F. Bipolar II disorder : epidemiology, diagnosis and management. CNS Drugs 2007; 21:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/3/44088/abstract/50\">",
"      Bond, DJ, Noronha, MM, Kauer-Sant'anna, M, et al. Antidepressant-Associated Mood Elevations in Bipolar II Disorder Compared With Bipolar I Disorder and Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry 2008; :e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15267 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44088=[""].join("\n");
var outline_f43_3_44088=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48563801\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3148202429\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3148204449\">",
"      STAGE OF ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48563594\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89770741\">",
"      SPECIFIC TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3148203905\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3148203912\">",
"      Lithium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3148203920\">",
"      Lamotrigine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H710474\">",
"      - Lamotrigine plus lithium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3148203927\">",
"      Valproate (Divalproex)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3148203934\">",
"      Second-generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H317515\">",
"      - Quetiapine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H317524\">",
"      - Olanzapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1583076\">",
"      Electroconvulsive therapy (ECT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3148203941\">",
"      Omega 3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92878688\">",
"      Investigational approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3148203948\">",
"      SUGGESTED PATIENT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1136242\">",
"      Medication combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1136249\">",
"      - Adjunctive antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1136256\">",
"      - Other combinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3148204931\">",
"      TREATMENT FOR BIPOLAR II DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26973987\">",
"      SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26974003\">",
"      Elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3148204938\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48563801\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=related_link\">",
"      Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11226?source=related_link\">",
"      Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37417?source=related_link\">",
"      Bipolar disorder in adults: Treating major depression with antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38248?source=related_link\">",
"      Bipolar disorder in pregnant women: Treatment of major depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40329?source=related_link\">",
"      Bipolar disorder in women: Contraception and preconception assessment and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2874?source=related_link\">",
"      Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/60/16330?source=related_link\">",
"      Geriatric bipolar disorder: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21145?source=related_link\">",
"      Medical consultation for electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19574?source=related_link\">",
"      Principles of teratology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=related_link\">",
"      Technique for performing electroconvulsive therapy (ECT) in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_3_44089="Sertraline: Drug information";
var content_f43_3_44089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sertraline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/43/23222?source=see_link\">",
"    see \"Sertraline: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/18/7465?source=see_link\">",
"    see \"Sertraline: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zoloft&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sertraline&reg;;",
"     </li>",
"     <li>",
"      CO Sertraline;",
"     </li>",
"     <li>",
"      Dom-Sertraline;",
"     </li>",
"     <li>",
"      GD-Sertraline;",
"     </li>",
"     <li>",
"      Mylan-Sertraline;",
"     </li>",
"     <li>",
"      Nu-Sertraline;",
"     </li>",
"     <li>",
"      PHL-Sertraline;",
"     </li>",
"     <li>",
"      PMS-Sertraline;",
"     </li>",
"     <li>",
"      ratio-Sertraline;",
"     </li>",
"     <li>",
"      Riva-Sertraline;",
"     </li>",
"     <li>",
"      Sandoz-Sertraline;",
"     </li>",
"     <li>",
"      Teva-Sertraline;",
"     </li>",
"     <li>",
"      Zoloft&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F220727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Selective Serotonin Reuptake Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F220689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression/obsessive-compulsive disorder:",
"     </b>",
"     Oral: Initial: 50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     May increase daily dose, at intervals of not less than 1 week, to a maximum of 200 mg/day. If somnolence is noted, give at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Panic disorder, post-traumatic stress disorder, social anxiety disorder:",
"     </b>",
"     Oral: Initial: 25 mg once daily; increased after 1 week to 50 mg once daily; maximum dose: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Premenstrual dysphoric disorder:",
"     </b>",
"     50 mg/day either daily throughout menstrual cycle",
"     <b>",
"      or",
"     </b>",
"     limited to the luteal phase of menstrual cycle, depending on physician assessment. Patients not responding to 50 mg/day may benefit from dose increases (50 mg increments per menstrual cycle) up to 150 mg/day when dosing throughout menstrual cycle",
"     <b>",
"      or",
"     </b>",
"     up to 100 mg day when dosing during luteal phase only. If a 100 mg/day dose has been established with luteal phase dosing, a 50 mg/day titration step for 3 days should be utilized at the beginning of each luteal phase dosing period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of sertraline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing sertraline and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate sertraline in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving sertraline and potential benefits outweigh potential risks, discontinue sertraline promptly and administer linezolid or I.V. methylene blue. Monitor for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume sertraline 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F220706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/18/7465?source=see_link\">",
"      see \"Sertraline: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Obsessive-compulsive disorder:",
"     </b>",
"     Oral: Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      6-12 years:",
"     </i>",
"     Initial: 25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      13-17 years:",
"     </i>",
"     Initial: 50 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     May increase daily dose, at intervals of not less than 1 week, to a maximum: 200 mg/day. If somnolence is noted, give at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F220690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 25 mg/day in the morning; increase by 25 mg/day increments every 2-3 days if tolerated to 50-100 mg/day; additional increases may be necessary; maximum: 200 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Patients with Alzheimer&rsquo;s dementia-related depression may require a lower starting dosage of 12.5 mg/day, with titration intervals of 1-2 weeks, up to 150-200 mg/day maximum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F220691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple-dose pharmacokinetics are unaffected by renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis effect: Not removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F220692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sertraline is extensively metabolized by the liver. Caution should be used in patients with hepatic impairment. A lower dose or less frequent dosing should be used.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [concentrate]: 20 mg/mL (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zoloft&reg;: 20 mg/mL (60 mL) [contains ethanol 12%, menthol, natural rubber/natural latex in packaging]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zoloft&reg;: 25 mg, 50 mg, 100 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089832.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089832.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F220662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral concentrate: Must be diluted immediately before use.",
"     <b>",
"      Note:",
"     </b>",
"     Use with caution in patients with latex sensitivity; dropper dispenser contains dry natural rubber.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F220661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depression; obsessive-compulsive disorder (OCD); panic disorder; post-traumatic stress disorder (PTSD); premenstrual dysphoric disorder (PMDD); social anxiety disorder",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F220723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Eating disorders; generalized anxiety disorder (GAD); impulse control disorders; treatment of mild dementia-associated agitation in nonpsychotic patients; treatment of paraphilia/hypersexuality",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F220738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sertraline may be confused with selegiline, Serevent&reg;, Soriatane&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zoloft&reg; may be confused with Zocor&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F220725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache, insomnia, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Ejaculatory disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, hypoesthesia, malaise, nervousness, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite increased, constipation, dyspepsia, flatulence, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, hypertonia, myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual difficulty, abnormal vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Yawning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, acute renal failure, agranulocytosis, allergic reaction, anaphylactoid reaction, angioedema, aplastic anemia, atrial arrhythmia, AV block, bilirubin increased, blindness, bradycardia, cataract, dystonia, extrapyramidal symptoms, galactorrhea, gum hyperplasia, gynecomastia, hallucinations, hepatic failure, hepatitis, hepatomegaly, hyperglycemia, hyperprolactinemia, hypothyroidism, jaundice, leukopenia, lupus-like syndrome, micturition disorders, neuroleptic malignant syndrome, oculogyric crisis, serotonin syndrome, SIADH, Stevens-Johnson syndrome (and other severe dermatologic reactions), optic neuritis, pancreatitis (rare), photosensitivity, priapism, psychosis, PT/INR increased, pulmonary hypertension, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, serum sickness, thrombocytopenia, torsade de pointes, transaminases increased, vasculitis, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Pediatric patients: Additional adverse reactions reported in pediatric patients (frequency &gt;2%): Aggressiveness, epistaxis, hyperkinesia, purpura, sinusitis, urinary incontinence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F220665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sertraline or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either sertraline or the MAO inhibitor); initiation of sertraline in a patient receiving linezolid or intravenous methylene blue; concurrent use of pimozide; concurrent use of sertraline oral concentrate with disulfiram",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F220646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Sertraline is not FDA approved for use in children with major depressive disorder (MDD). However, it is approved for the treatment of obsessive-compulsive disorder (OCD) in children &ge;6 years of age.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Sertraline is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: Relatively devoid of these side effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin, NSAIDs, warfarin or other anticoagulants. Bleeding related to SSRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sexual dysfunction: May cause or exacerbate sexual dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly. Volume depletion and/or concurrent use of diuretics likely increases risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight loss: May cause weight loss; use caution in patients where weight loss is undesirable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Other concurrent illness: Use caution in patients with certain concomitant systemic illness; due to limited experience.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Uric acid nephropathy: Use with caution in patients at risk of uric acid nephropathy; sertraline acts as a mild uricosuric.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agents which lower seizure threshold: Concurrent therapy with other drugs which lower the seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Monitor growth in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex sensitivity: Use oral concentrate formulation with caution in patients with latex sensitivity; dropper dispenser contains dry, natural rubber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal syndrome: May cause dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, electric shock-like sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. Upon discontinuation of sertraline therapy, gradually taper dose. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, then resuming the previous dose with a more gradual taper should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F220720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2B6 (moderate), CYP2C19 (moderate), CYP2C8 (weak), CYP2C9 (weak), CYP2D6 (moderate), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F220651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Acebutolol; Atenolol; Betaxolol (Ophthalmic); Betaxolol (Systemic); Bisoprolol; Carteolol (Ophthalmic); Esmolol; Labetalol; Levobunolol; Metipranolol; Nadolol; Penbutolol; Sotalol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Moderate) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.  Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of Sertraline. This is specifically related to sertraline oral concentrate due to its alcohol content (12%). Management: Sertraline Oral Concentrate contains 12% alcohol, and its use should be avoided with disulfiram.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Sertraline. Sertraline may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Galantamine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Galantamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents.  Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Sertraline. Sertraline may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F220679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Sertraline average peak serum levels may be increased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, tryptophan, kava kava, gotu kola (may increase CNS depression and/or risk of serotonin syndrome).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F220669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Sertraline crosses the human placenta. An increased risk of teratogenic effects, including cardiovascular defects, may be associated with maternal use of sertraline or other SSRIs; however, available information is conflicting. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, women who are pregnant may require adjusted doses of sertraline to achieve euthymia. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F220695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4040416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sertraline and desmethylsertraline are excreted in breast milk. Adverse events have been reported in nursing infants exposed to some SSRIs. The American Academy of Breastfeeding Medicine suggests that sertraline may be considered for the treatment of postpartum depression in appropriately selected women who are nursing. Infants exposed to sertraline while breast-feeding generally receive a low relative dose and serum concentrations are not detectable in most infants. Sertraline concentrations in the hindmilk are higher than in foremilk. If the benefits of the mother receiving the sertraline and breast-feeding outweigh the risks, the mother may consider pumping and discarding breast milk with the feeding 7-9 hours after the daily dose to decrease sertraline exposure to the infant. The long-term effects on development and behavior have not been studied. The manufacturer recommends that caution be exercised when administering sertraline to nursing women. Maternal use of an SSRI during pregnancy may cause delayed milk secretion.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F220668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Sertraline HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (60 mL): $64.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Zoloft Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (60 mL): $133.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sertraline HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $85.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $85.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $85.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zoloft Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $168.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $168.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $168.86",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F220655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor nutritional intake and weight; mental status for depression, suicide ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks; signs/symptoms of serotonin syndrome;  akathisia; growth in pediatric patients",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aleval (MX);",
"     </li>",
"     <li>",
"      Altruline (CR, DO, GT, HN, MX, NI, PA, SV);",
"     </li>",
"     <li>",
"      Aluprex (MX);",
"     </li>",
"     <li>",
"      Anexin (ID);",
"     </li>",
"     <li>",
"      Antipres (ID);",
"     </li>",
"     <li>",
"      Aremis (ES);",
"     </li>",
"     <li>",
"      Concorz (AU);",
"     </li>",
"     <li>",
"      Conexine (EC);",
"     </li>",
"     <li>",
"      Deprax (CN);",
"     </li>",
"     <li>",
"      Dominum (CO);",
"     </li>",
"     <li>",
"      Doxime (PY);",
"     </li>",
"     <li>",
"      Eleva (AU);",
"     </li>",
"     <li>",
"      Emergen (PE);",
"     </li>",
"     <li>",
"      Fatral (ID);",
"     </li>",
"     <li>",
"      Fridep (ID);",
"     </li>",
"     <li>",
"      Gladem (AT, DE);",
"     </li>",
"     <li>",
"      Iglodep (ID);",
"     </li>",
"     <li>",
"      Lesefer (CO);",
"     </li>",
"     <li>",
"      Lustral (GB, IE, IL, TR);",
"     </li>",
"     <li>",
"      Lustraline (TW);",
"     </li>",
"     <li>",
"      Prosertin (MX);",
"     </li>",
"     <li>",
"      Purtraline (TW);",
"     </li>",
"     <li>",
"      Seltra (KP);",
"     </li>",
"     <li>",
"      Sercerin (BR);",
"     </li>",
"     <li>",
"      Serdep (HK);",
"     </li>",
"     <li>",
"      Serenada (IL);",
"     </li>",
"     <li>",
"      Serenata (PH);",
"     </li>",
"     <li>",
"      Serlain (BE);",
"     </li>",
"     <li>",
"      Serlife (ZA);",
"     </li>",
"     <li>",
"      Serlift (TH);",
"     </li>",
"     <li>",
"      Sernade (ID);",
"     </li>",
"     <li>",
"      Serolox (CR, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Serolux (MX);",
"     </li>",
"     <li>",
"      Sertex (MX);",
"     </li>",
"     <li>",
"      Sertra (AU, TH);",
"     </li>",
"     <li>",
"      Sertranex (AE, BH, CO, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Sertranquil (CO);",
"     </li>",
"     <li>",
"      Setrax (CO);",
"     </li>",
"     <li>",
"      Setrona (AU, NZ);",
"     </li>",
"     <li>",
"      Sosser (CO);",
"     </li>",
"     <li>",
"      Starin (TH);",
"     </li>",
"     <li>",
"      Stimuloton (BB, BM, BS, BZ, GY, JM, SR, TT);",
"     </li>",
"     <li>",
"      Tatig (NZ);",
"     </li>",
"     <li>",
"      Xydep (AU);",
"     </li>",
"     <li>",
"      You-Jet (TW);",
"     </li>",
"     <li>",
"      Zerlin (ID);",
"     </li>",
"     <li>",
"      Zolodin (PH);",
"     </li>",
"     <li>",
"      Zoloft (AE, AR, AU, BB, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CY, CZ, DE, DK, EC, EE, EG, ET, FI, FR, GH, GM, GN, GR, GY, HK, ID, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PT, QA, RU, SA, SC, SD, SE, SL, SN, SR, SY, TH, TN, TT, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Zolotral (PH);",
"     </li>",
"     <li>",
"      Zosert (IN);",
"     </li>",
"     <li>",
"      Zotaline (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F220645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antidepressant with selective inhibitory effects on presynaptic serotonin (5-HT) reuptake and only very weak effects on norepinephrine and dopamine neuronal uptake.",
"     <i>",
"      In vitro",
"     </i>",
"     studies demonstrate no significant affinity for adrenergic, cholinergic, GABA, dopaminergic, histaminergic, serotonergic, or benzodiazepine receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F220664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Depression: The onset of action is within a week, however, individual response varies greatly and full response may not be seen until 8-12 weeks after initiation of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; may involve CYP2C19 and CYP2D6; extensive first pass metabolism; forms metabolite N-desmethylsertraline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Bioavailability of tablets and solution are equivalent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Sertraline: 26 hours; N-desmethylsertraline: 66 hours (range: 62-104 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Sertraline: 4.5-8.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alderman J, Wolkow R, Chung M, et al, &ldquo;Sertraline Treatment of Children and Adolescents With Obsessive-Compulsive Disorder or Depression: Pharmacokinetics, Tolerability, and Efficacy,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1998, 37(4):386-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/9549959/pubmed\" id=\"9549959\" target=\"_blank\">",
"        9549959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bandelow B, Zohar J, Hollander E, et al, &ldquo;World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders -- First Revision,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2008, 9(4): 248-312. Available at file://www.wfsbp.org/fileadmin/pdf/guides/Guidelines_Anxiety_revision.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/18949648/pubmed\" id=\"18949648\" target=\"_blank\">",
"        18949648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benedek DM, Friedman MJ, Zatzick D, et al, &ldquo;Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.&rdquo; Available at  file://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=AcuteStressDisorder-PTSD_GuidelineWatch",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352:1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown DF and Kerr HD, &ldquo;Sertraline Overdose,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(11):1307.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):579-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/16467545/pubmed\" id=\"16467545\" target=\"_blank\">",
"        16467545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn CK, Shrivastava R, Mendels J, et al, &ldquo;Double-Blind, Multicenter Comparison of Sertraline and Amitriptyline in Elderly Depressed Patients,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1990, 51(Suppl B):28-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/2258379/pubmed\" id=\"2258379\" target=\"_blank\">",
"        2258379",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diler RS and Avci A, &ldquo;Selective Serotonin Reuptake Inhibitor Discontinuation Syndrome in Children: Six Case Reports,&rdquo;",
"      <i>",
"       Current Therapeutic Research",
"      </i>",
"      , 2002, 63(3):188-97.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doogan DP and Caillard V, &ldquo;Sertraline: A New Antidepressant,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1988, 49(Suppl):46-51.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunkley EJ, Isbister GK, Sibbritt D, et al, &ldquo;The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,&rdquo;",
"      <i>",
"       QJM",
"      </i>",
"      , 2003, 96(9):635-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/12925718/pubmed\" id=\"12925718\" target=\"_blank\">",
"        12925718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grimsley SR and Jann MW, &ldquo;Paroxetine, Sertraline, and Fluvoxamine: New Selective Serotonin Reuptake Inhibitors,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1992, 11(11):930-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/1464219/pubmed\" id=\"1464219\" target=\"_blank\">",
"        1464219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harel Z, Biro FM, and Tedford WL, &ldquo;Effects of Long Term Treatment With Sertraline (Zoloft&reg;) Simulating Hypothyroidism in an Adolescent,&rdquo;",
"      <i>",
"       J Adolesc Health",
"      </i>",
"      , 1995, 16(3):232-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/7779834/pubmed\" id=\"7779834\" target=\"_blank\">",
"        7779834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoaken PC, &ldquo;An Alert to Extrapyramidal Side-Effects From SSRIs,&rdquo;",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 1995, 40(1):51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/7874680/pubmed\" id=\"7874680\" target=\"_blank\">",
"        7874680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jackson C, Carson W, Markowitz J, et al, &ldquo;SIADH Associated With Fluoxetine and Sertraline Therapy,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(5):809-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/7726326/pubmed\" id=\"7726326\" target=\"_blank\">",
"        7726326",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kassner J and Woolf A, &ldquo;Sertraline HCl: A New Antidepressant,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1992, 34:343.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kassner J and Woolf A, &ldquo;Sertraline Hydrochloride: Correlation of Clinical Presentation With Plasma Concentration,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1993, 35:341.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klein-Schwartz W and Anderson B, &ldquo;Analysis of Sertraline Only Overdoses,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36:378.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lake MB, Birmaher B, Wassick S, et al, &ldquo;Bleeding and Selective Serotonin Reuptake Inhibitors in Childhood and Adolescence,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2000, 10(1):35-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/10755580/pubmed\" id=\"10755580\" target=\"_blank\">",
"        10755580",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau GT and Horwitz BZ, &ldquo;Sertraline Overdose in 40 Patients,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36:370.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lejoyeux M, et al, &ldquo;Serotonin Syndrome: Incidence, Symptoms, and Treatment,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 1994, 2:132-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Llorente MD, Gorelick M, and Silverman MA, &ldquo;Sertraline as the Cause of Inappropriate Antidiuretic Hormone Secretion,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1994, 55(12):543-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      March JS, Biederman J, Wolkow R, et al, &ldquo;Sertraline in Children and Adolescents With Obsessive-Compulsive Disorder: A Multicenter Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 280(20):1752-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/9842950/pubmed\" id=\"9842950\" target=\"_blank\">",
"        9842950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Markel H, Lee A, Holmes RD, et al, &ldquo;LSD Flashback Syndrome Exacerbated by Selective Serotonin Reuptake Inhibitor Antidepressants in Adolescents,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(5 Pt 1):817-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/7965440/pubmed\" id=\"7965440\" target=\"_blank\">",
"        7965440",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Myers LB, Dean BS, and Krenzelok EP, &ldquo;A Closer Look: Sertraline (Zoloft&reg;) and Pediatric Overdoses,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):551.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Myers LB, Dean BS, and Krenzelok EP, &ldquo;Sertraline (Zoloft&reg;): A Pediatric Overdose Approach,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36:361.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Myers LB, Dean BS, and Krenzelok EP, &ldquo;Sertraline (Zoloft&reg;): Overdose Assessment of a New Antidepressant,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1993, 35:341.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nasky KM, Cowan GL, and Knittel DR. &ldquo;False-Positive Urine Screening for Benzodiazepines: an Association with Sertraline?: A Two-Year Retrospective Chart Analysis,&rdquo;",
"      <i>",
"       Psychiatry (Edgmont)",
"      </i>",
"      , 2009, 6(7):36-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/19724768/pubmed\" id=\"19724768\" target=\"_blank\">",
"        19724768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Norden MJ, &ldquo;Buspirone Treatment of Sexual Dysfunction Associated With Selective Serotonin Re-Uptake Inhibitors,&rdquo;",
"      <i>",
"       Depression",
"      </i>",
"      , 1994, 2:109-12.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reimherr FW, Chouinard G, Cohn CK, et al, &ldquo;Antidepressant Efficacy of Sertraline: A Double-Blind Placebo- and Amitriptyline-Controlled, Multicenter Comparison Study in Outpatients With Major Depression,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1990, 51(Suppl B):18-27.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roose SP, Glassman AH, Attia E, et al, &ldquo;Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1994, 151(12):1735-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/7977878/pubmed\" id=\"7977878\" target=\"_blank\">",
"        7977878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, &ldquo;Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(9):1290-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/18628446/pubmed\" id=\"18628446\" target=\"_blank\">",
"        18628446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thibaut F, De La Barra F, Gordon H, et al, &ldquo;The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Paraphilias,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2010, 11(4):604-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/20459370/pubmed\" id=\"20459370\" target=\"_blank\">",
"        20459370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thornton SL and Resch DS, &ldquo;SIADH Associated With Sertraline Therapy,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(5):809.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/7726325/pubmed\" id=\"7726325\" target=\"_blank\">",
"        7726325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tueth MJ, &ldquo;The Serotonin Syndrome in the Emergency Department,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1993, 22(8):1369.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/8333648/pubmed\" id=\"8333648\" target=\"_blank\">",
"        8333648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/3/44089/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9886 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44089=[""].join("\n");
var outline_f43_3_44089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709410\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220684\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220685\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220727\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220689\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220706\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220690\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220691\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220692\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220658\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220642\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874831\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220662\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220661\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220723\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220738\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220725\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220665\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220646\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220720\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220651\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220679\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220653\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220669\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220695\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4040416\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220668\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220655\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869406\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220645\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220664\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9886\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9886|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/43/23222?source=related_link\">",
"      Sertraline: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/18/7465?source=related_link\">",
"      Sertraline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_3_44090="Dermatomyositis - heliotrope eruption";
var content_f43_3_44090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56879%7EDERM%2F68649%7EDERM%2F54230%7EDERM%2F77822%7EDERM%2F79924%7EDERM%2F63383%7EDERM%2F75246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56879%7EDERM%2F68649%7EDERM%2F54230%7EDERM%2F77822%7EDERM%2F79924%7EDERM%2F63383%7EDERM%2F75246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heliotrope eruption in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous erythema is present on the periorbital skin in this patient with dermatomyositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatomyositis - heliotrope eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous erythema and edema is present on the upper eyelid in this patient with dermatomyositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Confluent areas of violaceous erythema are present on the neck, chest, and upper arms of this patient with dermatomyositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Confluent violaceous erythema is present on the posterior neck, upper back, and shoulders. This presentation is often referred to as the \"shawl sign\" of dermatomyositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperpigmented patches are present on the upper back of this patient with dermatomyositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gottron's papules in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2fYMAZ3D0IxUizLHkNkj1Paufg8S23HnpLHgYOeaspqVvKCYbiNs87T1rmtbY9dX6m1JMqgYOc+lV3l4OTjNUre8j5XcAxNPnnQgnjB7e9O3UpPWwskoBK8885qnICcgNxURuMnByB2NQzz7BlelI1vbYoazcLbW8jscKikk18neNdafXNfubjdmFWKRDsFFe2/GPxA1l4cmjjcrPcHylwe3f9K+dh0yTj3rWlG+pxYuo0lAPu9ufpSHjGD83XrS8k46D3oAAJzkjPUcV1I80QA569eue9OH+rB2g9QaaFJO4DH07D2pVLAEc4PUDvTJYmT3HHSl/gJIJGewpQu9SMquDjJP6U9NgIUbiM8KRz/8ArNMBHBDqwwM8AZ4//UKE+UuVyFXkscZAP9TSg7QF2Dax7Hrj29B+tOClyW3kKoJ3kcj3PuaYhVUnaipuLHAX+96AGh4ilxtAV2yQTnAyP6ClwxzkAMABgcAD0Hue9NWXAYtg9AecEY6L9PWn6isIQDj5uT8ynjBPrSqp25XMZjBbJGCo9T6k9qTvubYxbovUN7/QU5Vd5Thj5vLlmGNoHf8AwpgIgO4oxC44zu4HfA9zTWGSEZSSnHrj2H9TRIWHGDyMjPoe/wBTRKrByAm3oOOqgjp9akBqqWIXavOQDyFY09SCq73bDHIOff71DAZCLhueSDwx/uj2FKFNzIu0AHOTgjAGev0FADAwznoOdrEdPc+9BXKncCAuPlBxgH09SaUqmWYNuXJAJ6H/AGj/AEpcBgCCVI5K5+6Pb1NADAQFLevAIH3eelNO3kvk8YKqMfQCpWJky+AFUDHt9fc00sSSAAvYKAePYGgdhuMkKCrE8LjgH6+woVcldpDc5wf1OfSnbWG5gRknAI9fT6Ug4woUPk9MDk4/lSARg3PzMecnI6H1NIuFX5QNxGVLNwPc0pODghi3q3XI7/SnZUKOh3d26N7mgBnTCE4AGT6qf/r0u1cAc4z97PX2FOblSqhsLzyOR7mm42DbkDsP8PrRcBqk528EcZwP5e1L9588HnuPlbH8qQJngE9MAdcn0FOwNv3SVPXrtJ/+tQAmdyA7gR+vuaQAZ5xn6f55pVUfexwRx3x6n6UMucEcKBw2OvuR60BYQYx8wYquB/tAegpW4kJBB7Db0+lKFG4kg4HTJ7d+fWmxr1PQD05ouFmKRkDI4f7o9f8A61GCoBUjJJOR1BHc+1HQkHgn+EdD7ChsdAv1z/npQFhigYyGGevP86fggADg9CNw5Gf508KgRS2C7fNkcD8aGCZUDnjj169aYDf4mQr8wHQDlfanAZAORtzgsF+9z0+gpCcIynAwO4yV/wD10+MYZ2ZgFVQGZRzgnoP60CBOOGP7tjj2YjOPwpVO5iOAzc4PGSPT2pCAfkUdSQSDx7AelCyMYmj2KA+CQepx2B7CmAYJO/JIB59Rz1I70gJViSRkc8jj/eNOZizDJLqpPI6n/wCsKarGQLuI2gZDbfTuf5UWAFPXdgADIGMj6D3pA3JGNo6KoJyM9h708r8284Q43hW7D1+pqIkK2DwMZAJ5Gf60MQ9m3Nvb5ccEKefpTSC4yVBZjjAHX2BoKbCwckFe644Pp9aXzCiLlhk/wDoB7e5pXA+vGtMtjJP1qNrPkbchh3HWt0x7jwR6c0xokA5wcda8s+g5jDMU6/dlcexNSJf3UACP8+O9aHlESHPKn2pksa5JwDz2FCbHfuV01tAQsgKn6YpJdRiZHIYAenrT5baGRfmQAY+lZdzpMT52EqfY8U1JjUkeHfGLVvtuvJaxsTFbrn/gR/8ArVwQIC+pr2LxT8K5725nvNPv8zSHcUmHB/EV5vrnhHW9Fy17YS+V/wA9I/nQ/iK3pyS0POxEZSk5GJ5Yzktx2I7UEHP9aRHKsfXv60qsOAcge1dCkjkaaBeeAM47ClIOMq3y9cj+f+FOKk9Ov505Qqrk98cY6+/1p3JaGMN53kKvp7460uDuHGxQOuOeafxgkuoUHAX0/wDrUwhgxBQ5z0PJH/1zVXFYQZYhQijdz97H4Z9v51Y2jYGDkepIGQPU/wBKag5wADn5sdv8ilHK/N8wHboR15PrQFhAxkZFwoQZwv1/9mNEwDSASFAUUYRW6dOPeldVQsN4zjPt9frUeBsznbgY64Iz0ouFhxVWKFADJ1II+U47fSkUFmyVLOTkE+vr/u0Mw2/eAJHQdPoKVfMmcqiF2IwQAfy+lDkluNRbGxybcvkbj/F6e+PX0pDGeyMMDOeuM/1NaNto+qzqWisJmB4zt4+taNl4N124+7bpCvX5mxj/AOvUupFGkcPOWyMAKQ21NuWOCwPHPYf1NDAZIWMjB7Y4PoPYV2Vr8O9RZv3tzEi/xAAnj29610+GUfltJdahK/tGgX8BUOtE0+qVOx5jvG0AnjPXGAx9TTo23MFXLkcgdfxr1CD4fWRuFSGKQgcu0r5/PtXQ2OgWtogSytYvMHyl9vJNL2y6G0MBOW7PEorW6lH+j2tw+D1EZOfrWjZaFeXWFYCEr/CcllHf8a92tNMkQ/LGFbH3gv8AKpbLSII3l3KPNYk5xyaj2rN1gIr4jw9/CV7uBiYtn/pmQMVt6L4DtrtSLq8kMo6qE2ge1ety6ZH94ptA9KrT6SW23EJ5Vgu9PX0qfayNVgqaOOi+GunqvJeVjjB3nGPSobn4c2bK+IJAVHLLJnH4GvUNMUywsHULNHwympjaB0JwOPvUOb3F7COzR88an4H1SzlbyGE6qchuh6/zqlJ4X1WOPPko+Bk7X59+vevop7FJGGV4HQmov7Ghd9xQEH1FCrPoZywdNnznF4f1abCraMg/2iOK6rS/h+rw7r27Jc9Uj4FeyJo8HOI19DxT/wCzFUEBAPwo9qxwwlNM8lPgCwjJMk0mF65frUtp4I0UyeYC8yjJ2NJgE+9elS6MmNzJuPoagfSoXePbGEOOwxn3+tS6skdCwdNnBQfDjT3hwJ52Izgl+M/Ss+/+G3yj7JcTbunIyK9dgsSqnPJHHPerC2qkleR3o52S8LDseGj4bahjAuk3YwQ0faqF34D1m2ztWCZccYbGBXv9xGkZYHDe3pVCdI5DgKBV+0a6kfUoS6Hz1NoOrW7P5llIxz/DyCf8KrNpl/HgmyuF5ycx5z7/AIV9Epp0buMBSWPGRThpcS5ZwGwfu9s1fPIl5fDufNksbxOMxSIAcjzFPHuaYpVQCOG5+bHQf419KR+GkuSokSNopDkAgHHtXLeLPhbBcbprMC3lPTyx8pPuKFVlu0c9TApfDI8UIXcfmAA5bng+31o3DaY2UMcgZzkjjoKv65pF7od2be8jZWydsn8LD/Gs4HcmwDGOAB/T3rZSTOCcHF2Y5SVHykspwGA69en0oUswAZlGenofc4obDv0JwcYHVvalfCSfPgrnB29G9vpVEATjlcKvUbhy3vQjEjcOApLc9Rnv7mlfDQjZye4P8RHU+wFNhbe6/KXRAW68gdzVXAODHlznAxlcYHHGfU0nlN87FQoUA4Pf2+tOxuBc8IOAVx6cEimIp3/OApXn5+n50hH3EFAzsycewFV8szkoParxiwPL+YnPQCmfZcdEPqc15B79rblIBieVb86b5fCkKfr61caBY2Jl2L34Of5U1iuwKh3D2XNMZSeEDLBcKf0NV3s2x8pwGrR8kqDkN+IxUUm8fKBz6E80XHbsZculMV3K5BPpVSXR7gqwSfj3XrWvJHO+cMVHamiykfPmTSfg1NMGn3PPtZ+GllqRLXAtVkdsmVY9rA/hXH33wc8tyYdbiRTyA6Zx+Oa9vOlwllLl3GDnqaz7mCwiONm9wcgBcmtFJoxlSjLc8A1D4a6jaq32bUbS5wPuhWHHpWBN4W123Zi9hJtzy24YP05r6NlS6uSY7S1SMDj5hk1EnheeVvMuGLMOeeg/oKr2rE8JT6nzxb+G9cncGLTpFOe+APb8qnl8Ia3HEzvZZbOc+YM47/nX0MdIdAybS/8Au9BTE8PxyFpbpsxr/COAf8ar2zQvqlM+bYtH1a5LJb6fctt+/gfKanj8N67LHuWwlKjnJxmvpVNGjcKGAijHRRxUg06JSVVBiP7oxkD3pe3YvqkLngNj8PNUnhR7p47dm+7GF3Mfc1p2vwyZnAnunfHAVFxj869vbT1EQZkLEnrnmo47D5mZN2QcIwrN1ZM2hhqa6HnWn/D7TLYgpAJGH8UnzE1vWXh6CA7o4EXHAAUV2a2AO1WJ3Y7dM1I2nhW4B46gHrUuTZvFRWiRz8ejbY1Uj5zySBipP7MV2CqvA4/yK6B42j2gMeeM45p0UZd+gBHSlcpXMRdMQsd6gMowPenixw0SgDkd62ymQrEDOcHNNEatM/soxx0oJbMhtPSGGQgdQcYFV9Lto0QsygZ5Fb98m7TpMcMV6iqlrAn2baithFwxbnDd8VpF9CoP3XcitbQLDvlIJJ4welI1qDIGKHB9O9atvDCiE5YEoCBjjd3ohVd5Lc7enGRntTWoubVspRaYoA3y+XPvwyEdDjkVnXFtIwKyKgwcMoXBJHc/hWzIjSsVEhBHOc8n8ajkAEb+YWJyCxH9aqysCbvqc8kci3jJCMs6dRx0qeCS4tpWW46Z6gdakKB52PQleNvXr6VNOpZYW5J5GMdDUKLepu7N2LcarLG5UcAdRU/2b5BT9PgZIJST8pwcelXo4AVHPbNScsmk7GcLfajcD1pGACkMOo4rSaMAyYBIqGSNdp7jFOxKkrlWOBHOCcngc0y5i2OqLGuw8kAVMw2eU2duTio5HJuXQnICdfTmhOxtHVleKPbETj1NV5j+9yvK7cVbdSkJA4GO9EsYMYwuB1NG5Savc5+4ik8wluOe/FS2VmB+8l2mMj7xPf0q20HmSMoBAxVu80yV7a2aEKoc+Xg8Ejqa1hHS5pOolZDYXt7dQ0nljjHzLuqrJK902ILOOIEHJJ659u1Xr6BpdQdgMQx/IoPtVu1g57UNykjnulr1Mf7NdlQN0aqBwETGKb5V5GQ3mSMfSupW2GORTWtAQdwqVGXcylV6Hn3ivw1H4qsHt5VWBx0YLll9DXinjDwDrHhiP7TMBNZE4NxEMbc9mHUV9RyWgjdJE4Knn3q3faTDeWjxTxpJbzIVdGHDKeoreCk9zz8TZnxGzMPkbAx+f0pyOpGWGcDBx/d/uj+prS8V6aNG8R6npyHK207RKT2APH6VjrkHA4Hc+1aRkcbRJGrOGCgAnnHIz/8AWpwCFmGW29ucZP8AhQHAQoSduMcNwx7Af1pMqwACsQerHGR9ParIFGWVmIJA4JPQ8dTTXyxzjAHOG6fWkVsseMqMduD6Ej0puCTjGB19j70XA+9JLdEYEOPoMn9O9RvGWfdsYL6DitGbCIwYM4B4C/L+ZqlJho8gcYztGQM/XvXkPQ+gWowRlwQAit2Gc8fypuMIAJScf3P58UGF5nAIZgvYjaBUrQiOPEsoGeNifeoXcLIqSBHYAZbP94/0pywb89ePbFToScGC2VF65b7xpwVCd0rM3qAelMZTeNQcZ59AM8/Wo/Kk6gIoHG49qlvbtLVMkKF65Y4rEuNXMqDyYnZf70nCj8BQmOMG9i1cKnPmSSSDtt4FQxWwdsHECE9ByT9azpLrzJMzyTMP+ecWFx+dN/tNy3lW6tFnqc8n61SNFRkdB5tpZR/KEGRgs/y/lVf+19Nmfywy788DdwRXNzw+cTvkYFR3Ocmsx4IkucgGMP8AdLHPNWuZm8MHF/E9T0UvayBTknHYYArPnmhMg5LjH3feuSuJmhgieORtrcNg8CrVirsgmBZT1xu5YUNMSwfLrc31Qb94xgjgHmlKExg5xzuPqadZMXQochuCuR2781dCBMqAeKzMXDl0KRjB3qOMDnAzzTlgMYjQBsEc81oBBvAUjBOM1O9ukkTiPAcHaKEQ3YysbCu485xg9qn8kbxG5+g9KkkhKy4OPmXGR2NSJCfk6HFMTM+SDGUYk45BNSRxnYNud4/MVdnRhIrFD5ZGMjmlSDIf+9t47UWHcynhdk3EnGcgimIDHI5bJzkD16VtW9uvkr5i/lVe8tAGjwDy+KHsUpK9mVDEJtKPOCVx9Kr6XFiyA79/XNaNpA32Nl44yKg5gZSoysgwT6GmpdQUr3S7lZ3eBQzD5QcHvSmQBsqNgPIbPWn3Me8HjANV4LT5cFjuU8A/zquZ7GiUbXY4sAwZuufSluHIO4YwRnBHBqTy9w2v8hBxVWfzGcoGUZGM+1XEWlyO3iW41GN4zn92dw9D+FaUVixueRtAyT37VW8PwkOz4AGQq49q3SSUYgctx+dRzWInNqXKiBIBHauc8sOKsLCwIBGRinpEHUKDxuC/l1qdmUXKMD90HOaErmEncqeSC0inqDVcwg27Y4IHGauCRVlk6YLZqtOxLvtPU4x+FPSwkjNMbGyDde/SqsnN5Hxw6fn3rViYCNYT0xWZcp/x7sG74PsOlI2hvYc7q8ZUkccYx0pokD25BPJHGarSEAnPEinH1qzbBQxLfMMY5po0cUkMRQG28bu5rWjjP2ErIyH5x5THkc1jXEgSTKnBzk1VvbxjbQoC2Uk3kg9ea2i9LETpOpZI35RFGZVbcW3559Kntmjz3FYtxexTSfao8qkmMq3Y4xU8F4M5BH51PMkrGXsnbU6VHgwPlalaWEfwmsZb4AdR+dI96ozlx+dCqIx9maFxPbhX3Ixxz1qxb3FuLdN0cgBGQAa5oXkc9wdzr5a8n5uvtXDfE74lWei2VzY6fMk2qyxmNVjPy24IxuY+vPArWFRHNiIdDwbx1erqXi/WbxD8k11Iy59M4/pWAM/w59yKkJLsOrEnB55Of603HGM5x7cj2qkjjZKvOxAF4G05bg/So8k45yB69fw9qUELkLgjoS2SPoPT60dQcjPbAPP4H0rQgQgAklww7YHH40DJUCTnPIBHDcdfpSZB47r1I/lSE8ZOc+uODQB9+qFWPe4aVwcBSMBc9KR2dTtdmdyOVVeai3qSqrvDDuOST7VIrLbRk8eY/QZywryb9j3rEnzxplswbh9WoLxwwkooWUHGX5J+o7VA92sYDE75j1PU/T61Xe5jGRtLTHHydST7ntTuFncWW42ghQ8jH+9wSfYelZ093MCUWTLkYZY+Av40vlSXEpCOS7cHZwAPrV+CwAi2QjH95iMkn2qbNmkUkYo07zWDXHzNnv0FMvrWTB2LtjBxgDk10ws1VowpBUjIx19xTbiNVxHnET8ljyQewpxVjaM7HGixcOScrG3JPT8KnNrBNh0cBidoyc8D+VdJJbm6strORIv3c/dBH+NZ40uGd2VLRmk9A+FzW6klobc6lq3Yyri1FrdIuUdDgE+noTVa5tvNZHlXOzOMc100lgrRGIwbDnDNuyFHrVGO2kUmNnRUX5WJ4zinFq9ioT69TmRZSwmWOaP9ww3ZBz5ZPfHeui0q386yUSLGzcAYHOB61amsgACFDluDzT7IfZiUTo57+tJ+6E6nPEa8QEUewNlT37j/AAqUqTKH3YVeOmee9S3G1WZRu4G3jpTbVGIQEkf3vrWL1ZzN6XJIoi6+rryAKsxE+cWOQpG/HU05E2udi9RtI9TSbT83bBB69jTMXK4gj3AnDZByDjge35UiRMHUgDGDkdM1M2AiZAGGAPr6U4KqsykkksPvDnpVWM2yGSIxxxhwSpbr1xQYdm7BJG7IDDj6VZRmKFQFKhuRioXAGFBPHIpsLkaYERA4IPT0pbiPKFlJYIQ34U5s+WRwfmPSn7gmSDlWG3HpST0BlIKIbkp/BJyD7+lV5YsFojyc5StKZfNi2DG9TlTVd2WaMhxhl7jqDUjRlShlOCuCKUnL7lx054qa5faPnXd7joaz7icqOFOPYVSdjaMm9Ca5GQTkEf3T2rHeSSW4NurAK3f0FWAJ585yiHqT1/AVJHbRQkkLlie56076FRaW5pWYSCJVQ/Ko6+pq7Hyy5HCjPPc1mpMiAZIyKBeLnlsVBk02aiSbU57VCZuWPbFZk2oR4+/+AqrJqka7gSMU7kqLZtPL8uQRVWSfgjPvXP3GvwRnBkUVl3Pim2HJdcUFxpM6v7SCxPAwKrefHvK5P49q4m58YWQzm5iUnjG7FUX8baYnBvYPTk0WZsopbnoBmQ5d/XINNaQmParYbrmuFj8YadKM/bYCB6OOBVqPxTpSjm9hb3Mg4q0mJtdzpJgcEqxJ9Kpm4MbgTKSvfb/nrWPL4u0lVLfbbfA6/OKyL3x1o33ftiZH90GqV0UqqWjO1sbyC3kmTDS27nJ3Dt6fX3qSNrV1ZiRHknCqTxXmsvxD0mIEo8kmPRD1qhdfFGNFb7LZSSHrliFBqkm90Zzr0k78x67L9mCAmSUBvQ8D6ZqpI9mFLyTTKAMfe4rw3UPiPq86YgWGFTwDjca5291vU77K3N9NMD0RWwp45+gqlTfRHNPG0orRtnsHjD4jafo1hJaaSFuNQbIDZyqDHU14VcyyXErzTMzyyHezdck9TT3U7W2qCRyfl6+/0pgIDZTcCB948np1raMLbnmVq7qMbtZGwOCPT+lObIj4X5+5A5U+n40i+hYDHQk8f/rpgOeDlR29R/8ArqznuKGwuMAepHcelIvzcA9+AO/HrShQQe4zjIFLhV4P3ehx/F9KEIbgn7vY+2SfT6UHBPzMNucZUUFienJIwexH40bdx4HyjuQMn6+1MD7qmlMZATCn0DZP4miJ8ncDsPdl4OPrVWSM+XtclWfJCIOtWEDNGRswq8hAePqTXj3Po+Ujl3SkBAseTtDDsP8AGkNo2MfdhPQvUquDvd1OV4VV/rSm8jgiDdWbjCjO38/50423Ym3sWbZEEQCpsPdm4zVma9I/gAUcfLjr3rGafKAkEKOpLZJ/ComlExAiLAdScYp81hpdTYW/ZcIEATqCTk0SXPmhj1LdAF4NZPmiEFlQknjk1OLqVvlKZz1YZNK4/Q0YJlB2yHYw4wTj8akkIY9cOpyCBway1Cg/MpJbndJwG+lWUhuCMgGQHtuwRVXYXsy4jQyK0ofYR8rMWz+lZ8JP2giIqG5Ksw7f1qGdbreXMLL6lV/nTDDJOy4XYR1YfzNHMUvUusBIoy4RTlt3OT/9aoGCoi/Nl8YVQOnualCSJtWdlVSPlb1A7CrNvDG/EMbOx5+Y4ou2JzsVLOIyvmZn2L2HTNXTbGBQ7DMT8k4xj3qaS2it9isrbzw3+IqKSWSMMsuXUfLweo9KdrbmblzbDTKFUZwzDhjnqO1Dsi+WQBtBKnjkg1QkkCF5Il/d9wTyKZDcxyEoDnjK/wCFLmQcl9S8ZGZXHIIGKk847MA8gjI4qorqX7DcOfrUTyhHOOlO5LhcvCTGcFeT+VRMdrdRjp1qlJdquRyDjrUTXQHGeB3FK9wUWaUkjZw3AHpUZlYLnOF9DVBr1AAu8Ee/eoWv4wpww+lAWZpfatpGDz60x7pGycgH+dYFxqsXOWx7jvWFqHiuwsgftF5DHjsWosyuTudlcXK4yW+oFZ1zqVvGcMwz2zXletfE3T7fclu7Ttj+AdDXD6p8Q9Sumb7JEkI9W+Y1pGEn0JdSlT3ke9zavGpBMiqpPAzWbe+KLKBmMt3ErDqSwFfOV9rGpX7j7TeyP3G04BPpxWe4EjnJZifvbm5J79e1aqi3uYSx0E/dR77f/ELRbb/l+SQ+iAmsC++Klthvs0Ez47425rx9V5zxjnkjt6mnFwCSpYDIK54/4Eff0q44ddTKWOm9keg3fxPvZARDaonH8TZOfSsW88c63OeZUj7YUd/SuXUA53Eqw/Qf4mlUlAXIGOnIyMeg96tUYroZPGVX1NCbW9Tnb572RiTjPT/IqlJdTyf6+eSUEkqWfIJ9/aoFXqWXd22Z6+w9hS/xk8M2cZBwpx/QVailsjF1qj3bA4xxlu/POPf3PoKahA3ZXHbPcD/E0BT8rDgkbsk/rQSNpBA4/iPVfr6k07Gbk2APzYwOeOO/tTyqsp4yM5GOT7/hTCpB28LnggHj6fWljL5KKCQRhkGATjsD6UJBcAu4DhQhyQxXg+5oyMnjCgZwTjj1+tNUFuAee/PDH/AUA4bcMEjkc8ZHf/61OyC7EZsnJJHr7ClIY5YFVAH+R9aBg7nbdtB5JPIz3puDk7hjt06//XosIcG2gsSQTwVHBPoPpSHAQMQDk85PDe30FIV6b88ccdfpSL9/O0E56D7ppgPXezckEN1A44H9KUHYyuhGeqtgjb15NR87c4HPr3H+FOypI+bLYyHHBB9TTuSxDkZAI59f89aYwwTHty445I4+lABJJBG85+Yn/PNKAcBD82O3p9D60hDMMwyobHTjtT2PAwRx8p29MdvxpuSucArj/wAd/wDr0rAbgBnGfvA8UCGDPfp+tKQpfIJbJ6+p+npQV3EAKeeOT/I0pw5AA474/wA9KAPuyeNFlX5849P6CoxtGfKBCrySanfaqDYRgdx0NU7lgE2qMyN8zAjgf4mvHcdT6JSIzK0krrvAyc4wenvTZpdpxEu9geC388VWVWDsiFlLEO7E8nHarkFv5gUAANgn3oXYH3IkjLk+ZueRunvU0Fs24GNQF6sDwBU0i7CuQSxwB6VYXy1TLruIb5Qe/wCFNxXULuwxYR0RS7EZDHpQLaQfxYz3XjFaECSvGvIC9MnjI/wqSNIWYtlnPU7vlRf8avluRzMyI7aVWKRgv229vxod7lH2xlVx25P5GtBIZLhz5h2Iv3cDAI9/Srf2OUDKIR23joaSj2Kc+5kLdy7GE4lYnknOAKkFv5qGXzDHnodxIxWkmkOWyVO0+rdTUD2IgLeWwLDqBn+VVytbi509EQC0kiG7KTLx1yTj2oklK7VeCRQOhHUfSrILxyHywFyOGQHHvSiWUt+9yqk/eIzmkHqNS7YqwUGQHq7LhgahnQbCrFic9M8j8KtMQ3ygHyzwdvWq07Sf8s8Mv95hzSuCdtild2wJ3BiM+lYd1bXCSebC4Vl7EYyK35S+OgLY65NZtzbTzsV3/j0AqHqbQk0zCfW3t2K3QKhWBB/veoqNvEdr5jRrKCxG5c9xV6XRotw81A/fLHrUFxpVjh5Gt42YjA+WqRreDOe1LxJI8xhgjOBg7s9aztQ8VPaRs0zFQoyf/r1r3vh+Gd/ki8tl5BU4IrndW+H8OpgfaLq7PbYj4XPqaa5eo5Npe6kcvf8AxSbzClrbyOOm7dgE1jXPxD1u6ysJiiP0yR7/AErrv+FTaailWubt36feAH8qWH4UWA+/c3bZ4OXAzWilTW5xTjiZbNI8y1DX9YvOLjUZmQ84U4U+/FZqpvkXJBc8hpDyvqW9q9jf4YaRtOwT47lpDUcfwx0oElmuDnnJk6/WtFWgtkc8sLWluzx9gF3KMbsZ3N/Me9RgE5A47cjke1exTfDLT5yRCZkyeArmkX4RWRXebq5QD0YZq1XiYvBTXVHjrHDDcSQRtJXv6D/GmruZMbQQfvZP8vavW774Y2SMsNn57SnuZP51esvhDZC3BvXmdgMsVfH5VXt12BYOfc8VJT+Iqw7N0z7n2p527gVdWA5G7vgck/4V7b/wr3TrLJgQZ7mRQ+cdqktPC9is3lXtrCN/SRVwD9aXt0+hosA+rPClKsPmIVU9T8wz39zSbhyTng5wRxj0+pr6Hm8AabMG320Ldx8tczqnwwtPMY2ke1eu3J4+lV7buiXgn9lnjxUbj/Eo/h7Z9B9KCFxx7DnufT6V6FP8NnTBSaUD0OCBVSb4d3pYtHcDnoCtHtombwVVHDNgrn5vm5JOOff2pWGDgc4zjjBHvXUyeCNWXKgxSeuf5VC3g7WVOfJjbHfdyTVe1j3JeErfynOENGcMQpx2OcD/ABo3cYA2rjBXOSPYGui/4RHVt4KQKpA678k+p+tTf8ITqxRsxoq4wOc7R7e9P2ke4vqtX+U5Vfv4HPbIHP0x6UrKDlQQ3OQ/QMfX2AroJvCupr0WPI74x+tNHhbVBGB9mXnJY7+G9B9KPaR7g8LWX2TAPDAj7p5G7kj3P9KQcjcxbI6n+n1rpV8G6pKqn9yD127jnP1qnd+GNWtmG+0dyOAUINP2iE8NVW8TFCrgscccY5/IUEsc85Pft36fSrE9jdQHM1pMgHABQ4qHpncCGAx3/KmpJmThJboZ91AAoZSc5/vfShg7EFsb88+o9/pQSPUHI6DufT2pyclSPm746U7ohxYgT5xscEkZyTx75pAPmIBxnk5/hHr9adgEcspY8nnp7mhsYJOMt0X1/wBrP9KYrEbdCE3cc46kHHU0rbkACdDnkZxz2pCGBx6DnjkU5OfmXAA6tzz7fWgQwZZQuTj06ClbLjaBnGe/Ue3tRIADjkDoeePpSAEkZIPoOg/OgR9xyNIclz+86jHaiD97dOSGOMDLfStB7ZZyigMzyMCQF/pVmS3ay3KqqGPXPavJULn0HOioLUFkyuWJ6etSCHyFPlDMrnB2nJHt7VMZkWMLKVZUGduep9z/AEqzmJEMxwS3KR9Cx9T7VSS6GbbRW2FNqgpLI3JXHA9qDbLGuZVBlfhAD8w+gq7AtvHEHklQSY3Mf7pPYUbxbs0kMZEj8guedvv6VTXViU2tCNY3VFEj8HkREE0knmOUiyrTE8RqvCf4VH9olBUMzM7dCw4X02+v1p4H2eXDske/qB8zH3z3otfYtXLzJHz5zmSQgEgHv7kcCoysWWZ5VUngBDx+NVknlkBKOGVDznC7efaoZXMMgmmCkH7qr8waqCMGy1LcDJXztyj1P8qh+0BVJ6bhtGVOAPX3qG3u5Li7zPGXQEbQqgflU8jS3MXJWNS2EXvSktC+WzsxISwYeXlsDHmev0qVtygbnaRsfdHGPxqHyXWNT5mVXIxjH4CrKIAoLSNu64A4FZpsTVhhV+MxZIH3iMAfSom+VQdhLHgbj1/Cpw7Ab52Dg8AHggfSqs5d5cxR7VQY5/hHrTbBIjZSCwK7mPUMeBVWQAKQgG0dT1zU7x+YpUsSjcZ7tUE6eWdrZWHPA9TSBIzLtTuC5ye3HaopYv3W50OF+6DxzWj5PlAyOd0h+6tRyo7MPMO5gMn2pJF8xlOrbQgQYPJxUMqBGRQRj0rZ8jMjFwABjv1qrNbR71IG7nPTpQ1oUpozzH+93Dp0x2qZYkdACMPV4wK/yk8g5pIowZdvUAZ6UWYOehlzwqvQHIqRIPlKlclsmtKSNT8mAOpohAUD+I9OadtSXJ2KFralJFwoOFJ60541kmKbeEGSPetJYl34TqKrxx7rm5I65AP5VSuQ3zO4zT7JFLSMMM3P4VNLGhJA6VM7KuIxw2RjPpUF648sAY5YnNVcIxbdyhLbwY5GCP8APFZl/ZKUwqYUjOc5NbCxcZOAetRR24nIYtwCflH3j9Ko20jqzL025YERSnLDlT6/WtmS3SaEPx69Kx721kgmSQqVRjkN7nt9a6HTiHtEB9cUtepnUS0lEzLjTUYH5RzzVNtNwcKtdOY/kzioJYwuOOtS0TGbOXl0teuwVA+nqoxtGDXS3MqxsIyBn1qIRhx2FKxvFvdnOHTE6kYFPGnrgLjIroPs5cEYyKa1v5bAj8aLFKZzk2lR7CPLUHvxVJdJUOPlIX0NddLAS6KB97OcmoTbfvGGCeMkVVrmkZHPR6MMEAAY6GnjRFI3DjHbHFdDbqAVAOWwaszwDys4J78U0Zym0zkZtLgWJgY1yeTxWK3hyC5fYtqrn/drqriNpp/l3YHGB2onWaykCcrG525XvWsY31BxSVnucnN4GSOF5ZbJVjDAFioHWki8HWDExvFbw4O3cVBBP1rtnubqMrG4ExC43MSV/EVF5dzLneyYPBGzg024rQzSbWpx2p/DO2nQLNaIGZSVeAdR6gjrXmPirwBf6LHLcWgNxap98EfOnuR3r6DWG9jWNbeVYghJUKvSq01pdOjLPiRTnOBg0Rkl1OWrRjPe36nylnI2kcg9T1+tLjGQFYFeeOq//Xr2HxN8JrvUJ5LzR57dGbLGJ8rz/Q15Tq+l3ujX0llqdtJBcJ1Vh+oPfPrW8ZHlVKbi7EK2V1JBBKkEipcObeJwvySPx8gPc8jNLqsYtr427W9xbyQqI5YbhskSAfN0Awvt6VuxjT9d0nTknvbqzmsYjbuq2rzRMuSQy7OjHPOfSs7xXdreasGhW4EMUEdujXClZJlRcb2Hv/LFO5nY+8IsiTKZ/dJwAcbT3/CoLqQy7i7M0p9Ow70TzC3tDyC2S5U/rWUbqWVsBQC3JwefoTXnXsrHsqPUt2sIJyy4I6E8ke596u2+yNnC/Og5+bkt6c1lCT7+4Ej7oweM/wBatI4lfZ5jBE6svf1NCstAaZdcAu0h+baMsMgKo9z61HLcoC0srDc3AQ9SO30FUZbwXDiC2VdikMFY8Y9z+uKzrm9to2dJmLyDvFjBPoaHbc2hRbNNC7SmdySCdhcnj8B/WpkubeMEh0nm+6qnkD2rnvK1PUkRgDDaDjbnANaVlA0LGOHIC8liOQenFXBvotDV04x6lhw7FXnU+YfmVlGBgeoqyRGyMjAl2z8x4wPX3ql58okkjLhUXhjisyS6l83IORuxkjmk5di40nI6EyKjbY5CBgZbFS4OMF/kA4KYOK5+G5lLN/e9cU5LlnVlYqcHkjj9ahNjdFm1DdIwXaxkEZIUHjJ9anPmR/PcAAE7geuc9qwbeRhLuVdqoMhh9a0rp3IeR5VlbH4fgKEyJUrOxciAkjMp2hQO/wDOq8sbSvGqkqh7f1NFuGESpIVVBjIPenSTllaRRjsCf5ChmdrMcWSIA5O7OFGO1RFDNKOCxHJJ6D6VA2JGEkzgnPTOasFmwBnBI7nge1LclqxHIkbSkqwAHJb/AAqCMbkJ2lcn7xNTElvkUAHv9KJIx5RMi4GeADyapIlsqhSSsXO08k9c1FMpMyhcAbcnI9DV1iMyA4ATAHNVoIykO87gxzyOtVYA8ld8rJnO3pinwxpsDbMHb1z3qSFcyRsd21xg9uaNuP3bEhS6g8dMCgRSZMSg7R7g9OtQtC6oxXON5wPT2rSmjO+UAZGzOP61C/NmjBcOrkn35qXEaZUdmWSN1U/eK8dxVa0c/a7kAH7wOO+MVrMqpIwUZAO/9az7dduuXCgHBUHBp2sNNWfoQqwlvwPvbEPOabdp90AH5SevSpryIW+pRyDgNlW989qaYZN5C8KT9xuRT2NIvZlVWO05zj6VNBLLCWkhYKew25pJCYyQUxJmpoSsT7nyD3Ht9KpajnaxRv5GubeLzifMOdoHQHP6Vf0iIpaJu6FutVnt983QhRliM559a07IEW8K4+836U35mTfu8qHzJjCgHrUV0Ngz/Dtz0q8MNJI3ZcAVG6csG53ttHHQUJXM+YoS2KTyI7AHjO4U2W0RCpGcGtEusbHcuFXgEDrQrRsgZj97nFOyH7SSKi2+1nzwcVFdIEjHy8kgVek2ksU4J49arzgmWFG69SfpQ0JSd7lKQBrhcAkFSRxVHDyzXG1jtziroBIkbPKZANQaXIPJZmGCWLH86lHRCTSuitb2zif1wMn8atyHdGQH5HWppJh5hAXGRTUjAtiOpck4PHFO2o3JvVmetusbljlhnkjuK2ZLYb7d5VBit/3i/wC0T1B96rxunkSIQCwwT6U2wkDapP5+WkOSgzxjHpW6domdW717FRoC0iOI8Bhnbj8asRwkHlcfhWtK67VO3HyZot5F35YcUrGam+UpLCePlP4Cmvbk/wAJxXR201rsYNBkY65qS6lt5G+SJUXHAzmnyruZubXQ5JVeGXKjAP3h7VzPxG8IW3ibR5YTGFu0jMlpP3V8fd+h6Yrub0oSxQDioUkIhgfapIfABGauCOXEK+p8qrNd/wBi6VBp3iWy0lreFop7RrkxESBzljgck989MVy2vvctqTfbdRi1ObYubmKUyKwxwuSB0rqPFnii4i8TatHBZaQyJdSKCbJCcbj39a5DU719SvGuJYreJyAu2CIRoMf7IoTaORn3XM5lhYscDOCMdKqx4y5Pyu3Az6VLekvGFIbdnn1z6U77L/rCo/fgjGee1cCTuew3pYpbfmRC5VSc8nnrWhdyqII4kIyoPA5zn1psmlKVQPuzInLA9cjtUpsRBawxoAT03k5Ykdqrlsrs0XKrFURPJEekefvFBk0yOztoT8oQnIy+ck/X3zWrbKPszmTAdSSCByP/ANdMFuTDtKbvMbO3IwW7UNpamntHaw2MAwlZGCknaSG5Aq7FDGkRbP3Rg59M0yG3hjlRQQXJyQ3J+n0960JIEaYIVVGkHzY5x9KFJy1MnO2hlPEgleWTHzHgegx1qlKsW0sGQ9iOh+tat4YY38oncV6EHP4VFJaxSozvCFHYMeKnmZvGdldmfpUCK8ijD7vun371L9njt/MaIYXGOR94+9XPLAUFG46fLwBTRAkjDH3V53E8E+gpc3Qv2l3cit4h5QyRtVdoGPvVM8Mcdsiu3LY3ZqSR0BDbh05A5I/CoS6Z812JUDC570r2Icrj5gMFwvlJ2z1NVidxxIMYHyr3I9TU91cNPsYhYo1HC/xE/SiGA4JkyGbn3p7si9lqVwASXcBR2Ap8Z8tNzZZlPQ9xVw7EJGAm0dAMmmvGryDBwjcFieapKxi5XKxQic7hkOepPSlb5UXbt3B8ZAJzUu0LJ8zlip2Z9hULLgZP3iQSc+9PZCHW4AkYsTtYHjHeo3jCqI43A+Yjml3MokTd8u7ikaTocEEHmlcOokZbh1XhD09KcArbXLfMZN3PtR5nyrg5JNQ7W+0A/wAOc49KLj3LEzBzMOodTx3BqpApksJFJBYHgj61K5U/ezn1qNGCKRt4pOQegLmR9zEA7cHHsaqyjydZDjkMMA+9WFfB5Oeaiu4w4L/xDBBpX0GlrqSavEl1ESOBwePWmxoFiG7744PvSuS1ux6HFZ7XwVMMSNvBqr63CzeiGXmPORido6Z9PrWfJdL5kknmGR3GAuOlWGv450zsbOe9Q29sZJTKUACnANPmNoaL3i7YJI8QWTlm4P0rWUhJc/wqvH1qpagIuTwMYFOZi4xjGeT7incxerLEcvygepyaJJQAvOSvNVg2GB6AU8spGQM0cxPKRTTls/16VDHMwUBhg9PwpZsE5HIqFmUSY6GkpFq1iZJDwd3vUof97v6nGB9aq7kAzxTEuADkGjmHy3Jem5MfKxP4GskCW3meMkFOoxV/7UMFWI9etUpZVeRmzn0oua07xepJpiu5kaQg9jz196tXUyrEFUE9uKoRzmIEKQSTk1FdX21SCRVJ2G1zSuElyQzNgkgYwPWtext0Fpb3FyrpcxnexA+9HjoRXGXF8u8MXAHrXQW3iOB7ZEeUhgv1GRWkJJ7jxEJcq5UOmvh9pI3s0Ywu79RU8V6CRhjWNcSQSGSN5yypyrqOTntjvUUKXARTbu0hPADAA5oafQiMFy6nUfa+nzH86cbv5fv1kx2dy6uIL23eVVBMbDkf/qrPk+2Mr7prcBeoyRmlaRi+V7M2JrsFgoYkk/nXM+P/ABfb+GNBeUuDesjLbQ5+ZnI+9j0FefePvH0ulXrWWgXatcr8sswUMqnuBmvJ9U1C81W8kur+4knnbq7nJx6Y9PatY3ODETTdhsNhqGozw/ZraeaS7dhEQvEjDlsHpxnJ9KfrKJbSCzbS2sLuDAl3ysxY45JB4APUY/WumsL4v4Xa4hstSM1vZHTmlSPNvCjPl5Ac/fIOCPWsHxXcpPq4jihuIo7SGO0RboYkIQYy47H2+lWkch9vyIst4uxTs2nAAxkir1rFIqvNESsikkbhw3tj1qFnH2m3kMYVdpUY43H6VdjdlhZGYFgcg4rkTR6ruRQ+ZJKVkAEeNxyMYFDpg4jbBAJz2H0/SmzMwT92SXH8R96fbRu0bF1ckD73bPfmok76FK+5PEFMSuWXf0AA+4B1qvKhiILjYAdwZfenPK5QmOMKrNgY6/Tmq8wd3AkZFiByXdsAkf4VLd0UvMTMcT5YSM3908Gq0txIwIBkHbA68+/erUf7zEYmygP3lGM/T/Gn7VtiGRtjY+8eWb6VHKWp2KKRzrztKnsW6mhMq+cq7e46VdlhDR75DNISclSMUQrtB8uMJkdWHQUJW0KU7lV1MmDJgL2CjNOXZsClUyozlnyT9BVmNFZcsTgcZpYrYZzFC7d95OMU7dhuZTaWRW2W0e4HqNuBSJHcM2/dk9CcYxV4Ft+BtXAxtUYH4mowdxwiZI6nrj3yaLApvYZDZohBaR8jlsf4mp4PLQEKXLnqFOf1p+FKguOPQ85NQuplOwZVeuFPH501oQ3fcUy+WOMAr03N0qFrnDSAPy4+bA6fjSvGpTD8e+OBVC5ZUOenoSeop8zBRTLZmBUqzL0z1qNXyNpyea52+1mK2cqwIcc7AMn8h2qvH4hnk+eKxlkiwRu+7z6YNLmNVRfQ6mRgN3UHrTWkBJB6H3rmW1W+kA22TDnB3OOKgnu9WLErDEG93zS5h+xfU6lJQCQO1Cz4JJIzXIibWCynbb89eTxTi2sFgPMtx3PB/KlzC9j5nWNMAeo6VELlT8oIIFcjJNrTMdqQlfUkioPP1ZScJBgcFtxFFw9j3Z2LTom4FhzUTXyD7/TGK5OG41a6J2xxBQcFixFVbubVlfYkSO3fGcfjTuCpdGdfJejy9yyAge/aqUksU5ySCPY8muCubjWXLIFig/2d5IP6VD9i1yUgwXdur9uTQma+x5dT0iPycgIBgDHrVhZYokJGMD1NeVzx+OYP9V9gkPoZCuf0rNub7x6gI/s+3Zf9mXNUtTKSPX2vkLHe4H40f2pEqn5wa8LuNQ8eD72nH/gODVaXUvHBXjTpFOOoTP8AWqsRLl7P7j3h9XTOAwxioJdYiXgOPpmvn2e98buPmtrxR3Cw1WMHjO4b/U6hz6qFp8vmieePSL+4+gJtdt1yGkAX03Vm3Hii0hbLTqAfUivEP+EX8W3LfvILgnrh5sVYX4deIZirTGKNT1LSlqOVdxqpLpTZ6tL42sgDm5j+m4Vm3XxC02Lrdx8dlOa4+z+FUrY+2aiAOuIo8/qa3bX4X6NGAJXu5mHJJfbmj3e5V6nSKXzFuPiXpqN8kjH6DOaqv8U7QDGH47ha3Ifh9oEAwdOWT3d2Of1qX/hHdGtSBDplsgH+xn+dO8UVGNaXY51PidZsD/rRzzhCTSSfECylOFW6Ze2Iia6lLGxj+WOC3Ruo+UCtmz0bd96LYxAKnb8p/GmlfoaezlHVy/A8xl8Z2x6wXZTpnyGqqPHVjG2NsyjOCGSvZJNKiSFmYQRBBhi7dT7Cse+0rQr2Ipc2KXIxz+6/rTUbCcp292X4f8E84Tx9Yg/dmPvt6Cn/APCw9POc/aAPTaelWfE/wwWZDP4Z8wuDk28nK/QHtXnWv+HtX0KRRq1jNbhj8sjjKsfqOPwrVRTOGpiq9N+9Y7t/iPbQhmghumfGAfu/hXPa9431W+heKEC2iY7WZX3MfbNcfHJyfMGQOeeNo7/jUZYZymecjpyorSNOJyVMZVnpsOVcvlhuYjgZ4J+voKjcgL2ODwcc0ZySM5IGB6H2+lMc/l15/nWmxyPudppV3Y3+hi3fVraxdNOeya2uWZVEhk3eYMAg5HXvxWB4qv7e91VPsc7XUcNvFbm4YYM5RcF8Hn6Z5rp7G41xvD+kJ4YitLlIomW4PlRPLHLuOVfcMhcYwe/PNHjCeG+0vUpLj7ATbtbxwvbqi4uCv76NCvLIOvOQD0qeoH2L9n+chs5HcHJNWAfJJl4IUbFIOCx9cUsx8kSbGUvnJOc9ugpzt5n2eNW27AXz1rz0evuQKMzvkrtQEsx7+1I9+Cpjwvl4APP8qSZooY2Wc5y3THOazJooi4Z0dpF7E/doasUrPctyXvnO7INkajCA8gZomhjeLnLtjIaTtjqQKrfaA7QwooyvOSMBj6k+lShhljuLsxxtXof/AK1K1wehct4CqLLKSm4YQEAHHrirJMQASKJRJkB5Sc4/wqnIZFkZJDmXqq5yo/H+lW4IC6bRIFQEFzjkn6U0raE6bkjMqudjPPcv128CkEG8qryb5SM4UcIPT61KfIBEUTMkAPzkdW9s0txcRiIqifO5wFH8s1VkSm+hFKFO1IYk69Qc4/Gq9wZFLRBgSvJAOF+pPemTTMp8tXCu33pOyj0AqDzlzsRXdRyAD1PqTU77G0YMnQBcMpPPVj1b2FOUgbSvQdB6fT1qBZArhr1y8w4WNRxj61eljSGITTthjwFHQewp8oPTQhbczHcxHOSR39hSSFAxOe2Pp/8AXqWQiAq0hLSt9xAOgqq6yXTMkYVADhm9Pb61L0BGdeXB3bI/mYdTngVkPFcXUhCOVTuw6n6Gts2Rldgg2wJ1J70+KIKNyqQvBHbAqLNmqkorQxItOS1J/dDzG5LHk/nTo7UJjzPm56dq1XjYlvQ8kmmvFtTGQWxnmhoPaNlDyOOfXpTWTBIx07VcKfuAwGTnHFNkjPkkoMHPOe1FhXKDFjIAF6+1SbBtII+Y08RsswcjgVL/AMtwMDp0NJIJMrSx9EUcnihrZURAyjA4rQt4czEkDOBxSCMTzlQDiNssatR0MuYoyQ7EbYB83NZ0ah3IQjIPz5PSuivUURu/ARRjP9a5VY5C8jxrlS24jviqUbG1Jcw+XTlZzvDMpHbrmootNj84hA/TILDBBHtWnauWbGSQD1NaEcWJxjklepq3FdipVWtCj9kBhQuMkDmo5LNOQExz19a2xHiJCeh4xUUcQMjDGRWbRipmJJp6beFB9qatjGByorcMQAPQVXQKXwaSQ1JszDZI+BsA+lDaanUDitgwnOQOlL5Q2dOadg52YElirEAJz2pog8o4xweDkVvLGOT2PIqAxq0kobkbRxSsy1UMlLRQxyM56U9bZlJBUHPtVtEVlib+6cZq35LOhcnI7etXFXFKZgXcThTwAB+tUf7ODQGaTfhhkY5Oa2b6Jt3lkcHpVdpXW0eE/OD90EZx9K1hG5spNR90zNItIYI7iZ4llZGG0NyA3pWgIpLkDzWcr127jgfT2rSSzcQLG6KrBQz7f4j61bt7TY+18Kw68U+QxlW5m2zLi09FwNg9uOlWPsKkYC8VvQ2sQI3FiO9aEdgHjYxW7EDuaapoylWZx/2YxOGj4PsOtGp6RbanpssV3brLbygpJE/IHH+ea6q5gKREHC444FZwKiObLEjANawgjmryurnxt460KTw14lvNLc7o4X3ROR99GGQfy4/CueZssT90DoK9i/aJtozq2kXyg/voXhckf3WyD+Rrxx8A/LnB9ao89iKQSQcDPenfxDt70zFKC2O/XimmI7zSLSwi0q0UaJb3s0+nS3azylyZZUY5iABHRR061z3jSCGHWY2gtI7OGa1hnS3RcGLcudrf7Xv9K0bT7Hp+laVcLaarfysrT+dbXRjSCXJBVQAcMABk9TkVg63cpdanLcLBdQ71BZbqUyyFscksQDzQhPY/QCM7hLHIxBxuGFGAaqXalJFAkbGASwOcU4XDTuzKDgEFi3GTiqizLl9xy5b7o6kdvwrz2exewkbSbgX2hFOQxH8/Wka3mlbYkjBXP3z/ABCrF26GEJCAihwck9M9qqzzi3JVWL5PznvTce4cz6bluOBI9ry7SV6OeSfaq092POcQIAWPPpVSS48xAzEgDoT3p1oC0gXOADlt3BpOdvdQowbd2WYpJypY9cYG0Yp8LsiFYyQp+8x9aklbzJo0QkRLyCo61LIwZ9kSJgcEnoB/jUvY0UbkbuWQ+WrFBxx0z61AGk3KHOHPXnoO9XZJBHCCuDIvCrt+771Xlj/deaWGSckt1b/61GppGN9zPupcMSwIHRRntSCYAKqMp3feLHkn+gqSeCRtzIcswy2ewNZbMEkEc+/A6fLV03Y6owT2NSO6ctstg0bcbg/IPrip4LtnkQSfvWQY2Hop7VhI3mTh1Dl84APpW3p1u6HcSfOP3m/uj/GrnMznBJal5d7yHzOZD95x/CPQe9WnYQwGNMK54AH8I7/U1FbIARt+VF5Bbue5NKeCCg+Y/n9TWSOZpNiuY0jFqDkKMyEDGM/w5qOUZmbIAghHzEH7x7CohIEJ2kbR0J/japWl8iNWfnuF/vH1NNPQVrAEV8b8jJ3MO4UdBUMsYAkcAhdu4j8eBTnkwwRgcY3ufWmvu3Ev1cghR29P0puwWGXER/cRheqliB9eBTJIVSMqMgjBPpk1cicpM5YgKANxI64qGQo9w0bZydv0PejRjuyvcxL5SuCvoB702OJWvcN1A79auSMhiVAo25Jz+NMjRXv5ZFP8I/ChpCva5RuJTbwSOcFgCP1qO0YpbRISBLOdzY9KNT+fTTnruIH50xojHf26nOBHgUkx2TRJrzEWZSMjBAGD3rnUl2jJXgcYB5Nauro3yOrH5Wy2T2qhFaxNPLHGW2ryFI56dfpWi3NaVox1GxTbSiqrBS3JPUVvqPnhIbjnH5VhTWYjlJSTdtwxJPrWhZXQk2Kp+6eCKbJq2klKJrtj7GrA8jmk2/vSO7KDSKf9D564zVgDD5OMhRSsc60RW8gPKVJOV61GLYByQpxnr6U2S4wzsvLM3OT/ACqKXUd6s8SFyOCBT5UaJMuKgUnJzT1iXfg4PTpWTZ35d2yCCOPrV8TZYBTz3NCsKcHF2GmMbnVRkqWH4dqzoDuu9uckoM/gcVoLII5JyM846/Ss+ZBb3EEo5B+VvxqdNGOPYdAAtsygA/Mfr1qW0kV7bB4IyD60xikcjEkgNyPSoLQq0QYcEGnEJK6uS3Ko0se9shecewrMcQy22ZJjHtDDOeTkVPqswEJZTg+gHWqumSRSWbW06bvMOAM4x681rA1jfkuaFhMf7NgedwzOmGI6ZHarCXURYEEkkY5rk57xF1iWKObZYABI93Xgf48ZqaK88t9ro6v0xg02xOh17nXrfIB246YpTq0gG1WKg9cd65b+0ARlFkcf7KmnfaHdQwQqG6FjgUuZmbp2Ni9v2MZzIcfWsqbUEispZGfapBJZmwFA7k1Q1AyRkidiGA3bVHb3NeF/FnxVLf6gdLsrl/sMP3wh4dvT3xQuYwrOKgZ/xV8VJ4k1eKO0JawslKRMf42Jyzf4Vwzc805jn2HuetNX7ua1SPNbu7iDnPBJxS5IGG49zQwAORyKmsrg2d1FcLFFK0ZzsmXejf7w7irSsTc6+01EvoWkxWfiuHSDDEUltk8wAtuJ3naOWIIz9K5vXnkl1Jnm1Qaq+xR9qBYg8fd+YZ46VoDxVKemj6H7f6EOn51kanfNqF4bloLeAlQDHbx+Wgxxnb6mkkDPum3nB37ctEO6r1A70rCNZVkBwzKSH9COgq2YDJIyRxRxqACB64p1yIlg8oSbVPOdnU+lcNklqer1Ma/ufLiw/BB3hR6ViXGtfMFYhVYZUYrfuLZXjO4bsdQc1Wg0fzpkaWNBgZ45rGbk3ZG0FHdkenXCXBwMlwOOOK2rW3SMF3CqG+6p5LH+gqW2sYYMjaVRR1KYzT4IGa5HWPjHsAfWqUddRc3YkRWkkkIfI6DaMEn0FLIBtCNy6/kppyP5AOHJz0HH55pEU7CWB2nj0wfanYfMRLGY22xyNvbrx+nNKtoYW2MGd2+ZfarabogNpUZHORk/jQI9uTvHXdnGaLKxXOyD7Mytzy/buKjubIOB9oYNz/q1GSfarrNvHd8888AU1Y23kjG/+92AoGptdSqluq8IixdsKMkVOiKqBQox2HYe59anVQYh8uEHXb1Y00oDlmYKMct/QUrBz33GD5hkngHjIxz/AIU2ViwKodwJ5I4ApzsGztXYgH3sc/SoypG1FUDnkZ6D1pkgAu4cAKvQmoZNsknG1gvcjqaWR9xCBsr16dahlAA/h2+1AXHuiyHcfuA8gDGaYZTtfG7dzyahllODsz+fBpGnDLyDkdhRcEPllOwEZY4xgdqjSTDtIQDIRxk1A83zk52v2qESeWWZvmPtSuXY0IrhUy7n5lycMOOaW0uAhL5GWQD61m+czZx90jnNSxzBcL0UVVyGtCaYeZpmDgsCf51buUV4o5R12jB9Kz45F2shx1PWrEEo+zeW/AXjr0pxZEmVLoCQYfAGOnrVGFxDC6sm5wfvNxx2pNTv/IkBK7h0OBk/Wsu71G2mQ5cBvcGmmbwXMrG3c3sNvAjN5LNJguCPmxjtVXRkXLPHnbkhc9TWHbwTXU6yuCI1GACOtdRp6pAigjhefxq27kzSgrJmlMxVWCHhVAoec+UpbqAM4qm0+BtDYPWmTzgpg4x7VNzFIhuQXbf0HpWfKzRgSW7sJPUjOKtG5AGM5X0NQtIikNngdKLm0ZNC2IYbCQeF5JPJNXxKFKjrWY18iSZypB9+lRSX0ZPDj86TYpXk7s1hNvkYk4waimk8wMC3BHesO41aJDgMPXr1rPudY4yWC/WkVGDOikmbYAxBYDGKr205iQK2O+cnrXNSa8gGXmQn6gVBJ4kso+XuYgfdxTSLtZWZ1V5MJYs9McVjzTNbsGV8Z9D0rmrzxxpcO5ftkJPoGzXL6j8RdNPEbPKewRa0V+go1Iw3eh6a2p2H2dVubctMpyjJySff2qtqd9Hdsgh32aoATO8mMeoAHUmvHLz4iSFm+zWhI6bmbrWZL471OVvkjhB6AEk5rR8z0IWJoRd7nvsGq26bJMq0gBIbceuew9Kmj8UWFvJ9ruzH9px0PCg+vpmvnJvFerztlZo417lU6fhWTf6leXgK3VzJIvPGcKf/AK1NKZhWxdCW12en/E74nC/mubfRnIaUlZJs5CjGMLivH3bJ7+pJ7n1p7YCYbvyD3+v09qaRxk/dHHvWihY82pV5xgGeOSf50EAHnvznvSseOMc9aX5t2G5b061SRi2NIyMjAB9TUtlMkF5HK9ul1Gh5hlziT2OOcVCQMk+tJnnGKYHfadYNf6fHer4e8OQQSIZFFxcujFAcb8buFzxmuZ8VWps9aktzb2dtIiLuis2ZkQ4z1PU+vatbT73FjpEt5p9yYZ4ZdJaVWAWaMngpno6luSeOKy/F8hOsmA209r9jgjtVScjzWCDG5scc+3bFShs+8ItgkLoGYgfMevH9KbcNGsg807mIyrNlljFSGSNJX2uVTr8vc/4VWdmllR5yBFnB3Dlh6fSuBy0PXS1HLIsojSGILGOnuezGrarsUsinbnczE8u3Y1niVtx+zhdgOMnk5rQcBLaMqWcnjC+vtSTvqVJW0CdRjAfIA5c1XMTB/MClQRleeAKmiVh98kNnOcZH5Vm6jelBIrymPJx0wdtKTsrsEtbGnBExjYps2g/ePOTU7bd4LOZZMcnjaK5qw1CTKRszsvUOxx9BxW9EXMYIC59SOn1pRlzBKLTFbfvxuA/3v88050bhhjPXFQsyoDvJd+wXnn69qcJHXGVCt2YnoPaqHYkQtlwy8Y+lPxwRk7euaiLtjazc9cHrSLKQxwMYPT1oDUnA3YByAR09PeoXHzBwoEQ+6f7xpplDEjll7knqaQys/PIx0A4/WnoLUfO4O3BLSH7o9Pc1WbAYplmHcjvTGnVtwHAPf3pj3A2rsxgdqWhSTFkOzO5MZ7VQluBjr07dKmlu4xhmO/jJArndZ8Q6bpse67uooVHXewFK44xbNKa6QDrj696rNfAfdORXm+rfFbQLdmWKSScjp5SE5/HpXKah8XEk3C00yU46mRwuPwFNRb2QOcIfEz26S9jYbiw3fWqkmoIp5cZHb0r58uviTqkpO20hhHqWY4+tZ7+O9dZj+8iQdSSDVqlN9CHiKK+0fSQ1RCuQQSPSgakgAOcpnrnpXzQPGmvsxYXKKR1O37v1py+NdfXpcxgnnlcZGcZ96fsJC+tUu59NNfLMgaFw2B1BqP8At6OPctx+7boT2P418zr4z1xpB5d4seOrIuNo9SPSnt448RSZV72KVACQzxgAj3o9hMn6zRvufSJeKYmVmDEjnn8qVRa45RN/97HSvmmPx1r8eRFdqoP8Oz9eamf4g+IjsAvEHGT+7AP4+1V7KQ/rNLoz6WjnhjUAMNoPrTZtWt1G5m4B55r5nXxx4imyqXgZuTwnUDvmqE/inWbnHmalKFP90cmj2UxfWaPc+lrjxFapk+YAax73xnp8CsZbuJfYvivnOe7v50Esl3O6scBmkI3n0Aqgx8xhuO/d/ePJ+hPb3qlRl1Zm8ZTXwxPdtQ+JmlRsVS53kf3ATmsO7+LEA4hhnk/QGvJgmCT1QH8cf4U0ndjaAAw9Oo/oKtYdLdkPHS6JHolx8ULuRm8izzgZ5f8ApWXP8QtalYlTEiDjgE4rkWcsAqAbyfvdOPQe1KmDMFbG3BUMnAb/AD61SoRRm8ZVfU3Z/F2uyN/x+FFP9xRyfQVQl1jVLk4l1C5ft8rc/Ss1eRycA8KFJw30Pan7sEDB2A4yvBI9B7VSpx7GTxFR7sllkkkCg3MzsfvEucZ/uj/GoFQuejSDGSByT9P8aaMsvC4jY4BHf2+nvTgzqSE4DDbhTww7gHsKrlXYzdST6igLwy7tp/ujG76f401MNhApIJwAOpPop/rTnLTtgksw4AXrj0HoB60xixIRCG3cccfgPT61VkRckGxgSzEFR2Ayf9kev1pm4kkLt2n0PH0HpRhWRVLbj0B759B7DuaibOGIIwSenRv8BQO4biQM8Z6Hpn/61L1UnkjjnHBHv6Um4s2X5JHAJx+P09qTJwRkjHOf/rf0oC4HBOCcY7ntSBuSCBzwf8KQDBzjjoTTPw6e1IQ4sDjAGfWkwRjIozn6ehNIAevp096AAn/PrUkEUssixwRu8rfdRBuJ+gFRY2nOc96kimkgmWW3keKRTkOjFWH0I6UAdVBZwa5pOmfaxqtrJaQeQHhsWnimTcSCuMYPJB9cVmeK7n7Rqqj7PdQRQQRW8a3S7ZWRFwGb3Na0FzZaTo2lfbdT8Qxz3EPneTaXCrHGm4gEZ9cE4o8VaPam3uL20vdRuZoI4JnN6wYyQyj5WU9QQeCp/CpQ2fZVuwLgswIxxz+QqXzEwoLt1KgKc4rIsZ1KSEdQf3atyRVm1YR4did38JNecux7Ulys2rSGOFS4IZzk5H8NLJOskuAx39jjofWqUhAhLgNg85z1pkcxjZJiFAxtCjqaqStoSnzamrL5MMefM3SqDksCefpXGXdxJdyMCPuk9VxwP5CumM/7lzl2dxhnb+EH096xTp7NcbgNo6/N/X3rKqnLRGlPTcpwBpJ1yDnOQCckD1PpXWWsknl4ZVLYyN3P1NZkcaAAIi/L95zVnzcx7Yo2ZWPOTjf/APWohHlHJuRNJIy/MJOp2ll4H4UjErgBNmR97OW+vtVcyKrAPIpfkbscJ7AdzT4ZBK58rOzPryx9zVjUWWY3PzeXwp4LHrTQit8q5YE8c8H/ABqQIGRt2D3I9KkijCKCD8uehpktWGooTBbBK+vOKbKykkc+uSOKfMUiUmQqoAJBBrCub17tttmSB/z1PCj6etJ6BFXJ9Ru4oY8lh65btXLahr8ynZZwtM5/vHArVurMBQGzLO/O9uce9Vv7KVVYrkuepPWobOiHKlqcVrMmrXcTIt2Y+uTFwF+nrXz14k+0R6xcwXk7zyRSEFnYnP519WXulExFU+UAY+tc1efD2zvInkuIld2OTlASc+9XCaTIxFJVY72Pm5EBiDgAgHnPT8PU05+BzkMvAGclD2+pr2u9+EtmyExBovTDEY+lc9qXwpvUfNndLkLtAdeg+orqjXiebLBVFtqeayKAiB2yTn5hyB6jHdj69qam5UYkLx/CxzyemPU109/4E8QWBdjZCZemYXzgdxiubngltZCl3BLAQCNrIR27ZrZTi9mc06M4fEiIqAqszYCk+5HTt3pHHzfMCq54A6fn6+1AJZRvbbsGBzyPYDv9aeSgDMdpOQd68gc8qB3PvVozGByY8OcKnOB1+p9aGQN5j428Zyx4P1Hr7UjcYU5GOBg5/AeppTGApLnaQeSedp/qaYhSzfd2qBu3EHp9SfX2qPcz53/MO5brjnBPt7U4lSu3GyMNu29gM9fc1GwVl3Ekc4+bqvHU+p9qAHKSVYRtwQcjpuA7n0HtTGxICMMcH1xnnv6ChgCzFflXryeD/ve/tTyWVHUny1YgsjHgj1Y/yFADM7gdoJIGMken8h/Ol+d2BCAfxEc4I/oKaGBzkEJjknnPHBb19hT1yULFtqN8zr2A4GT/AIUCbGuwO7Z86hfmJ4JGeCfRfahcMd7E8g545YY7+gpyKxBU8xghmBODjPBP+FMwrqXXgDnd9O7CmIYrs4VCevUMflx/hTlG5wsfK5/i44/wobG9Q6hcksFfhT7n/Ck6sA24gYOH7jPU+3tQAEmRCoOV9hw2B19loIR2IQkrgfK3BPrj0FPUs8bIxCqwDF8YzjoT7e1MZ+TsXdGTuy38ZHr6D2oACzyOzZLAjBCjGR7+goZsphNpz3OQG+g7ChpNwffnnnpjeM9/b0FODDy9zkuuMgDq2Bxn0UU0ISRRsUhTtckgDhm/wWmKhZAVKjccDtn8OwpVbDHOWB/hJxuP1/u0k3Uvw4HG4f4elIQhbd8u1c85IOA3/wBamtw5wVxjrjg49aVseXxtUN2Jzu9yewprdBk5J6Z6/U+3tQMC2SzZyep4/WmZJzkYPY98+v1pzsM7uFJ6qOn4+/tTXyBtJyc5wT0pAJg7e2Ogz0pP4j1/E0pIx06jqKGxxj60gELdjjFISfakPPXrSj+VAxDnPNL15oI9aUcUCO00i7TTNEsV1q/tykymW0t5NPW7aFCxG7JI2gkE7eazPE95qUE9zZXV3FeQXhju/tCJt+0IV/dn1CgdE6A1Dba1atY29tq2kRah9lUrDL5zROqZztJX7wBJx6U3xUbl9SiluhApltYZIY4AQkURX5EAPoKXUfQ+xdPBH7zGCTjA6kVoxsu4CQYGPzqFWMgDJhWXv6+1MJ2Y3sSf1+teWtD3Je8WbhygLBjtP3VPakt94kVrgHJ5AFVGf51z83qTVlHXOVJJPQk9Kpu7BRsrFxnYbWPD5zt/u+9NjZrg+WAcD9fc1FM0auG3bj3HvSR3rt+6A2r/ABEcZ9qNyki/IEKRxp9xjgD+/wD/AFqkuP3SAM2SRtKr39h6Cq8FzHGFf70nQAHGPYVXv5zsP8MhHzf7I9BRYqKu0ivcl55cQjodueg+g9qFaaPaHlUjooTjNZjzSm4VFVmhYjbjpmr0FysE6eaJGT/pmR8pHrmt4xR1TXKjStJmSdklz8hwRnqa0HvUiikYkD3Pb2rnUvBPdvJHkKxLEkdPb3rVt7R7mVGdcqv3VP8AWolZbHNOK6kEscmoMWnBWAjiMHBI96sJAII8qOnAH8hV9IwMCMA54XH86JFUOQcbY+v1rOxHN0RRjtPvO457mholRgoXkCrjbhGu7ALnIHU1HDmSVyV6cDjGaVhp9yH7MrBcgetLJbgAYAzV1R8wGxhgdxSiMOrMCML61ViW+5kzWgYdBn1NUjYAk4XAHU10JgAGTgf1qhI6u37vlQcDH8RpWaGpGNNptuWO5cmqN/oVjdwslxbQSr6MgNdJLDtViSNzdz/hVVIi0DblHPcHk0mWpOx5N4g+FWjXZZ4YXtnI4aI4x+Fee6/8LdVtCX06aO4RRwrDYcfyr6dgiWeBQQMfyqjNZI6suNwU8Zq4zktmROnTnpJHxzfaZqGmuVvrKaADj7nHTsen41SBQq2D8w44PT2Hv719b3+hJKfmjUq3UEA1ymq/DnRb/cZLGMP/AHo/kP6Vsq76nLLBRfws+dEUMVfAC5xleTn29/elYYIZywI9idhxx9Sa9d1b4S2wJNhc3EJ/uthhXK6j8N9btyRbtFOo4UBtpH0zW0a0Wc8sHUWyucQ2XJYkbx8x4yAT6+pp2QVUFMIh5TJIz3Pu1dXH4B1+Q5aKJD6F+n/1/erlv8N9dk2/LbEAEFd54Ht7+9WqkSHhqv8AKcQ4KDq3loeBwShI7+rVHIACJAvy57chee/q1drcfDvxJGArW0RC5KFZMEev1J9azZPBmvxsGOnSZHQqQQPw9fenzxJeHqdjnW+VQHGwZ6Hn159z7UhAVx+7xsHU84OOrep9q1ZPDerxbS9hcIFGcBd2Pp71RntpYuZ4p4sdihG38xyaakjOVKS6ETAbzvwmGyFYZ/4Eff2pJChYpksgOQHOGx6n/Ch9j7iqhUHzZY5/E+rUDJjDCNdkXOf7uT1J7n2qrkEYLNuLHc3+0OSMdT7ClOzJOGJK8ZGAT/ePoPalKmQqGYKAMl2PI9C3+FE7ArkHanXBH3/9pvr6UCG5Em1eDs5O4/e56/T2pp+Y7EIKtzuIwT7n29qdjYo3Ahhhgp6H/ab/AAphOPmkO5jyAeuPU+3tQApcfdThTyS3Ab/Ae1Irc5KAsORu7fX/AAoZf3QZsAepGcn396aWwAJFbC9B0x/jQIUsA2/Kkk55HGfUj19qZksWZiSwOeT0/wA+lDkEllGFHQHrn396b2yT06ex9qQxSRxknqfqPr700kcFscdvWjJzknHHpSqcYJwT+dIAOQMcj2PX600j/wDXSucknqc9T2pDxQAcfjSHgYoHf0NL160DG9sVZsXt0u4mvopJrYH95HG+xmHoG7VWq7pFjJqep21lCyrLO+wM/RR1JPsADSA2PtnhQj/kB6pj/r/H/wATVHxJqMGp38c9pby29vFbx26JI+9sIMckVa8jwuvyHUNYkwceclsgQ+4UnNUdc04aXerCk4ngkiSaGYDaJI2GVJHY+3tQrAz7PW5P8Snr83an8F8gZQjA9AKr2sTPu3gkDnOOlW4wXYhWA9SfSvMV+p7jstiF42Ukqu0Fs880ySQR7gmfUgj+VaMpTygrE5HU1GIhs2pyM8A96LdilO5WaZZIl2oyOB3/AIqSV3jjKxkMy857D1qxcpFFGC75Y9cdqYIEypXhT29KLMamiFJGjCuSSQOKZdTPJEd2d5561alhJPABTv70xSC2VB25xg0ItVEncoK+bbJchl5KZ5J9qn00faWYD7gOeOtF5DG7qFVVY8kjtVnTgkBIQDB6k9615zT2i5bl/T7EeY08mMKdsagY59cVuF0gi2JxJJxn0WsiGZVAfr6D0pr3RYOzjGfU9Klvsc0rzepqGZUj3g5Y4AH8qUMTEEZQdxzuPVuayFk3KuxgMHJJHSrsdwksqvv+VOwoBqxfmYCQFyHcHgAdz1/KnFRFMpOAC3QetZwmBYSDruOMdBU6TKHV3bOD19aaZJou2LpQp4APGP1pA0Xl5K/Jn86qm4DrI27B+6P8ailkVmUE8RD8zVXsSO1G4YReXHgPKdoz2FU2aG1gZurKPlHvWfJcPLcSOcAJwp96rXTvI6pHklfmNTe5ooPYvRFVG65YmU9/r2qzJEkcCtz6bc1jRJK10wkYFk7dRWr5qkwxuCPmBzSRTViS2j2vEuACQWxQkBdpQOgb8qWN92pbs8IvHtmr1syjz8/xPTUUzOTZnzW4wCeR9KzpLRWfjPvXS+UC0Kkc7SSaqPADuJ7ZpNCiznprPjIHXjBqhcWY3FQq+5xXUy22dnqRxVKSABHYjGTgGkzaDOWe0VZcbeR+tPSOFf4QD05rYurbZ84+bnn3qCS3DOCoxkZxSvY2smimwJXlQVFVngRjnaOfUVpmEKhYfd/lVafKKcYII/KtE2SopvQyr21jjUHZlSOtZRtbO6DI8ccg9CM1LeX073a26RhgeWcnAQepqfSodlkl1gSLK/yR/dI981Vzd0fZxvI47Vvh/o+p73W3EEnZ4vlI/CvN/FPgLU9DVp7Um7s0OcKPmX3I7/WvpBNzqN8aqy8ggZyaqXib9263jGeDjNNVLbHFVo06m6sfJQmXdlow2FwM84Pdvc04OI1GzkZzhuQDjq3qfavSfin4HezkfVtLtm+zMczpEMhD/eA7CvMvNPA6Y5AxkD/E11QndHjVaThKw9jkqxIGTuO7nJ9T7+1RkkEsBkLkjfyRn+Z9qdJg9QVGeNvTP+NRLjGGDYJyB/h/jV3MRxIVVww3c8ddv/16aSMAZyf0/A0YyOmB0x9f89abknAwOPyxSAXJXpx2/wDrUin+EAe+f5fSkPXgUh796LjBjkj1xRwOw+oNAFDdDQIXOTTc+go9KO1AwPJoxj3+tKBwM/pSMc9aAAH1q3pZu01G2fTRKb1ZA0IhGX3Dpgd6qCpYPME0Yt/M8/cPL8vO7OeMY75oEdjnWJG8yXwTaSzkkl/sMgDH1Kg4rnNfk1GbVZJNZiliu2Rf3bxeXsXHyhV7LjpXQ6ppXinUbr7RKq29y6KJIhfKjO4GNxTdwx7jjmuVv47uG9ki1ETLdRtsdZid6+xJ7UkNn2xHK7blXIX1xxTbfcJcZ3Z5JrHl1VlOAcL6CmR6nI3AIx78V51j27XOh8+NJDg9+QaerrglSA3Xk8VzZuh5vmNxx0qaO8UscuNp7ZpDtY2mkRyDtHPf0qV7iNYwqDPPJPc1ipclVYgjaegz0qFdQXftHIHr6+tWiZLsbj3DBsKNuMnOapPcMuWU4PesqfUgAQjbQDkg9TVOTUkKMzH5PbtSsCZ0KyiQZYhSfzp6OA3B4Fcyt/EcfvevTnrUn9qqDsMi4xnrRYep03ngjIyWz0NJJc7gQTyOgrln1lY2GXDZ6fN0qtL4htzlPPB9TnG2lYaZ2vnsV+fAHpmnRXaKSFyF/nXFJr8PkqvmA+mTz9alj1dSAqvyeVOeBQaLXc7U3GRnOEx1BqUXP7pQoyCa5OHVo2UDcp5yxJq9Bfhmzu2g/lQDR032vfHnhQDjFI1yWXywOTzzWEb6NHBc5U8A471PY3qidt7AnGOaBW0LwhP7qNRhmBc+5pFjKPLgYI7mnpcA3eT/AHMDmob+42xSOAQSMfjVbFQd9CGyZt5Y9WOa1YiC+ScFOmax7ebyok+b5gOP8Kc9+VjY9Ceaadhzi2zUhky0jnuwAxVtJMTBc991YkE4AgGQSPmIq3BcBpXkJ9gKSMZG3HKGk5ByFxxSzzILdwoGScCsea7Cvkk8c05rkSBcdOv0p3IUS9JLicngBU2jnvWfeykW8ESnlmyfzqvJcDzCBnODmqc11m7jPJUDAqXqbQWpfceczFh8qcE9cmmyxBJlYZJyM5Hamw3S+RkN8zHOPeq8l7HEwEjDrnNPlK97oW5EUE7RkMMfU1S1CzAtJXjbARdzL7U2O+DByDxk4aqWoalJOPs8YKqx5Cjr6fjWkbBBSTOcTTzd3O0A5lYR4+vpXS2+mLasYRyE+UH196SJYdP1OETNu5LAnHy46gj1zUkGomWQue5J6dKrlW5pWrSqPTYtpbDH3elEsA29B+VTJfj5TkE/SlkvFZTnFFkzkbZiSweXMPkBRjtIx2NeD/G3wVHodzDq+nRLFZXMhilReiSckEDsD/SvfLm5DTKgx8xArzr9oG8j/wCEMWI8SSXqbR64BJIq4pJHJitWj5zBI/lThgtgfN6DGP8AIpp4HtQucYwNp6j1rRM4WPcg7eTu75H6D2pvqMECkz1GM56n0/8Ar0E5/LFWIaOpxQfSgZNHrUoABx1pd1IeO2aUdCMUJgIcnmgDOfajnPNAPNUAue1A5Az3pvXNOBHtQALxyRxV/QtQ/srWbO/8vzPs8m8rnG4d8HsfSs/n6CtTwzcW1pr2n3F8AbWOYM5K7gPRsd8HB/CgRoXOleH1laSXVNSgEnz+XcWBMmD77sE+9VPFN8t9qUTxwzxRRW8UEXn/AOsdFXAdvUn+Vas2rPLdXOk+Jr4anZO2UvY28027kZEkZ67em5fT3FVfHBjbV7VILmK6ijsreLzYWyrlUwcf54pIbPZpvFWmrP8APcovuGBBqnP450uMkm4iOD1Df0rxRI4zGxCAEDO5uAwxjn0o2AFVBRSTwehUHvnsKy9gdv1zyPYLv4l6cqZUlz/uk4rPufibCZFWG0kYnqoGM+/NeZxxg7AAMcAOARu57eg9zRvQMGWNCTgkMcgN7epp/V0ifrkj0Z/indrA0cdkQD3ZwCB9KzZ/iLqc+fLhgTHRgSSf8K43a6zfvCNyYyzfNt4/U007Gkc8q3Q724I/2v8AAVSoRIeKmzqZPHGtyN880APXAQn8B61TufFusyMT9pEaMcEou78MdzWMu5n8soplGQc8YHQYx90e1SyxmMJK2TuGV4w4GecL2T36mrVGK6E/WKnclfWNUExkOoyhz1UD5R6A44z9KsDXtWfIN2yjHOTwPce/tWaqDKs5XYw+RV6MOT/wH6mnJCgAWdmAU5ESkjcSOkfv3yafs4kqtPuST3t7MhZry4bnBJfgYHOcfyquCWZmDynaoLb3bBH94nt9KXcAMM+QCVDJyB26d/8Aep67jHtZVSMN8iA5DZPT/aanyIl1JPqJDNdh8JczED/pqQQPU+361ai1TU4Y0NvfzlPQnJz6kdhVckRpskwmwjvnYTk5z/E3tQSWUOWCKOHOMkEDq47nnpSdOPYaqzWzNa28Wa5bSKJZFd8ZCuPvAfyrds/iPfpIFksw4POA+Dj1+lcaxixLHlQA27Lk4PPU47+iio0/eBg5LHjCs2DjsT/hUOjBm0cXVXU9Tg+KEMhjE0E4BP3hg/pUs3xS09ZFeISntjbn8a8p8wCFhgqrAEuQPmYD+L0HPAFNcoyMrDII3gcguRjk+g9ql4eJosdU62Pb9K+LmjTBRdSS28o4yyHafxFdVonjHStbtt0F9CWVjuVmwfyNfMQQvIXOWUDezcDAz/KmosZkRpDhTwAnBPHU+gqHh+zLjj+6PqufWrRBxPHgdwwxWbJ4it559kUqvg87ea+ZsufkjaRQRnbvPzHHb296mtJ7y1cPYXcyg85R8Z9cD29al0JGv9oR7H1Xa6gjjfkZ7A9qtpqMSAZYbq+W4fFOuKg2alMRnGW5DewqaLxn4gzk3SyYOOVHJ9Aal0ZB9bpvc+nn1JGYbiKlivgW3bgAelfNkPxC1qIKZBC6djzz9K0IfijeIV8203cfwNxUOlPsarEUXopH0E16oVnZuelUb26B8oq3ftxXjcHxVWSPa1pOC3THOami+KFmThreZ1PA+WlyS7Gsa1NdT1RNSVGYZw5IBzwKbPcwxSna63LjpgkqCfavLj8Q9NmYb2KDOBlScVes/HWioNy3kfJ5yhyfpVWZo68OjPSLeTZb5kYA44HpVCS8eGXzI5ChBznvXGz/ABH0Qpj7Vk+wJrEuvHmlmT5Lh9o9ENVZ9BU68U7yZ34lkTUDcXrNHDNuVWwTk+tadubpYN0CCVOfunJ6d68muPiXBJGqN5jxoeMR4yfb0qb/AIWwPsoRLSZxGNq7RtAz1zzyTV8qfQipXi9VJfeepve3SRh/Jk2+uKp6lr7WEDSXamJAm8lzgYrye8+LGpMki2dpDExI+eQ5Ax2xXE694i1bxBIX1S9eY/3PuqPYAUezvscs8VBeZ6nd/FjTYZi8UNxcMB8oUbRn6mvMvGXii98U6gs118kMYKwwg5CDP6n3rCKgH1/2sUE4UYJ4PXt+FXGnY4aleVTcjwemDSjpxSnjGOtBYE8Aj+dXymLY09OmPpSZpcZ4P5Uh+vP6U7iAdM0HqKD04oPtSYITufWlHWjvmkouGgvekpc0lPcBRQR7UAnPBwKXp1/+vRsIUsTg8Y6VJbwyXE8cFupeaVgiKOrEnGKjAbaOSF/StDQLqKz1e2muGKwAsrsoyYwyld/1Gc/hTAuHRrJJvs0mpyfaQpZnitGeAAdTvByVGDlgMVl31jLZXclrOu2RCOQcqQRkMD/dIwQe+a7aOwuF1ax1EJqDzWsMaLFbx7oJQi7RtmztWNhyQeRk1y3iOaCW+ihilWVLa2jt/NQ5VmUckeoBOB7ChARW/wC8J3dBKEA7fX60+SMN5wYk+WMjPPPv60UVbAkI/wBIEP8ADtDse7nZ3pioJJURhhHGSB25xge1FFPoAkLEuw6FGKKR1UZqYqEt3lXhw5jB64GRzz396KKfQB8KKIL5tvEbR4UkkEk8sfU1ErHz95JLIu/JPUhe9FFIOo1XIiEpAYvywYcNx0qxGQbgWzKrRyguxPXgjgHsKKKaBjpE2x28gZhJLwzZ5xk/L7Cq6nKxAgYc7Bx9wDsvpRRQIbvLbY25UHy1/wBkY7e/vVqfLRySl2LRSFEyeAOB+dFFIZWkl2XDFUQAShQuOBz1+tEJ/eTHvD/qz6HPX3/GiijqAMN1vPMT88Z9Bg8Dk01wonRFGFY8gE4J45oooY4iiPM8kZZtqkHr1PvSAghAVUgoS3H3sA4zRRUgNEhSLavCyqCw9eOBUgXayoGO1jyOOnXH0ooprYYyRsm12gJ54JfZxxn7o9BSH5vKB+66k47DHYf1oopMQ9CZ/s6Sc5OMjggZ6fSoi+IkAACu2GXscZxRRQ9xsmlQCeKPJ2yJuI9OOg9BUUjHYh7nK8cYA7UUUPcEKg80Qs3DSEq2OOAKgBO9E6BjjPcD2oopdRjmOApHBL7CR6ZpszbGYJhQ3HHb6UUUALzhADgZAAHbim7zsKjj955YI7DNFFADJBtVscASFMdsUFQTGOzMQfpRRSJZEf8AWbe2SPoM0OefzoooYhjEjb3z60MSHYdgaKKXQBByMmg9D9aKKgsMk9fSkooq+hIGiiiktwCl7fSiimhBGNwOfegdj3oopgxy8nnnnFGcKWHUHFFFAiQSOIiiuwjc4KAnb+VMIAjYjqGwKKKYH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple violaceous, scaly papules are present overlying the joints on the dorsal hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gottron's sign in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Macular violaceous erythema is present overlying the joints of the hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44090=[""].join("\n");
var outline_f43_3_44090=null;
var title_f43_3_44091="Clinical features of Laron syndrome";
var content_f43_3_44091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of primary growth hormone insensitivity (Laron syndrome)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Growth and development",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth weight and length near normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postnatal growth failure, moderate to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone age delayed relative to chronological age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short limb length in relation to trunk length",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Puberty delayed 3 to 7 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal sexual function and fertility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intellectual development normal or modestly impaired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Head and neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Face small in relation to head circumference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delayed dentition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blue sclerae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia, especially in infants and children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperlipidemia and variable degrees of insulin resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obesity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Reiter EO, Rosenfeld RG. Growth retardation in: Kronenberg HM et al, Eds. Williams Textbook of Endocrinology, 11th Ed. Saunders Elsevier, Philadelphia, 2008. p.903.",
"       </li>",
"       <li>",
"        Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004; 89:1031.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44091=[""].join("\n");
var outline_f43_3_44091=null;
var title_f43_3_44092="Management sexual dysfunction";
var content_f43_3_44092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Second Princeton consensus panel recommendations for risk assignment for sexual activity and management of sexual dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade of risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        CAVEATS",
"       </td>",
"       <td>",
"        Phosphodiesterase-5 inhibitors contraindicated with any nitrate preparation should not be taken with alpha-blocking agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrates should not be administered within 24 hours (or longer in patients with renal or hepatic dysfunction) of sildenafil, 24 hours of vardenafil, or up to 48 hours of tadalafil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"9\">",
"        Low risk",
"       </td>",
"       <td>",
"        No symptoms and less than three major cardiovascular risk factors (excluding gender)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Controlled hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild, stable angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-successful coronary revascularization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncomplicated MI more than six to eight weeks previously in patients who do not have exercise-induced ischemia or who have undergone coronary revascularization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild valvular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymptomatic LV dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patients at low risk can safely initiate or resume sexual activity and can be treated for sexual dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Intermediate or indeterminate risk",
"       </td>",
"       <td>",
"        No symptoms and three or more major cardiovascular risk factors (excluding gender)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate, stable angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent MI (more than two but less than six weeks previously); in patients who have not undergone revascularization, the risk can be assessed with stress testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymptomatic LV dysfunction with LV ejection fraction &lt;40 percent or NYHA class II heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noncardiac sequelae of atherosclerotic disease, such as peripheral vascular disease or prior stroke or transient ischemic attack",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patients at intermediate or indeterminate risk should undergo further cardiologic evaluation, such as stress testing (particularly in patients with a sedentary lifestyle), in an attempt to restratify the patient into the high risk or low risk category",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"9\">",
"        High risk",
"       </td>",
"       <td>",
"        Unstable or refractory angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NYHA class III/IV heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MI within the past two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High-risk arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obstructive hypertrophic cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate to severe valvular disease, particular aortic stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patients at high risk should be stabilized by appropriate therapy before resuming sexual activity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MI: myocardial infarction; LV: left ventricular; NYHA: New York Heart Association.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Kostis B, Jackson G, Rosen R, et al. Am J Cardiol 2005; 96:313.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44092=[""].join("\n");
var outline_f43_3_44092=null;
var title_f43_3_44093="Lawton daily living scale";
var content_f43_3_44093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The Lawton instrumental activities of daily living scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1\">",
"          Activities",
"         </td>",
"         <td class=\"subtitle1\">",
"          Points",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_left\" colspan=\"2\">",
"          Ability to use telephone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          1. Operates telephone on own initiative; looks up and dials numbers",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          2. Dials a few well-known numbers",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          3. Answers telephone, but does not dial",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          4. Does not use telephone at all",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_left\" colspan=\"2\">",
"          Shopping",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          1. Takes care of all shopping needs independently",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          2. Shops independently for small purchases",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          3. Needs to be accompanied on any shopping trip",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          4. Completely unable to shop",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_left\" colspan=\"2\">",
"          Food preparation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          1. Plans, prepares, and serves adequate meals independently",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          2. Prepares adequate meals if supplied with ingredients",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          3. Heats and serves prepared meals or prepares meals but does not maintain adequate diet",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          4. Needs to have meals prepared and served",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_left\" colspan=\"2\">",
"          Housekeeping",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          1. Maintains house alone with occasion assistance (heavy work)",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          2. Performs light daily tasks such as dishwashing, bed making",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          3. Performs light daily tasks, but cannot maintain acceptable level of cleanliness",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          4. Needs help with all home maintenance tasks",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          5. Does not participate in any housekeeping tasks",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1\">",
"          Activities",
"         </td>",
"         <td class=\"subtitle1\">",
"          Points",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_left\" colspan=\"2\">",
"          Laundry",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          1. Does personal laundry completely",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          2. Launders small items, rinses socks, stockings, etc.",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          3. All laundry must be done by others",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_left\" colspan=\"2\">",
"          Mode of transportation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          1. Travels independently on public transportation or drives own car",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          2. Arranges own travel via taxi, but does not otherwise use public transportation",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          3. Travels on public transportation when assisted or accompanied by another",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          4. Travel limited to taxi or automobile with assistance of another",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          5. Does not travel at all",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_left\" colspan=\"2\">",
"          Responsibility for own medications",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          1. Is responsible for taking medication in correct dosages at correct time",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          2. Takes responsibility if medication is prepared in advance in separate dosages",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          3. Is not capable of dispensing own medication",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle2_left\" colspan=\"2\">",
"          Ability to handle finances",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          1. Manages financial matters independently (budgets, writes checks, pays rent and bills, goes to bank); collects and keeps track of income",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          2. Manages day-to-day purchases, but needs help with banking, major purchases, etc.",
"         </td>",
"         <td>",
"          1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"indent1\">",
"          3. Incapable of handling money",
"         </td>",
"         <td>",
"          0",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Scoring:",
"    </strong>",
"    For each category, circle the item description that most closely resembles the client's highest functional level (either 0 or 1).",
"    <br>",
"     A summary score ranges from 0 (dependent, requires significant assistance to live in the community) to 8 (independent, no assistance required to maintain self in community).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9:179. Copyright &copy; 1969 Oxford University Press.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44093=[""].join("\n");
var outline_f43_3_44093=null;
var title_f43_3_44094="FOLFIRINOX for metastatic pancreatic cancer";
var content_f43_3_44094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    FOLFIRINOX chemotherapy for metastatic pancreatic cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 14 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Oxaliplatin",
"        </strong>",
"        *",
"       </td>",
"       <td>",
"        85 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 to 500 mL 5 percent dextrose in water (D5W)",
"        <sup>",
"         &Delta;",
"        </sup>",
"        and administer over two hours (prior to leucovorin).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Leucovorin",
"        </strong>",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL D5W and administer over two hours (after oxaliplatin).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Irinotecan",
"        </strong>",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        180 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 mL D5W and administer over 90 minutes. Administer concurrent with the last 90 minutes of leucovorin infusion, in separate bags, using a Y-line connection.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV bolus",
"       </td>",
"       <td>",
"        Give undiluted (50 mg/mL) as a slow IV push over five minutes (administer immediately after leucovorin).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        2400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 to 1000 mL 0.9 percent normal saline (NS) or D5W and administer as a continuous IV infusion over 46 hours (begin immediately after FU IV bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose diluted in 100 to 150 mL NS.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (greater than 90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        No standard premedication regimen. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Oxaliplatin and fluorouracil are irritants, but oxaliplatin can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with G-CSF is not warranted. However, given the risk of grade 3 or 4 neutropenia (46 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ), primary prophylaxis with G-CSF is used at many institutions. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of oxaliplatin and irinotecan may be needed for severe renal insufficiency",
"        <sup>",
"         [2,3]",
"        </sup>",
"        . A lower starting dose of irinotecan and FU may be needed for patients with hepatic impairment",
"        <sup>",
"         [3,4]",
"        </sup>",
"        .",
"        <strong>",
"         NOTE:",
"        </strong>",
"        We do not recommend administration of FOLFIRINOX unless serum bilirubin is normal. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Maneuvers to prevent neurotoxicity:",
"        </strong>",
"        Pharmacological methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during, and for approximately 48 hours after each infusion",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Electrolytes and liver and renal function prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Irinotecan is associated with early and late diarrhea, both of which may be severe",
"        <sup>",
"         [2]",
"        </sup>",
"        . For patients who develop abdominal cramping and/or diarrhea within 24 hours of receiving irinotecan, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide for late diarrhea. Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) should be provided as needed. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in neurologic function prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        <p>",
"         &bull;",
"         <strong>",
"          Myelotoxicity:",
"         </strong>",
"         Do not retreat unless neutrophil count &ge;1500 cells/mm",
"         <sup>",
"          3",
"         </sup>",
"         and platelets are &ge;75,000/mm",
"         <sup>",
"          3",
"         </sup>",
"         . The following dose reduction guidelines for hematologic toxicity were provided in the original protocol",
"         <sup>",
"          [1]",
"         </sup>",
"         :",
"        </p>",
"        <p>",
"         <strong>",
"          Neutropenia:",
"         </strong>",
"         If day 1 treatment delayed for granulocytes &lt;1500 cells/mm",
"         <sup>",
"          3",
"         </sup>",
"         or febrile neutropenia or grade 4 neutropenia &gt;7 days: reduce irinotecan dose to 150 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         and delete bolus FU and leucovorin. For second occurrence: reduce oxaliplatin dose to 60 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         . If non-recovery after two weeks delay or third occurrence of granulocytes &lt;1500 cells/mm",
"         <sup>",
"          3",
"         </sup>",
"         on day 1, or febrile neutropenia or grade 4 neutropenia at any time during cycle, discontinue treatment.",
"        </p>",
"        <p>",
"         <strong>",
"          Thrombocytopenia:",
"         </strong>",
"         If day 1 treatment delayed for platelet count &lt;75,000/mm",
"         <sup>",
"          3",
"         </sup>",
"         , reduce oxaliplatin dose to 60 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         and reduce both the bolus and continuous infusion FU to 75 percent of original doses. For second occurrence, reduce irinotecan dose to 150 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         . If non-recovery after two weeks delay or third occurrence of platelets &lt;75,000/mm",
"         <sup>",
"          3",
"         </sup>",
"         , discontinue treatment. For grade 3 or 4 thrombocytopenia",
"         <em>",
"          during",
"         </em>",
"         treatment, reduce oxaliplatin dose to 60 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         and the infusional FU dose to 75 percent of the original dose. For the second occurrence, reduce dose of irinotecan to 150 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         and the dose of infusional FU an additional 25 percent. Discontinue treatment for third occurrence.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Do not retreat with FOLFIRINOX until resolution of diarrhea for at least 24 hours without anti-diarrheal medication. For diarrhea grade 3 or 4, or diarrhea with fever and/or grade 3 or 4 neutropenia, reduce irinotecan dose to 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        and delete bolus FU. For second occurrence, reduce the oxaliplatin dose to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        and the continuous FU dose to 75 percent of original dose. Discontinue treatment for third occurrence.",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Mucositis or hand-foot syndrome:",
"        </strong>",
"        For grade 3 to 4 toxicity, reduce dose of both bolus and infusional FU by 25 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        Any other toxicity &ge;grade 2, except anemia and alopecia, can justify dose reduction if medically indicated. For transient grade 3 paresthesias/dysesthesias or grade 2 symptoms lasting &gt;7 days, decrease oxaliplatin dose by 25 percent",
"        <sup>",
"         [2]",
"        </sup>",
"        . Discontinue oxaliplatin for grade 4 or persistent grade 3 paresthesia/dysesthesia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; G-CSF: granulocyte colony-stimulating factors; CBC: complete blood count.",
"     <br/>",
"     * Many centers routinely infuse oxaliplatin via central venous line because of local pain with infusion into a peripheral vein.",
"     <br/>",
"     &Delta; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Leucovorin dose is given for d,l-racemic mixture",
"     <sup>",
"      [5]",
"     </sup>",
"     . Use half the dose for LEVOleucovorin (l-leucovorin).",
"     <br/>",
"     &sect; A lower initial dose of irinotecan is recommended for age &ge;65 years of age, poor performance status, prior pelvic or abdominal radiotherapy. Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Conroy T, et al. N Engl J Med 2011; 364:1817.",
"      </li>",
"      <li>",
"       Eloxatin (oxaliplatin) US FDA approved product information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 23, 2011).",
"      </li>",
"      <li>",
"       Camptosar (irinotecan hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 23, 2011).",
"      </li>",
"      <li>",
"       Fluorouracil injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 23, 2011).",
"      </li>",
"      <li>",
"       Leucovorin calcium injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 23, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44094=[""].join("\n");
var outline_f43_3_44094=null;
var title_f43_3_44095="Fungating gastric cancer Endosc";
var content_f43_3_44095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of an ulcerated gastric adenacarcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rome Jutabha, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_3_44095=[""].join("\n");
var outline_f43_3_44095=null;
